It is my pleasure to present our 2010-2011 report from the Orthopaedic Research Center and the Orthopaedic Bioengineering Research Laboratory at Colorado State University. Our principal focus continues to be solving the significant problems in equine musculoskeletal disease as can be seen in this report but we also continue to investigate questions relevant to human joint disease and techniques and devices for human osteoarthritis and articular cartilage repair when the technique can also benefit the horse. There have been a number of notable projects in this regard. The studies, led by Dr. Dave Frisbie at the ORC in partnership with Dr. Alan Grodzinsky at MIT on an NIH Program Grant in cartilage repair, have been completed and results are still being analyzed. We have three other ongoing NIH grants in partnership with collaborators. One is with Dr. Connie Chu at the University of Pittsburgh looking at stem cells in fibrin/PRP and articular cartilage repair (Dr. Laurie Goodrich is the PI on the sub-contract at CSU and other collaborators include Dr. Lisa Fortier of Cornell University and Dr. Bob Sah of the University of California, San Diego). This was a 12-month study that has been completed and results are still being analyzed with the other collaborators. The work with Dr. Jude Samulski at the University of North Carolina on Dr. Laurie Goodrich’s NIH KO8 grant on gene therapy (co-mentored by Drs. Samulski and McIlwraith) is progressing well and we have some exciting results with regard to long term protein production with the AAV vector. The third NIH grant is with Dr. Steve Trippel at the University of Indiana in which Drs. Frisbie and McIlwraith are co-PIs on a sub-contract of an NIH grant involving gene therapy and articular cartilage repair and the equine study will commence in the summer of 2012.

There have been some significant publications from the horse-human collaborative projects in leading journals in the last two years. At the same time, many projects addressing equine specific problems have been completed and published and all of this is detailed in this report. We handled the challenges created by the economic recession well in the 2010-2011 period. This would not have been possible without a number of our donors stepping up to provide supplemental funding.

I’m particularly grateful to Mr. Jim Kennedy for providing supplemental operating funds and continuing the legacy of his mother, Barbara Cox Anthony. I’m also grateful to Abigail Kawananakoa for continued support over and above the Endowed Chair she donated three years ago; and Herbert Allen for continuing to provide considerable support for investigation of cutting edge therapies.

We have added an Equine Sports Medicine Ambulatory clinical arm to the Orthopaedic Research Center and also initiated two residencies in Sports Medicine and Rehabilitation. This follows on from the accreditation of a new specialty college, the American College of Veterinary Sports Medicine and Rehabilitation. Drs. Haussler, Frisbie and Kawcak, as well as myself, are Foundation Diplomates and felt we had the appropriate ability and responsibility to train residents in this new specialty. Dr. Dora Ferris is in her second year and Dr. Erin Contino is in her first year. I would like to extend special thanks to Gail Holmes for providing funding for the three year program for Erin Contino.

Accomplishments at the ORC over the past two years are detailed in this report. Validation and clarification of the benefits of mesenchymal stem therapy, platelet-rich plasma (PRP), as well as autologous conditioned serum (IRAP II) are all in this report. These accomplishments could not be achieved without our team of faculty and staff as well as the excellent support of equine funding agencies (Grayson-Jockey Club Research Foundation, American Quarter Horse Association, and United States Equestrian Federation), corporate funding, and individual donors. With this help we continue to achieve our goals and also make new ones as new clinical questions arise.

Best wishes,

Wayne McIlwraith
# Table of Contents

**Preface** ................................................................. 1  
**Mission** ................................................................. 4  
**Research Focuses of the Orthopaedic Bioengineering Research Laboratory** ................................................................. 6  
**Research Focuses at the Orthopaedic Bioengineering Research Laboratory** ................................................................. 7  
**Musculoskeletal Research Program** ................................................................. 9  
**School of Biomedical Engineering** ................................................................. 10  
**Faculty** ................................................................. 11  
  College of Veterinary Medicine and Biomedical Sciences ................................................................. 11  
  College of Engineering ................................................................. 20  
  College of Applied Human Sciences ................................................................. 22  
  College of Agricultural Sciences ................................................................. 22  
  College of Natural Sciences ................................................................. 23  
  Affiliate Faculty ................................................................. 24  
  Collaborators ................................................................. 26  
  2010-2011 Post Doctoral Fellows ................................................................. 33  
  2010-2011 Equine Sports Medicine Residencies ................................................................. 34  
  2010-2011 Ph.D. Graduate Students ................................................................. 35  
  2010-2011 M.S. Graduate Students ................................................................. 37  
  Research Scientist ................................................................. 38  
  Research Associates ................................................................. 38  
  Research Coordinator ................................................................. 41  
  Administrative Staff ................................................................. 41  
  Director Gait Analysis Center/ ORC Staff Veterinarian ................................................................. 41  
**Orthopaedic Research Program** ................................................................. 42  
  Areas of Expertise of Personnel ................................................................. 42  
**Student Hourly Assistants at the ORC 2010-2011** ................................................................. 43  
**Volunteers at the ORC 2010-2011** ................................................................. 43  
**Graduate Students – Placement Since Inception** ................................................................. 44  
**Surgery Residents Supervised (and Outcome)** ................................................................. 46  
**Program Synopsis** ................................................................. 47  
  History ................................................................. 47  
  Research Activities ................................................................. 47  
  Impact ................................................................. 48  
  Program Trends ................................................................. 48  
  Program Goals ................................................................. 49  
  Goals Accomplished 2010-2011 ................................................................. 49  
  Current Goals ................................................................. 50  
  Research Goals ................................................................. 50  
  Research Goals Achieved 2010-2011 ................................................................. 50  
  Future and Current Research at the ORC ................................................................. 54  
**Research Techniques Available at the Orthopaedic Research Center** ................................................................. 57  
**Research Techniques Available at the Orthopaedic Bioengineering Research Laboratory** ................................................................. 59  
**Scientific Publications and Presentations** ................................................................. 60  
**Funded Research Projects** ................................................................. 87  
**Revenue and Expense, FY10 to FY11** ................................................................. 92  
**Honors and Awards** ................................................................. 95  
**Editorial and Scientific Advisory Boards** ................................................................. 96  
**Professional Associations 2010-2011** ................................................................. 97  
**Advisory Board 2011** ................................................................. 99  
**Our Donors** ................................................................. 100  
**Summary of Research Projects 2010-2011** ................................................................. 105  
**Focus 1. Musculoskeletal Tissue Healing** ................................................................. 105  
  Consensus on Equine Tendon Disease: Building on the 2007 Havemeyer Symposium ................................................................. 106  
  Equine Bone Marrow-Derived Stem Cells: Comparing the Ilium and the Sternum ................................................................. 109  
  Equine Mesenchymal Stem Cells in Vitro Differentiation Capacity: Differences Between Sternum and Ilium ................................................................. 111  
  Equine Models of Articular Cartilage Repair ................................................................. 113  
  Evaluation of Intra-Articular Mesenchymal Stem Cells to Augment Healing of Microfractured Chondral Defects ................................................................. 116  
  Expansion of Adult Equine Bone Marrow Mesenchymal Stem Cells on Fibrinogen-Rich Protein Surfaces Derived From Blood Plasma ................................................................. 119
<table>
<thead>
<tr>
<th>Focus 2. Early Diagnosis of Bone and Joint Disease</th>
<th>Focus 4. Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Radiographic Changes in Young Cutting Horses</td>
<td>Effects of Platelet-Rich Plasma Composition on Anabolic and Catabolic Activities in Equine Cartilage and Meniscal Explants</td>
</tr>
<tr>
<td>A Descriptive Study of the Equine Proximal Interphalangeal Joint Using Magnetic Resonance Imaging, Contrast Arthrography, and Arthroscopy</td>
<td>Gene Therapy Approach to Treat Osteoarthritis Using AAVIRAP</td>
</tr>
<tr>
<td>The Relationship Between Radiographic Changes and Performance Outcomes in Cutting Horses</td>
<td>Influences of Age on scAAV Transduction of Chondrocytes and Synoviocytes</td>
</tr>
<tr>
<td>Suspensory Ligament Ultrasound Using Oblique Incidence for Identification of Ligament Anatomy With Comparison to MRI</td>
<td>Mesenchymal Stem Cell Proliferation and Expression of Growth Factors in Response to Extracorporeal Shock Wave Therapy Treatment</td>
</tr>
<tr>
<td>A Technique for Performing Radiographic Guided Needle Placement Into the Collateral Ligaments of the DIP Joint</td>
<td>Review of the Scientific Basis for Use of Intra-Articular Corticosteroids in the Horse</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Focus 3. Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease</th>
<th>Focus 5. Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of an <em>in Vitro</em> Model of Injury Induced Osteoarthritis in Adult Equine Cartilage Using Single Impact Compressive Overload</td>
<td>The Role of Aquatic Therapy in Managing Equine Osteoarthritis</td>
</tr>
<tr>
<td>Effects of Early Exercise on Metacarpophalangeal Joints in Horses</td>
<td>Use of an Equine Back Profiling System for Objectively Measuring Trunk Contours</td>
</tr>
<tr>
<td>Influence of Early Conditioning Exercise on the Development of Articular Surface Abnormalities in Cartilage Matrix Swelling Behavior in the Equine Middle Carpal Joint</td>
<td></td>
</tr>
<tr>
<td>Racing Surfaces White Paper</td>
<td></td>
</tr>
</tbody>
</table>

---
Mission

To investigate the pathogenesis, diagnosis, treatment, and prevention of musculoskeletal disease and injury for the betterment of both animals and humans.
Musculoskeletal Tissue Healing

Until now, we have principally addressed articular cartilage healing and will continue to do so, but we have enlarged the focus to include tendons, ligaments, and menisci.

Early Diagnosis of Bone and Joint Disease

This includes the development of novel imaging techniques (present and future), body fluid markers, and also molecular monitoring. The uses of these early diagnostic techniques include:

a. evaluation of the pathogenesis of bone and joint disease
b. early detection of disease processes
c. monitoring of therapy, with the long-term goal of preventing severe arthritis or failure

Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease

These investigations use both molecular tools such as reverse transcriptase PCR for evaluation of tissues in various stages of the disease, biomechanical and modeling studies, and imaging techniques including magnetic resonance imaging (MRI) and computed tomography (CT) to monitor early events in bone disease.

Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse

These include evaluation of biologic inhibitors of critical mediators in joint disease, novel protein therapies including PRP, gene therapy techniques, and mesenchymal stem cell therapies.

Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease

These include objective assessment of integrative therapies including manipulation and acupuncture for management of musculoskeletal disease and pain, as well as rehabilitative techniques of swimming, underwater treadmilling, and hyperbaric therapy.
The Orthopaedic Bioengineering Research Laboratory (OBRL) is an interdisciplinary research and educational effort bringing together engineers, clinicians, biologists, and scientists all over campus. The goal of the laboratory is to provide an environment for undergraduate and graduate education in Biomedical Engineering while advancing treatment and/or prevention of muscular, neuromuscular, or skeletal injury and/or disease. The primary research focuses include:

### Computational Simulation of Orthopaedic Conditions and Treatments

- a. Finite element analysis
- b. Cadaver and animal experiments to validate and augment the computational models

### Biomaterials Development

- a. Enhancing wear resistance of polymeric orthopaedic implant bearing materials
- b. Biopolymer derivative synthesis and characterization
- c. Bioactive and osteoinductive bone graft materials

### Engineering and Growth Factor Therapy for Cartilage and Bone Repair

- a. *In vitro* cell culture assessment
- b. Animal models to evaluate repair
- c. *In vitro* micro-assessment of mechanics of regenerated and normal tissue
- d. Development and assessment of biomaterial carriers

### Retrieval Analysis for Failure Assessment, Design Improvement, and Tissue Interface

- a. Orthopaedic implants
- b. Allograft bone composites
- c. Synthetic bone graft materials

### Biocompatibility and Biomaterial/Tissue Interface

- a. Interface biomechanics
- b. Tissue response to biomaterials

### Comparative Orthopaedics and Animal Models

- a. Animal model development and validation
- b. Comparison of human and other animal disease mechanisms and treatment efficacy
Biomechanical Analysis

Equipment available include; minibionix MTS machine, standard MTS, spine tester, biaxial tester
  a. Range of motion/kinematics
  b. Materials testing for shear strength
  c. Tension and compression analysis

Hard Tissue Structural Analysis

  a. MicroComputedTomography (μCT) - High resolution imaging of bone to determine bone volume and morphology.
  b. Non-decalcified hard tissue histology
  c. Histomorphometric analysis
The Musculoskeletal Research Program has been designated as a Program of Research and Scholarly Excellence at Colorado State University (initially designated in 2004 and renewed in 2008).

The Musculoskeletal Research Program covers all orthopaedic research at Colorado State University and includes:

1. Orthopaedic Research Center
2. Orthopaedic Bioengineering Research Laboratory
3. Small Ruminant Orthopaedic Research Laboratory
4. Orthopaedic Oncology
Colorado State University’s School of Biomedical Engineering (SBME) was formed in March 2007 to address society’s needs in bioengineering, one of the fastest emerging areas of scientific discovery. The SBME is an interdisciplinary program built on strong faculty and research programs in the Colleges of Applied Human Sciences, Engineering, Natural Sciences, and Veterinary Medicine and Biomedical Sciences. In particular, Drs. Sue James and Christian Puttlitz of the Orthopaedic Bioengineering Research Laboratory are co-coordinators of the program, and Drs. Wayne McIlwraith, Chris Kawcak, David Frisbie, Kevin Haussler, Laurie Goodrich, and John Kisiday of the Orthopaedic Research Center are core faculty members of the program in biomedical engineering research, which is rapidly expanding to all areas of human health. New technologies being developed at CSU are enabling people to continue active and healthy lifestyles. SBME students have the opportunity to collaborate with faculty from these four colleges and eleven departments, including the highly ranked Professional Veterinary Medicine program.

SBME now offers Master of Engineering, Master of Science, and Ph.D. degrees. The M.S. and Ph.D. programs focus on three main research areas: biomechanics and biomaterials; molecular, cellular, and tissue engineering; and medical diagnostics, devices, and imaging. Within these three areas, students participate in cutting-edge research from therapies and imaging modalities for fighting cancer to improving equipment used in open heart surgery. In order to allow flexibility to explore the multiple research possibilities, fully funded (stipend and tuition) lab rotation fellowships are available for first-year Ph.D. students.
C. Wayne McIlwraith, B.V.Sc. (Dist.), M.S., Ph.D., D.Sc. (Purdue), Dr. med. vet. (hc) (Vienna), D.Sc. (hc) (Massey), L.Dr. (Turin), Dvetmed (hc) (London), FRCVS, Diplomate ACVS, Diplomate ECVS, University Distinguished Professor, Director of the Orthopaedic Research Center, Barbara Cox Anthony University Chair in Orthopaedics; Department of Clinical Sciences

Research Interests: Equine orthopaedic surgery and joint disease (arthritis), biomarkers and cartilage repair research.

Dr. McIlwraith has been Director of the ORC since its inception, advancing the Orthopaedic Research Center’s reputation through research and publications, scientific presentations at key meetings throughout the world, and also through his fundraising efforts. He is a Past-President of the American College of Veterinary Surgeons, the American Association of Equine Practitioners, and the Veterinary Orthopedic Society, and a recognized leader in the field of equine orthopaedic research and surgery. He consults worldwide as a specialist equine surgeon and has received national and international honors for his contributions to joint research and clinical orthopaedics. Dr. McIlwraith is the author of four textbooks: Techniques in Large Animal Surgery (two editions), Equine Surgery: Advanced Techniques (two editions), Arthroscopic Surgery in the Horse (three editions) and Joint Disease in the Horse. He has authored or co-authored over 300 refereed publications and textbook chapters, and has presented more than 500 seminars both nationally and internationally to equine practitioners, veterinary specialty meetings, and human orthopaedic meetings.

Honors include: Colorado State University AAEP Faculty Award for Excellence in Teaching Equine Medicine and Surgery, 1981-82; Colorado State University Alumni Outstanding Faculty Award, 1983; DLT Smith Visiting Scientist, University of Saskatchewan, 1992; Inducted into the George H. Glover Gallery of Distinguished Faculty and Alumni, CSU, 1993; Awarded the Tierklinik Hochmoor Prize at Equitana, 10th Equine Veterinary Conference, Essen, Germany, 1993, for international contributions to Equine Orthopaedics; the Schering-Plough Award from World Equine Veterinary Association for Equine Applied Research for outstanding research work in equine locomotor disorders in Yokohama, Japan, 1995; Jacques Jenny Lecturer, Veterinary Orthopaedic Society, 1997; John Hickman Award for Equine Orthopaedics for leading work in arthroscopic surgery and equine joint disease research, British Equine Veterinary Association and Equine Veterinary Journal, Harrogate, England, 1997; Dr. med. vet. (honoris causa), University of Vienna, 1995; D.Sc., Purdue University, 2001; D.Sc. (hc), Massey University, 2003, Laurea Dr. (hc), Turin University 2004; Inducted into UK Equine Research Hall of Fame 2005; Frank Milne Lecturer (Lifetime Contribution Award), AAEP 2005; Founders Award for Lifetime Achievement, ACVS, 2006; Elastikon Equine Research Award, Johnson & Johnson and Grayson-Jockey Club Research Foundation, 2008-2009; Colorado State University Scholarship Impact Award 2007, University Distinguished Professor, Colorado State University 2009; Distinguished Life Member, AAEP, 2009; CSU Graduate School Ceremony, Grand Marshall, 2010; Dr. med. vet. (honoris causa), Royal Veterinary College, University of London, 2010; Life Member, New Zealand Equine Veterinary Association, 2011.
Gary M. Baxter, VMD, M.S., Diplomate ACVS, Professor, Assistant Department Head, Department of Clinical Sciences

Research Interests: Initial research focused on the cause and treatment of equine laminitis.

Dr. Baxter has most recently been involved with research evaluating the use of corticosteroids to treat horses with joint disease, the value of oral nutraceuticals as a preventative for osteoarthritis, and the use of the diode laser for surgical arthrodesis of the distal hock joints in horses with osteoarthritis (bone spavin). He has recently obtained funding to evaluate the efficacy of urinary bladder matrix (UBM; ACell) in a model of superficial digital flexor tendonitis in young horses.

Dr. Baxter has a national reputation as an equine surgeon and is actively involved in the American College of Veterinary Surgeons and American Association of Equine Practitioners. He was chairman of the 2001/2002 ACVS examination committee and was on the ACVS Board of Regents from 2003-2005. He has spoken many times at the American Association of Equine Practitioners annual meeting and is currently chairman of the equine lameness wet lab that is given every year. Dr. Baxter came to CSU as an Assistant Professor in Clinical Sciences in 1990, became an Associate Professor in 1994 and a Full Professor in 2000. He is currently an equine clinician and surgeon at the Veterinary Teaching Hospital Large Animal Chief of Staff and Equine Section Chief as well as Assistant Department Head in the department of Clinical Sciences overseeing the veterinary residency and graduate program. He has been actively involved in research since coming to CSU and has authored or co-authored nearly 100 scientific publications, review articles and book chapters. He is certified in Medical Acupuncture for Veterinarians.

Nicole Ehrhart, D.V.M., M.S., Diplomate ACVS, Professor, Department of Clinical Sciences

Research Interests: Guided Bone Regeneration, Allograft Healing, Distraction Osteogenesis, Limb Preservation, Bone Substitutes.

Dr. Ehrhart is one of 20 fellowship-trained veterinary surgical oncologists in the world. She is an Associate Professor in surgical oncology at the highly acclaimed Animal Cancer Center and has been a member of the CSU faculty since 2002. She is the director of the Musculoskeletal Oncology Lab and has been actively involved in limb preservation research and sarcoma research for the last twelve years. She has been an invited speaker at various venues for MD researchers in translation medicine, both nationally and internationally. In addition to her research, she has held several prestigious positions in the American College of Veterinary Surgeons (Scientific Program Chair, Residents Forum Chair, Examination Committee) and Veterinary Orthopedic Society (Scientific Program Chair). She has authored numerous publications on limb preservation and translational cancer research. She is currently the co-director of the Musculoskeletal Oncology section of the University-wide Cancer Supercluster.

Honors include: Bloomberg International Sports Medicine Lecturer, 2003; International Musculoskeletal Transplant Foundation Speaker, 2007; President, Veterinary Society of Surgical Oncology, 2008-2010.
David D. Frisbie, D.V.M., M.S., Ph.D., Diplomate ACVS, Associate Professor, Department of Clinical Sciences

Research Interests: Gene therapy, intra-articular therapeutics, new methods of cartilage repair.

Dr. Frisbie began his professional career after obtaining both a Bachelor's Degree in Biochemistry and a Doctor of Veterinary Medicine (D.V.M.) from the University of Wisconsin. He then went to New York, where he completed a Surgical Internship at Cornell University and began his research in joint disease. After completing his internship, Dr. Frisbie came to Colorado State University, where he continued his joint research, completed a Surgical Residency in Large Animal Surgery, and obtained a Master's Degree in Joint Pathobiology. After completion of his residency, Dr. Frisbie began his work on a novel way to treat joint disease using gene therapy, which was the focus of his Ph.D. During work on his Ph.D., Dr. Frisbie became Board certified in Large Animal Surgery and is a Diplomate of the American College of Veterinary Surgeons. He joined the faculty as an Assistant Professor in 1999 and was promoted to Associate Professor (with tenure) in 2007.

His current joint disease research is in two basic fields: 1) the evaluation of intra-articular therapeutics and their effects on joint disease (well known therapeutics he has evaluated include Legend, Adequan, Vetalog and Depo-Medrol, Orthokine (IRAP), stem-cells); 2) new methods of cartilage repair. These methods include cutting-edge technology aimed at arthroscopic repair of cartilage in the athletic horse. Dr. Frisbie is also exploring methods to augment fracture healing using gene transfer.

Honors include: Pfizer Animal Health Award for Research Excellence, 2001; American Association Equine Practitioners Presidential Award, 2011.
Faculty
College of Veterinary Medicine and Biomedical Sciences

**Laurie Goodrich**, D.V.M., M.S., Ph.D., Associate Professor, Department of Clinical Sciences

*Research Interests: Gene therapy, stem cell therapy.*

Dr. Laurie Goodrich joined the faculty at CSU College of Veterinary Medicine in April of 2005 as an assistant professor in Equine Surgery and Lameness. Prior to joining the faculty, she obtained her D.V.M. from the University of Illinois, and completed an internship in Large Animal Surgery and Medicine at Virginia-Maryland Regional College of Veterinary Medicine. Following her internship, Dr. Goodrich joined the faculty at Virginia for one year as an equine ambulatory clinician before going on to complete her residency in Equine Surgery at the Equine Medical Center in Leesburg, Virginia. She also obtained a Master of Science in Pharmacology during her residency. Dr. Goodrich subsequently joined the large animal surgery faculty at Cornell University’s College of Veterinary Medicine and became Board Certified in Large Animal Surgery in 1999. At Cornell, she rotated as Chief-of-Service for the Orthopedic, Soft Tissue, and Emergency Surgery Services. In 2000, she began a Ph.D. in Cartilage Repair and Gene Therapy. Her research included the transplantation of genetically modified chondrocytes (cells of cartilage) into the defects of cartilage to improve cartilage healing. She completed her Ph.D. in the fall of 2004. Dr. Goodrich’s clinical interests are broad and include joint disease, lameness, arthroscopy, laparoscopy, upper airway disease, and wound healing, neoplasia, and pain management. Dr. Goodrich’s research interests are primarily focused on cartilage healing and cartilage repair currently using growth factor gene therapy modalities. Side interests include bone healing and pain management research.

*Honors include:* Orthopaedic Research Society, New Investigator Research Award, Semi-Finalist, 2006; Recipient five-year NIH KO8 Training Grant, 2008-2013; Clinician of the Year Award for Teaching Excellence, 2011; Elastikon Equine Research Award, 2011.
Kevin K. Haussler, D.V.M., D.C., Ph.D., Assistant Professor, Department of Clinical Sciences

Research Interests: Etiopathogenesis and objective assessment of musculoskeletal pain, spinal dysfunction, and sacroiliac joint disorders. Spinal kinematics and conservative management of spinal-related disorders. Clinical research in the areas of veterinary chiropractic, acupuncture, physiotherapy modalities, and musculoskeletal rehabilitation.

Dr. Haussler obtained a Bachelor’s of Science in Agriculture from the University of Nebraska - Lincoln in 1984. He graduated in 1988 from The Ohio State University, College of Veterinary Medicine, followed by a small animal internship at the Sacramento Animal Medical Group in 1989. Dr. Haussler was a relief veterinarian for multiple small animal practices, emergency clinics, and humane societies from 1989 to 1994, when he became interested in pursuing further specialized training in the diagnosis and management of pain and musculoskeletal disorders in animals. He enrolled in Palmer College of Chiropractic - West, a human chiropractic program, to learn how to apply human chiropractic techniques and principles to the treatment of animals with musculoskeletal-related disorders. Dr. Haussler started veterinary chiropractic practice with equine and small animal patients in 1992. After graduating with a Doctor of Chiropractic (D.C.) degree from Palmer College of Chiropractic - West in 1993, Dr. Haussler obtained a Ph.D. degree in Comparative Pathology from the University of California - Davis, School of Veterinary Medicine in 1997. The focus of his Ph.D. research was the evaluation of the anatomy, pathology and biomechanics of the lower back and pelvis of Thoroughbred racehorses. He then went on to complete a post-doctorate investigating in-vivo equine spinal kinematics in 1999 at the Department of Anatomy, College of Veterinary Medicine at Cornell University. As a Lecturer at Cornell University until 2005, he was responsible for teaching equine anatomy, biomechanical research, and initiation of a clinical Integrative Medicine Service at the Cornell University Hospital for Animals in both the large and small animal clinics that provided chiropractic, acupuncture, and physical therapy services. Dr. Haussler's research studies included evaluation of in vivo equine spinal kinematics, paraspinal muscle morphometry and histochemistry, and the initiation of equine chiropractic research assessing pain and spinal flexibility.

Currently, Dr. Haussler is an Assistant Professor at Colorado State University at the Equine Orthopaedic Research Center with continued research interests in objective assessment of musculoskeletal pain and spinal dysfunction.

Honors include: James M. Wilson Award for Equine Research, School of Veterinary Medicine, University of California, Davis, 1997.
Faculty
College of Veterinary Medicine and Biomedical Sciences

**Thomas R. (Tod) Hansen**, B.S., M.S., Ph.D., Professor and Director, Animal Reproduction and Biotechnology Laboratory

Collaborating on equine genomic research.

**Ashley Hill**, D.V.M., MPVM, Ph.D., Assistant Professor, Department of Clinical Sciences

*Research Interests:* Epidemiology of equine athletic injuries, simulation modeling. Research topics have included the effect of mild/moderate injury on the subsequent development of catastrophic injury; the effects of exercise and horseshoe type on development of catastrophic injuries; and simulation modeling of the incidence of metacarpal condylar fractures in California.

Dr. Hill obtained a Bachelor’s of Arts in English literature at Haverford College. She graduated in 1998 from the University of California, Davis School of Veterinary Medicine, then completed a Master’s in Preventive Veterinary Medicine (MPVM) at UC Davis in 1999, and a Ph.D. in Epidemiology in 2003. Theses for both degrees focused on the epidemiology of forelimb injuries in Thoroughbred racehorses. Dr. Hill came to CSU as an Assistant Professor in the Department of Clinical Sciences in 2006. She is interested in the relationship between exercise, rest, pre-existing injury, and the development of severe or catastrophic injuries. She is also interested in return to function following severe injuries or surgery.

*Honors include:* Mark Gearhart Award for Best Graduate Student Manuscript, Association of Veterinary Epidemiology and Preventative Medicine, 2003.
Faculty
College of Veterinary Medicine and Biomedical Sciences

Christopher E. Kawcak, D.V.M., Ph.D., Diplomate ACVS, Professor, Iron Rose College Chair in Musculoskeletal Research, Department of Clinical Sciences

Research Interests: Subchondral bone histomorphometry, biomechanical modeling of joint loading, and imaging of early subchondral disease in pathogenesis of joint disease.

Dr. Kawcak joined our faculty in 1998 as an Assistant Professor after completing his Ph.D. He is now an Associate Professor in the Iron Rose Ranch Chair in the ORC, and is expanding his duties to include clinical work in the VTH and veterinary student teaching. His collaborations with the Biomedical Engineering Program at CSU, the Mechanical Engineering Program at the University of Texas, the Department of Chemical and Materials Engineering, The University of Auckland, and other laboratories worldwide have allowed for more sophisticated assessment of joint disease and healing. Dr. Kawcak is currently involved with research projects evaluating a new type of horseshoe, the effects of exercise on the incidence of musculoskeletal injury, and the development of computerized models of joints. Specifically, he is collaborating with Dr. Reiser and Puttlitz to develop a functional model of the fetlock joint in horses. He has over 100 publications and has been an invited speaker in the U.S. and Europe and is involved with the American Association of Equine Practitioners and the American College of Veterinary Surgeons. He currently sits on the Research Committee for the Grayson Jockey Club Research Foundation.

Honors include: Ken Atkinson Scholar in the College of Veterinary Medicine and Biomedical Sciences, 1995-98; Pfizer Award for Research Excellence, 2003; Elastikon Equine Research Award, Johnson & Johnson Consumer Products Company and Grayson-Jockey Club Research Foundation, 2007.

John Kisiday, Ph.D., Assistant Professor, Department of Clinical Sciences

Research Interests: Mechanobiology of cartilage and repair tissue, tissue engineering.

Dr. John Kisiday was hired as an Assistant Professor in Clinical Sciences in a research and teaching appointment at the ORC in January 2005 after doing his Ph.D. at MIT in Bioengineering and a collaborative post-doctorate of fellowship with CSU and MIT. His doctorate work primarily focused on mechanobiology, the study of the impact of physical deformation on cells, and the use of a novel peptide-based material (discovered at MIT in the early 1990s), as a three-dimensional scaffold for cartilage tissue repair. Dr. Kisiday’s post-doctorate work explored chondrogenesis of equine stem cells for potential applications to equine and human therapies. The research Dr. Kisiday will focus on at the ORC will involve cartilage tissue engineering therapies and mechanobiology in order to build the bridge between basic laboratory studies and beneficial animal models.

Honors include: Young investigator Award, Engineering Tissues Workshop, Hilton Head, 2003; NIH Biotechnology Pre-doctoral Training Grant, 2001-2003; MIT President Pre-doctoral Fellowship, 1999.
Richard D. Park, D.V.M., Ph.D., Diplomate ACVR, Professor, Department of Radiological Health Sciences

*Research Interests:* Imaging in orthopaedic disease, including radiology, ultrasonography, computerized tomography (CT) and magnetic resonance imaging (MRI).

Dr. Park is internationally renowned in the field of imaging (previously called radiology). He has been actively involved in the Orthopaedic program, acquiring expertise in CT and CT osteoabsorptiometry (used for quantitative assessment of bone density), as well as the introduction of magnetic resonance imaging (MRI) for imaging in orthopaedic research.

Natasha Werpy, D.V.M., Diplomate ACVR, Assistant Professor, Department of Clinical Sciences

*Research Interests:* Imaging in orthopaedic disease, including radiology, ultrasonography, computerized tomography (CT) and magnetic resonance imaging (MRI).

Dr. Werpy earned her D.V.M. from CSU in 1999, followed by an internship at the San Luis Rey Equine Hospital in California which she completed in 2000. In 2003, she completed a residency directed by Dr. Norman Rantanen in collaboration with CSU, which focused on equine imaging. Dr. Werpy joined the CSU faculty in 2004, overseeing research imaging and directing MRI examination of clinical patients at the Orthopaedic Research Center. Her current research centers on MRI, ultrasound and histology correlation in order to develop imaging protocols for clinical patients.
Susan P. James, Ph.D., Associate Professor, Department of Mechanical Engineering

Research Interests: Biomaterials, wear of orthopaedic implants, tissue engineering of cartilage.

Dr. James joined the faculty at CSU in 1994 after receiving her Ph.D. in polymer science and technology from Massachusetts Institute of Technology in September 1993 and working for a year as an engineer at the Failure Analysis Associate in California. She initiated the Biomedical Engineering Program at CSU and served as the program’s director from 1999 to 2003, and is currently the Director of BEP. CSU and the College of Engineering recently invested in and institutionalized BEP, which serves multiple colleges on campus. Dr. James is also the Associate Department Head of Mechanical Engineering. Her current research is focused on novel hyaluronan/polyethylene composites for use in joint replacements, cartilage repair and other biomedical applications. She teaches courses in biomaterials, biomedical engineering and materials science at both the undergraduate and graduate level.

Honors include: Outstanding Faculty Member, American Society of Mechanical Engineers, Engineering Faculty Award of Excellence at CSU, 1997; Semifinalist for Wallace H. Coulter Award for Medical Innovation and Entrepreneurship, Georgia Tech, Atlanta, Georgia, 2002; Women and Minorities in Engineering Appreciation Award at CSU, 2005; Jack E. Cermak Advising Award at CSU, 2006; George T. Abell Outstanding Faculty Teaching and Service Award at CSU, 2006; Nominated for CSU Best Teacher Award, 2006.
Christian Puttlitz, M.S., Ph.D., Associate Professor, Department of Mechanical Engineering and School of Biomedical Engineering

Research Interests: Orthopaedic biomechanics, tissue and biomaterials interactions.

Dr. Puttlitz joined the CSU faculty in 2005 after spending 4 years as an Assistant Professor in the Department of Orthopaedic Surgery at the University of California, San Francisco. After receiving his Ph.D. in Biomedical Engineering at the University of Iowa in 1999, Dr. Puttlitz performed a 2 year Postdoctoral Fellowship in San Francisco. Dr. Puttlitz's research interests are mainly focused on using experimental and computation techniques to investigate orthopaedic conditions and their treatments. Examples of his current research include using the finite element method to study how loading changes in the spine following intervertebral disc replacement. Dr. Puttlitz teaches an undergraduate course in bioengineering and a graduate biomechanics class.


Kenneth Reardon, Professor, Department of Chemical Engineering, College of Engineering, Colorado State University

Research Interests: Collaborating on proteomic studies.
Faculty
College of Applied Human Sciences

**JASON BRUEMMER, Ph.D., Associate Professor, Department of Animal Science**

**Research Interests:** Maternal recognition, follicular cell differentiation, sperm physiology.

Dr. Jason Bruemmer, Assistant Professor, was born and raised in El Paso, Texas. He received his B.S. in Animal Science and his M.S. in Physiology of Reproduction from Texas A&M University, and his Ph.D. in Reproductive Physiology from New Mexico State University.

While at Texas A&M, Dr. Bruemmer served as a lecturer and manager of the horse farm for more than three years. He bred 60 to 75 mares a year, in addition to teaching reproduction, reproductive short courses, all levels of equine science, and conducting research in nutrition and exercise physiology. During his stay at NMSU, Dr. Bruemmer again taught many equine classes and conducted research in a variety of species including horses, cattle, goats, and sheep. Further studies were conducted at the University of Arizona Medical School.

Dr. Bruemmer joined Colorado State University in 1996. He teaches Equine Management, Equine Production and Industry, and other courses, and continue to conduct research in reproductive physiology with an emphasis in follicular dynamics of the mare, the area in which he did his dissertation work at New Mexico State University.

---

**RAOUL F. REISER, II, Ph.D., Associate Professor, Department of Health & Exercise Science**

**Research Interests:** Musculoskeletal biomechanics, fabrication and implementation of custom equipment/instrumentation.

Dr. Reiser completed his B.S. in Mechanical Engineering at Cornell University, his M.A. in Kinesiology with a specialization in Biomechanics at the University of Texas at Austin and his Ph.D. in Mechanical Engineering at Colorado State University. The emphasis of his dissertation was the biomechanics of recumbent cycling and the power output capabilities, pedal force measuring and analysis system, and inverse-dynamics analysis of recumbent versus standard cycling. After working as an Assistant Professor at the University of Wyoming in the Division of Kinesiology and Health, Dr. Reiser began work as an Assistant Professor at CSU in the Department of Health and Exercise Science in August of 2002.

**Honors include:** Elected Fellow, American College of Sports Medicine, 2007; Colorado State University College of Applied Human Sciences Tenure Track Faculty Scholarly Excellence Award, 2007; CSU College of Engineering’s Outstanding Research Assistant, 2000; GAANN Three-Year Fellowship, 1997; CSU Graduate Fellowship, 1997; NSCA Challenge Scholarship, 1996.
Jerry Black, D.V.M., Director of Undergraduate Programs, Equine Sciences

Dr. Black completed his D.V.M. degree in 1971 from CSU. He co-founded Pioneer Equine Hospital in Oakdale, Calif., for 34 years from which he retired in 2010 and then accepted the position of Director of Undergraduate Programs in 2010.

Hariharan K. Iyer, B.S., M.S., Ph.D., Professor, Department of Statistics and Center for Bioinformatics

Honors include: Fellow of the American Statistical Association, the College of Natural Sciences Graduate Teaching Award, 1993; Fellow Cooperative Institute for Research in the Atmosphere (CIRA), 2004-present.

Ann Hess, Ph.D., Assistant Professor, Department of Statistics and Center for Bioinformatics

Dr. Hess completed her M.S. and Ph.D. in Statistics at CSU. Her research interests are mainly focused on bioinformatics and experimental design. She has been involved in a number of microarray studies as well as other bioinformatics projects.
Affiliate Faculty

Elwyn Firth, B.V.Sc., Ph.D., Diplomate ACVS, Professor and Director, Massey Equine Research, Massey University, Palmerston North, New Zealand

Dr. Firth is an internationally renowned equine orthopaedic researcher. He has worked closely with Dr. McIlwraith for many years, and, more recently, has become closely involved in a collaborative effort with Drs. McIlwraith and Kawcak, as well as other researchers at Massey University, the University of London, and Utrecht in the Global Equine Research Alliance.

Clifford Michael Les, D.V.M., M.S., Ph.D., Senior Staff Investigator, Bone and Joint Center Henry Ford Health System

Dr. Les is a Senior Staff Investigator at the Bone and Joint Center, Henry Ford Health System in Detroit, Michigan. He is also a member of the Michigan Bone Center at the University of Michigan’s School of Medicine and an adjunct Assistant Professor in the Department of Anatomy and Cell Biology at the Wayne State University School of Medicine. Dr. Les received his D.V.M. at the University of California, Davis; his M.S. in Veterinary Biosciences at the University of Illinois, Urbana-Champaign; and his Ph.D. in Comparative Pathology at the University of California, Davis. His dissertation work was on material heterogeneity in the equine metacarpus and biomechanical consequences.

Alan J. Nixon, B.V.Sc., Ph.D., Diplomate ACVS, Professor of Orthopaedic Surgery, Director of the Comparative Orthopaedic Laboratory, Cornell University

Dr. Nixon is a Professor of Orthopaedic Surgery and Director of the Comparative Orthopaedic Laboratory at Cornell University, Ithaca, New York. His research focus is in chondrocyte metabolism and cartilage repair methods using chondrocyte or pluripotent stem cell transplantation. Dr. Nixon's research group has focused on the cloning of growth factor molecules for use in gene therapy protocols, inserting the growth factor gene into cartilage cells at the time of transplantation of synovial cells by direct joint injection. The laboratory group also studies the molecular changes associated with osteochondritis dissecans (OCD) in horses and man, and investigates treatment methods for tendonitis in athletes.

Dr. Nixon's current interests include the use of combination gene therapy using stimulatory growth factors, and, in collaboration with the Orthopaedic Research Center at Colorado State University, the combined use of interleukin receptor antagonist gene therapy to diminish degradation in arthritic joints.

Dr. Rodkey was formerly Director of Orthopaedic Research at the Letterman Institute in San Francisco. He is currently Scientific Director for Regen Biologics and the Steadman Philippon Research Foundation. Dr. Rodkey is one of three veterinarians with a long-term reputation in human orthopaedic research and collaborated with the CSU Orthopaedic Research Center on articular cartilage resurfacing research.

Honors include: Excellence in Research in Basic Science Award (American Orthopaedic Society for Sports Medicine); H. Edward Cabaud Memorial Award for Ligament Research (American Orthopaedic Society for Sports Medicine; Co-recipient of Albert Trillat Award for Excellence in Knee Research (International Society of the Knee); U.S. Army Research and Development Achievement Award (Secretary of the Army); H. Edward Cabaud Memorial Award for Knee Research (2nd) (American Orthopaedic Society for Sports Medicine).

Jude Samulski, Ph.D., Professor, Department of Pharmacology, University of North Carolina, Chapel Hill, N.C.

Dr. Jude Samulski is an important collaborator to our group investigating gene therapy at the ORC. He is a Professor in the Department of Pharmacology and the Director of the Gene Therapy Center at the University of North Carolina at Chapel Hill. Dr. Samulski earned his B.S. at Clemson University, a Ph.D. at the University of Florida in Molecular Biology. He did two post docs at SUNY in New York and Princeton University, respectively. He then was on faculty at University of Pittsburgh from 1986-1992 and recruited to UNC as Associate Professor in Pharmacology and Director of the Gene Therapy Center.

Honors include: Outstanding Young Men of America Award and the President's Distinguished Research Award; American Society of Gene Therapy Outstanding Achievement Award, 2009.

Kevin Shelburne, M.S., Ph.D., Associate Research Professor, University of Denver, Department of Mechanical and Materials Engineering; Affiliate Faculty Colorado State University, Department of Biomedical Engineering and Veterinary Medicine

Kevin Shelburne received his bachelor’s and master’s degrees in Mechanical Engineering from Texas A&M University in 1985 and 1988, respectively. He then worked as a Systems Engineer at McDonnell Douglas Space Systems Company, Houston, Texas, where he designed and tested assembly and servicing tasks and robotics systems for the International Space Station. Kevin completed his Ph.D. in Mechanical Engineering at the University of Texas at Austin in May 1997. The focus of his dissertation was the computer modeling and analysis of the normal and reconstructed knee joint. Following his dissertation, Kevin worked for Lockheed Martin Space Systems in the design of new satellite launch vehicles.

In 2000, he joined the Biomechanics Research Laboratory at the Steadman Philippon Research Institute. Kevin is the author of numerous articles regarding the modeling and simulation of knee mechanics and is a current member of the American Society of Biomechanics and the American Society of Mechanical Engineers. Dr. Shelburne joined the University of Denver in 2010.

Honors include: Journal of Biomechanics Award from the World Congress of Biomechanics, 2002.
Collaborators

Jonathan Belton, B.A., D.Phil., Professor, Department of Chemical and Molecular Biology, University of Oxford

Dr. Belton's research focuses on the molecular and cellular mechanisms underlying the regulation of cardiac metabolism. He has made significant contributions to our understanding of the role of mitochondrial dysfunction in cardiovascular disease.

Honors include: Senior Lecturer in Chemical and Molecular Biology, University of Oxford, 2000; Elected Fellow of the British Society for Cardiological Research, 2004.

Wendy Williams, B.A., Ph.D., Associate Professor, Department of Cell and Molecular Biology, University of Manchester

Dr. Williams' research interests lie in the field of cellular and molecular biology, with a focus on the role of cell signaling pathways in the regulation of cell growth and survival. She has published extensively on the topic of apoptosis and its regulation in various cell types.

Honors include: Lecturer in Biological Sciences, University of Manchester, 2000; Elected Fellow of the Royal Society of Biology, 2004.
Collaborators

Chris Evans, Ph.D., Professor, Brigham and Women's Hospital, Center for Molecular Orthopaedics, Harvard University, Boston, Mass.

Dr. Evans is world-renowned in the area of human joint disease research, particularly in the use of gene therapy to treat arthritis. He was an outside member on the Ph.D. Committee of Dr. Dave Frisbie when he worked on his gene therapy with interleukin-1 receptor antagonist to treat equine traumatic arthritis and osteoarthritis. He continues to collaborate with the scientists at the Orthopaedic Research Center at CSU.

Honors include: Kappa Delta Award, AAOS; the Cabaud Award, American Society for Sports Medicine; the Henry Kunkle Award, American College of Rheumatology; Osteoarthritis Research Award, OARSI; and the Synos Award for Orthopaedic Research (with Paul Robbins), Synos Foundation.

Steven C. Ghivizzani, Ph.D., Associate Professor, Research Division; Departments of Orthopaedics and Rehabilitation and Molecular Genetics & Microbiology, Gene Therapy Laboratory, University of Florida, Gainesville, Fla.

Dr. Ghivizzani is an Associate Professor in the Gene Therapy Laboratory at the University of Florida. He has collaborated with the Orthopaedic Research Center on several projects. Currently, he is working with the CSU researchers on adeno-associate virus and lenti virus delivery of interleukin-1 receptor antagonist.

Alan J. Grodzinsky, Sc.D., Professor, Director of the MIT Center for Biomedical Engineering, Department of Mechanical Engineering and Biological Engineering Division, MIT

Dr. Grodzinsky is a Professor in the departments of Electrical, Mechanical, and Biological Engineering at the Massachusetts Institute of Technology. He is also the Director of the MIT Center for Biomedical Engineering. Dr. Grodzinsky research focuses on the mechanobiology of articular cartilage, including the response of native tissue to physiological and injurious loading as well as the mechanobiology of neo-tissue development for applications to cartilage resurfacing.

Charles Ho, M.D., Ph.D., Director Imaging Research, Scientific Advisory Board Steadman Philippon Research Institute

Dr. Ho is experienced and active in musculoskeletal and sports medicine imaging and research, particularly in musculoskeletal Magnetic Resonance Imaging. He is a member of the Radiological Society of North America, the American Roentgen Ray Society, the American Academy of Orthopaedic Surgeons, the American Orthopaedic Society for Sports Medicine, and the ACL Study Group, among other professional organizations. He has published numerous papers and book chapters in the radiologic and orthopedic literature, and presented numerous papers internationally in radiologic and orthopedic conference proceedings. Dr. Ho is Director of Imaging Research and a member of the Scientific Advisory Board of the Steadman Philippon Research Institute in Vail, Colo. He has served as Radiologic Consultant for the San Francisco 49ers, the San Francisco Giants, Cleveland Indians, Denver Broncos, Colorado Rockies, the U.S. Ski Team, and the U.S. Decathlon Team.
Collaborators

Chris Little, B.Sc., B.V.M.S., M.Sc., Ph.D., Diplomate ACVS, Associate Professor and Director, Raymond Purves Bone & Joint Research Laboratories, University of Sydney Department of Orthopaedics & Traumatic Surgery, Royal North Shore Hospital

Dr. Little received his veterinary training at Murdoch University in Western Australia, where he also undertook an internship in equine medicine and surgery (1978-1984). He then completed a residency in large animal surgery and an M.Sc. studying arthritis in horses at the University of Minnesota. Chris was appointed to the faculty at the Ontario Veterinary College, University of Guelph and during this time passed his certifying examinations to become a Diplomate of the American College of Veterinary Surgeons (1990). He then moved to back to Australia and was awarded a Ph.D. degree from the Faculty of Medicine at the University of Sydney in 1996. Following a 5 year postdoctoral position at Cardiff University School of Biosciences in the UK, he was granted a two year Arthritis Foundation of Australia Ulysses Research Fellowship at the University of Melbourne. In 2004 he was appointed as Director of the Raymond Purves Bone & Joint Research Laboratories at the Royal North Shore Hospital, University of Sydney. Chris's research interests centre on the biochemical and molecular mechanisms of cartilage and more recently tendon breakdown in disease. In particular he has studied changes in aggrecan and small proteoglycan biosynthesis and degradation and the proteolytic pathways responsible in cartilage breakdown in arthritis and during tendon degeneration. Chris has been extensively involved in the development and use of neoepitope antibody methodologies, novel animal models, and most recently genetically modified mice, to study disease pathways. He has received over $3 million in basic and industrial research grants and has authored/co-authored 53 papers and six book chapters.

Marcus G. Pandy, Ph.D., Professor, Chair of Mechanical and Biomedical Engineering, Department of Mechanical and Manufacturing Engineering, University of Melbourne, Melbourne, Australia

Dr. Pandy is a Professor at the University of Melbourne and a leader in the study of musculoskeletal biomechanics. He is interested in applying the principles of mechanics and control theory to describe and explain the relationships between structure and function of the human body. By combining data obtained from biomechanical experiments with detailed computer models of the neuromusculoskeletal system, he is able to determine muscle, ligament, and joint loading during movement. Dr. Pandy is currently collaborating with CSU Orthopaedic researchers to develop a computer model of the entire equine forelimb to aid in the early detection of joint disease in horses.

Michael “Mick” Peterson, Ph.D., Associate Professor, University of Maine

Dr. Peterson is Libra Foundation Professor of Mechanical Engineering at the University of Maine. Prior to coming to the University of Maine, he was a faculty member at Colorado State University and was a Post-Doctoral Researcher at Northwestern University. He has also worked in industry at General Motors and General Dynamics Corp. His Ph.D. is in Theoretical and Applied Mechanics from Northwestern University in Illinois, and he also holds a B.S. in Mechanical Engineering from General Motors Institute (now Kettering University) and an M.S. in Theoretical and Applied Mechanics from Northwestern University. He has also done additional graduate work in Mechanics, Materials, and Mathematics from Yale University, Cornell University, and the University of Connecticut. His primary expertise is in the dynamic responsive materials and waves in solids.
A. Robin Poole, Ph.D., Professor Emeritus, Director of Joint Diseases Laboratory, McGill University, Montreal, Quebec

Dr. Poole is a pioneer in the use of markers in the early diagnosis of arthritis before other imaging techniques can reveal change. He is a world-renowned arthritis researcher, having previously led arguably the most prominent laboratory in the world in this area of research. He was the mentor of Dr. Billinghurst, and Dr. McIlwraith spent time with him on sabbatical leave. He is the co-author of two publications from the CSU Orthopaedic Laboratory. He is now retired but continues to be active and most recently was a keynote speaker at our 2009 Havemeyer Symposium on Biomarkers.

Honors include: Kappa Delta Award of the American Academy of Orthopaedic Surgeons, the Howard and Martha Holley Research Prize in Rheumatology, Carol Nachman International Prize for Rheumatology.

Christopher B. Riley, B.Sc.(Physics), B.V.Sc. (Hons), M.Sc., Ph.D., Diplomate ACVS Associate Professor and Service Chief of Large Animal Surgery Department of Health Management, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown PE Canada

Following military service in the Royal Australian Air Force, Dr. Riley received degrees in physics and veterinary medicine from the University of Melbourne, Australia. After time spent in an internship and private practice in Australia, he completed a surgical residency at the University of Saskatchewan in Canada. Concurrently he completed M.Sc. and Ph.D. degrees in the fields of tendon in-vitro biology and biochemistry. Dr. Riley then worked at briefly at Iowa State University and in private practice during which time he became Board certified as a Diplomate in the American College of Veterinary Surgeons. He joined the faculty at the Atlantic Veterinary College, Canada in 1999 where he is currently an Associate Professor and Service Chief of Large Animal Surgery. Following the granting of tenure, Dr. Riley has focused his research on the development of biomedical tests for animal diseases using the emerging technologies of infrared spectroscopy and bioinformatics. He established the first laboratory of its kind in Canada, developed to investigate the veterinary potential biomedical infrared spectroscopy. Dr. Riley has a special interest in orthopedic disease, but is also interested exploring the full potential of infrared technology as it applies to veterinary and comparative medicine. Dr. Riley has partnered with the workers from the Orthopaedic Research Center at Colorado State University, and the Institute for Biodiagnostics, National Research Council of Canada, to develop the first infrared test for equine traumatic arthritis in the world. He looks further to continued collaboration and advances in this new field of research.

Paul D. Robbins, Ph.D., Professor of Molecular Genetics and Biochemistry and Orthopaedic Surgery, University of Pittsburgh School of Medicine, Director of the Vector Core Facility and Basic Research for the Molecular Medicine Institute

Dr. Robbins is currently a Professor of Molecular Genetics and Biochemistry and Orthopaedic Surgery at the University of Pittsburgh School Of Medicine. He is also Director of the Vector Core Facility and Director of Basic Research for the Molecular Medicine Institute. He received his Ph.D. from the University of California at Berkeley and worked as a post-doctoral fellow at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is an Associate Editor for Cancer Research and Gene Therapy as well as on the Editorial Boards for Cancer Gene Therapy, The Journal of Gene Medicine, Arthritis Research, and Genes & Immunity. Dr.
Collaborators

Robbins has co-authored over 180 peer-reviewed manuscripts, 110 book chapters and reviews, and has edited two books on gene therapy. He is a member of the PathB study section, the Telethon Scientific Review Committee and the Scientific Review Board of National Gene Vector Laboratory.

-------------------------------

**Robert Lie-Yuan Sah**, M.D., Sc.D., Professor and Vice-Chair of Bioengineering Affiliate in Orthopaedics, UCSD

Dr. Sah received his Sc.D. in Biomedical Engineering from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School. He did postdoctoral work at Massachusetts General Hospital in Orthopaedic Bioengineering. He is currently a reviewer for Arthritis Foundation, NIH, NSF and Orthopaedic Research & Education Foundation, and the 2004 Chair of Gordon Research Conference on Musculoskeletal Biology and Bioengineering.

*Honors include:* “Mechanical Blueprint for Cartilage” cited as one of the Great Advances in Scientific Discovery in Disease and Injury Treatment, The Science Coalition, 1998; Accelerated academic advancements, UCSD, 1999 and 2001; American Academy of Orthopaedic Surgeons Kappa Delta Young Investigator Award, 2001; American Academy of Orthopaedic Surgeons Best Poster Award, 2003.

-------------------------------

**Kevin Shelburne**, M.S., Ph.D., Assistant Director of the Biomechanics Research Laboratory, Steadman Philippon Sports Medicine Foundation, Vail, Colo.; Faculty Colorado State University, Department of Biomedical Engineering and Veterinary Medicine; Associate Research Professor at the University of Denver

Kevin Shelburne received his bachelor's and master's degrees in Mechanical Engineering from Texas A&M University in 1985 and 1988, respectively. He then worked as a Systems Engineer at McDonnell Douglas Space Systems Company, Houston, Texas, where he designed and tested assembly and servicing tasks and robotics systems for the International Space Station. Kevin completed his Ph.D. in Mechanical Engineering at the University of Texas at Austin in May 1997. The focus of his dissertation was the computer modeling and analysis of the normal and reconstructed knee joint. Following his dissertation, Kevin worked for Lockheed Martin Space Systems in the design of new satellite launch vehicles.

In 2000, he joined the Biomechanics Research Laboratory at the Steadman Philippon Research Institute. Kevin is the author of numerous articles regarding the modeling and simulation of knee mechanics and is a current member of the American Society of Biomechanics and the American Society of Mechanical Engineers.

*Honors include:* Journal of Biomechanics Award from the World Congress of Biomechanics, 2002.
Roger K.W. Smith, M.A. VetMB Ph.D. DEO DipECVS MRCVS, Professor of Equine Orthopaedics, Royal Veterinary College, London, United Kingdom

Roger Smith qualified as a veterinary surgeon from Cambridge University in 1987 and, after two years in practice, returned to academia to undertake further clinical training as a Resident in Equine Studies at the Royal Veterinary College. Following his residency, he undertook a three-year research project culminating in the award of a Ph.D. for his studies on the extracellular matrix of equine tendon. He remained at the Royal Veterinary College, first as a Lecturer in Equine Surgery, then as Senior Lecturer in Equine Surgery before his appointment to a Professorship in December 2003. He holds the Diploma of Equine Orthopaedics from the Royal College of Veterinary Surgeons, and is both a Diplomate of the European College of Veterinary Surgeons and a Royal College of Veterinary Surgeons Specialist in Equine Surgery. He currently divides his time equally between running a specialist orthopaedic service within the Royal Veterinary College and continuing to direct research into equine tendon disease. His main area of research is understanding the mechanisms of tendon ageing but also has projects investigating the epidemiology of tendon disease in the horse, the development of a serological assay for tendonitis, and stem cell therapy for tendons in conjunction with a commercial company, VetCell Bioscience Ltd.

J. Richard Steadman, M.D., Head of the Steadman Clinic and Steadman Philippon Research Institute, Vail, Colo.

Dr. Steadman graduated from the University of Texas Southwestern Medical School in Dallas. Following internship, two years in the army, and an orthopaedics residency at Charity Hospital in New Orleans, La., Dr. Steadman moved to Lake Tahoe, Calif., where he practiced orthopaedics with increasing emphasis on the treatment of knee disorders. While living there, he was named Chief Physician for the United States Ski Team. During his time at Lake Tahoe, Dr. Steadman developed special surgical techniques which allowed several ski team members to return to competition and win Olympic medals and championships. At Lake Tahoe, Dr. Steadman started a non-profit sports medicine foundation in order to conduct research in knee surgery and rehabilitation projects. That organization exists today as the Steadman Hawkins Sports Medicine Foundation in Vail, Colo. In 1990, Dr. Steadman moved to Vail, Colo., and was joined in practice there by Dr. Richard Hawkins, a specialist in shoulder disorders. By this time, Dr. Steadman had limited his practice to the surgical and conservative treatment of knee disorders. Today, Dr. Steadman is regarded as a world-renowned human orthopaedic surgeon. He is a prominent knee surgeon and the inventor of two significant new techniques in orthopaedics. His Foundation has supported several research projects at CSU. Dr. Steadman serves as a consultant regarding clinical relevance of our research work, and the CSU orthopaedic research lab has done controlled studies investigating his techniques used in human orthopaedic surgery.
Collaborators

Brigitte von Rechenberg, Dr. med. vet., Diplomate ECVS, University of Zurich

Honors include: SSRS Award 1996-1997 for the abstract, “Spontaneous production of nitric oxide and prostaglandin E₂ in media of cartilage explants.”

René van Weeren, D.V.M., Ph.D., Diplomate European College of Veterinary Surgeons and Specialist in Equine Surgery, Royal Dutch Veterinary Association; Associate Professor, Department of Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands

Paul René van Weeren (1957) graduated in 1983 “cum laude” from the Utrecht University Veterinary Faculty (The Netherlands). He obtained his Ph.D. degree in 1989 and became a Diplomate of the European College of Veterinary Surgeons in 1994. Currently he is the coordinator of scientific research of the Department of Equine Sciences of the Faculty of Veterinary Medicine of Utrecht University and a member of the Management Board of the Department. His special interest is in equine orthopaedics. He has been a supervisor of 14 Ph.D. students, who have obtained their degree in the past years and currently supervises five Ph.D. students, who will be graduating within the next few years. He is a member of the board of reviewers of the American Journal of Veterinary Research and a member of the advisory board of Equine Veterinary Journal. He has been external examiner for Ph.D. students abroad at various occasions in the UK, France, Austria, Sweden, and Finland. He is author or co-author of more than 150 peer-reviewed scientific publications or book chapters.
Kirk McGilvray, Ph.D.

Kirk is currently working as a Post-doc at the OBRL. He is a Colorado native and received his B.S., M.S., and Ph.D. from CSU. His research efforts included soft tissue biomechanics and computational simulations, focusing on heart valve replacements, spine instrumentation, and cardiovascular mechanics. Kirk's overreaching goals are to improve surgical techniques and cardiovascular health through solid research efforts in the field of biomedical engineering.

Katie Seabaugh, D.V.M.

Katie received her D.V.M. degree from Washington State University. Following graduation she performed an internship at Pioneer Equine Hospital, a private equine referral practice in Oakdale, Calif. After completing a residency in equine surgery and lameness at CSU, she is currently a post-doctoral fellow.

Snehal Shetye, M.S., Ph.D.

Snehal obtained his B.E. in Mechanical Engineering from the University of Pune in India. He moved to Fort Collins for higher studies and obtained his M.S. in Computer-Assisted Engineering under Dr. David Alciatore in the Mechanical Engineering department. Snehal completed his Ph.D. in Biomechanical Engineering under Dr. Christian Puttlitz. His Ph.D. project involved the development of a finite element model of the canine antebrachium. This model will be instrumental in developing novel designs for limb-sparing endoprostheses for the treatment of canine distal radius osteosarcoma.
**Erin Contino, D.V.M.**

Dr. Erin Contino joined the ORC as an Equine Sports Medicine resident in July 2011. Erin is originally from Concord, Calif., but moved to Fort Collins to attend CSU, graduating in 1999 with a Bachelor's Degree in equine sciences. In 2009, she completed a Master's Degree in equine radiology with Drs. McIlwraith and Park researching abnormal radiographic findings in yearling and two-year-old cutting horses. After graduating from CSU with her D.V.M. degree, she did an internship at Pioneer Equine Hospital in California and is now returning for the Equine Sports Medicine residency.

**Dora Ferris, D.V.M.**

Dr. Ferris started an Equine Sports Medicine residency at the ORC in July 2010. She initially joined the ORC in July 2008 as the staff veterinarian responsible for the clinical management of research horses, overseeing treadmill training of the horses, assisting with clinical cases, and aiding research associates. She received her D.V.M. from Washington State University’s College of Veterinary Medicine in 2007 and she completed an internship focusing on equine lameness and surgery at Oakridge Equine Hospital in Edmond, Okla., prior to coming to CSU.
Caroline Adrian, M.S.

Caroline (Carrie) received her Ph.D. in 2010 in canine biomechanics at Colorado State University. Her research interests include the application of physical therapy on animals, more specifically, compensatory gait analysis, biomechanics, and neuromotor control of normal and pathological canine gait.

She received her B.S. in Biology in 1994 from Allegheny College in Meadville, Pa., and gained animal experience working in veterinary hospitals since 1990. She received her M.S. in Physical Therapy degree from North Georgia College in 1999. Carrie has participated in a number of continuing education seminars on animal rehabilitation, both as a participant and lecturer since 1998. She has lectured nationally and internationally on the topic of animal physical therapy. She is a contributor to the book, *Canine Rehabilitation & Physical Therapy, Veterinary Clinics of North America* and the upcoming edition of the *Clinical Textbook for Veterinary Technicians*. She presently serves as Vice President for the Animal Special Interest Group within the American Physical Therapy Association. Carrie is the Director of Physical Therapy Services for VCA Hospitals and manages the Physical Therapy and Sports Medicine Department at VCA Alameda East Veterinary Hospital in Denver. Her department serves as one of the few nationally approved clinical practicum sites for the first formal animal rehabilitation training program offered in the country. Carrie also teaches canine anatomy and pathology at the Boulder College of Massage Therapy.

Kaydence Cowley, B.S., M.S.

Kaydence completed an undergraduate degree in Mechanical Engineering from Lafayette College in Easton, Pa., and a master’s degree in Bioengineering from the University of California Riverside. She did previous work in orthopaedic repair and injury at the Colorado Health Science Center and has presented work at the Orthopaedic Research Society, Biomedical Engineering Society, and Biophysical Society Conference. Kaydence joined the ORC in May 2009 as a Ph.D. student under Dr. Frisbie and Dr. Kisiday. Her dissertation project is to develop a clinically relevant *in vitro* model of tendon injury utilizing tissue explants in order to understand the biological mechanism of healing and repair.

Ben Gadomski, B.S.

Ben received his B.S. in mechanical engineering from Tri-State University in 2009. Since then he has been a Ph.D. candidate under the guidance of Dr. Christian Puttlitz. Ben’s past research areas include spinal implant design as well as lumbar spine finite element modeling. His current research focus is in the area of bone fracture healing in microgravity environments using a large animal model.
2010-2011 Ph.D. Graduate Students

Daniel Hemphill, B.S.

Daniel Hemphill graduated with a B.S. in chemical engineering in 2008 from CSU and started his Ph.D. in Bioengineering. He worked with Dr. Laurie Goodrich doing gene therapy research after completing lab rotations through the school of biomedical engineering.

Devin Leahy, B.S.

Devin graduated with a B.S. in mechanical engineering from The Ohio State University in 2004. He is working toward a Ph.D. under Dr. Christian Puttlitz. Devin has industry experience in the areas of composite materials, ergonomics, aerospace, and motorsports, and is currently researching ligamentous trauma in the cervical spine.

Valerie Moorman, D.V.M.

Valerie Moorman graduated from North Carolina State University in 2004 with a D.V.M. She completed a large animal medicine and surgery internship at Auburn University in 2004-2005, and then stayed on as a clinical instructor in Auburn's large animal ambulatory service. During this time, she worked with Dr. Robert Gillette and the sports medicine service on a research project using 2-D kinematic analysis. In 2006, she began an equine surgical residency and combined master's degree at Oklahoma State University, which she completed in 2009. In July 2009, she accepted a position at Colorado State University as an after-hours large animal emergency clinician and Ph.D. at the Orthopaedic Research Center. She has an interest in equine sports medicine and surgery, as well as lameness and imaging. In her free time, Valerie enjoys sailing, hiking, and riding hunter-jumpers.

Trinette Ross, M.S.

Trinette Ross is an instructor and advisor for the undergraduate Equine Sciences Program and is also the Equine Teaching and Research Center Event Coordinator at CSU. She received her undergraduate degree from Montana State University and then completed an M.S. at Texas A&M University. Trinette is now a Ph.D. student at the ORC (Advisor, Dr. McIlwraith) evaluating the effect of omega 3 fatty acids in equine osteoarthritis model.
2010-2011 Ph.D. Graduate Students

Kevin Troyer, M.S.

Kevin received his B.S. and M.S. degrees from Colorado State University. He is currently a Ph.D. candidate studying soft tissue mechanics at the Orthopaedic Bioengineering Research Laboratory under Christian Puttlitz. His dissertation work seeks to characterize and model the complex time-dependent mechanical behavior of musculoskeletal soft tissues, such as ligament and tendon.

2010-2011 M.S. Graduate Students

Myra Barrett, D.V.M.

Myra's undergraduate degree was awarded by Stanford University. She went on to receive her D.V.M. from Colorado State University in 2006. After a year internship at Oakridge Equine Hospital, a busy referral practice in Oklahoma, Myra returned to Colorado to pursue a specialty in equine orthopaedic imaging. She received an M.S. in 2010 at the CSU Orthopaedic Research Center as well as a resident in an equine-focused non-traditional diagnostic imaging residency. Myra's master's research is focused on the clinical significance of various radiographic lesions in cutting horses. In 2011, Dr. Barrett became an Assistant Professor CVMBS Environmental & Radiological Health Services Department.

Hannah Hudson, B.S.

Hannah joined the James Lab as a sophomore during her undergraduate studies in Mechanical Engineering and is currently pursuing her M.S. under the supervision of Dr. Susan James. Currently, Hannah's work is investigating the feasibility of penetrating DOPS coatings into 3D titanium lattice structures and expects to graduate May 2012.
Lacy Kamm, D.V.M.

Lacy, originally from Toledo, Ohio, graduated from the University of Michigan with a B.S. in cellular and molecular biology and a minor in Spanish language. She then went to vet school at CSU. Afterwards, she completed an internship at Rood and Riddle Equine Hospital in 2008 and spent a year as a graduate student at Cornell University where she studied cytokine expression and inhibition. Lacy returned to CSU as a resident at the Veterinary Teaching Hospital in 2009 and joined the ORC as a Master’s student under the direction of Drs. Laurie Goodrich and Dave Frisbie. Lacy, under the direction of Dr. Goodrich, is working on a project where she will explain the anatomy of the pastern joint in order to perform arthroscopy on the joint. Lacy is also working on a project with Dr. David Frisbie comparing protein biomarkers in osteoarthritic joints with microarray and PCR results. The goal of this study is to determine if gene expression in peripheral white blood cells can diagnose osteoarthritis in the horse.

Kirk C. McGilvray, Ph.D.

Dr. McGilvray received his Ph.D. in mechanical engineering from Colorado State University in 2009 and is a research scientist within the Orthopaedic Bioengineering Research Lab. His research foci include monitoring and improving fracture healing, bio-micro-electro-mechanical systems, and cardio-vascular biomechanics. Dr. McGilvray leverages comparative animal models, ex vivo biomechanical techniques, and computer modeling methods to assess both basic science and industry driven questions in the field of medical bioengineering.

Lynsey-Ann Bosch, B.S.

Lynsey graduated from Michigan State University with a Bachelor’s Degree in Veterinary Technology, and worked there as a technician throughout her education and for one year after graduation. At MSU, Lynsey helped with equine emergencies, daily treatments, and out-patient appointments. Lynsey moved with her husband to Colorado and worked at an equine private practice for one year, and taught at a veterinary technician training college for two years. Lynsey came to the lab in 2005 as an administrative assistant, and to implement an archiving computer program which will digitally document the research studies and associated data, and will make the wealth of information produced at the ORC easily searchable.
Cecily Broomfield, M.S.

Cecily received a B.S. in microbiology from California Polytechnic State University in 2000, and an M.S. in agriculture from Colorado State University in 2006. She is currently working as the research coordinator for the OBRL.

Susan James, B.A.

Susan earned her B.A. in Biology from CU and worked as a Biologist at the National Institutes of Health in Bethesda, Md. before returning to her native Colorado. Susan has worked for CSU in the histology field for the past two years. Previously she worked as a research associate at the CSU Arthropod-borne Infectious Diseases Laboratory where she assisted with research on ticks as vectors of West Nile Virus and Lyme disease. She also assisted with cancer treatment research at CSU’s Vet Teaching Hospital. Susan joined the EORC team in June 2007 as a Research Associate and Histology Technician.

Christina Lee, Ph.D.

Christina Lee received her B.S. in animal science at UC Davis in December 2002, during which time she worked in Dr. Sue Stover’s lab for Dr. Hill collecting data to investigate correlations between equine suspensory apparatus injury with suspensory apparatus failure and metacarpal condylar fractures. She then entered graduate school at UC Davis in 2003 in the Molecular, Cellular, and Integrative Physiology graduate group working in Dr. Clare Yellowley’s laboratory. For her dissertation studies, Dr. Lee investigated the effects of oxygen tension on the expression of proteins associated with bone remodeling and hypoxic regulation of gene expression in osteoblastic cells. In 2007, Dr. Lee came to Colorado State University to work at the Orthopaedic Research Center as a Post-Doctoral Fellow under the mentorship of Dr. David Frisbie and Dr. John Kisiday to develop an in vitro model to investigate the cellular and molecular responses of chondrocytes to cartilage injury. In early 2011, she transitioned from her postdoctoral position into her current role as Laboratory Manager and Research Coordinator for the Orthopaedic Research Center.

Nate Jensrud, B.S.

Nate Jensrud joined the EORC as a Research Associate in March of 2010. He earned his B.S. in Forest Resources with an emphasis in Biotechnology from the University of Georgia in Athens, Ga. Jensrud managed a Plant Pathology laboratory at UGA for several years, studying the effects of Phytophthora ramorum, Sudden Oak Death, before moving to Colorado in 2008. He spent several seasons working for the federal government with the U.S. Forest Service and U.S. Geological Survey before coming to the EORC.
**Research Associates**

**Bob Zink, B.S.**

Bob received his B.S. in biological sciences in 1969 from California Polytechnic State University. He has been at Colorado State University as a histotechnologist since 1990 and with the OBRL since 2007. His specialty is immunohistochemistry.

**Nikki Phillips, B.S.**

Nikki received her B.S. in Cell and Molecular Biology in May 1997 from Tulane University. She has been at Colorado State University since 2001 working in the Department of Pathology for a year before working for both Clinical Sciences and Biomedical Sciences. Nikki joined the ORC in January 2008 as a research associate to assist in the ORL.

**David A. Prawel, Ph.D., Associate Director, James Biomaterials Group, School of Biomedical Engineering, Department of Mechanical Engineering**

*Research Interests:* Biomaterials, biomimetic orthopaedic implant coatings, drug-delivery, tissue engineering of bone analogs.

Dr. Prawel is the Associate Director of the James Biomaterials Group, which is part of the Orthopaedic Bioengineering Research Laboratory and also a Senior Research Scientist in the School of Biomedical Engineering, Department of Mechanical Engineering. His current research is focused on developing “smart” coatings for orthopaedic implants, which are capable of enhancing bone growth while delivering drugs such as antibiotics directly to implant sites.

David earned his Ph.D. in the School of Biomedical Engineering at Colorado State University in 2010. He earned a B.S. in biology (1978) and an M.S. in natural sciences (1980), both at the State University of New York at Buffalo. He earned a second M.S. in comparative physiology at Rutgers University in 1982 while working towards a Ph.D., which was overshadowed by the then-fledgling computer industry. David also earned a certificate in Technology Mergers and Acquisitions from the University of Michigan Business School in 1992.
**Director Gait Analysis Center/ ORC Staff Veterinarian**

Melissa King, D.V.M.

Melissa graduated from Colorado State Veterinary School in 1997. After graduating, she did a one year internship at Rood and Riddle Equine Hospital in Lexington, Ky. Upon completion of her internship, Melissa returned to northern Colorado to begin her career as an equine ambulatory clinician focusing on equine lameness. After practicing for 10 years, Melissa sold her ambulatory practice to pursue a Ph.D. in equine lameness and rehabilitation, which she recently completed. Dr. King has moved into a faculty position as well as the Director of the Gait Analysis Center and the ORC Staff Veterinarian. Melissa's research interests are orthopaedic rehabilitation and the effects of underwater treadmill exercise on the biomechanics of the equine limb.

**Research Coordinator**

Jennifer Suddreth, B.S.

Jennifer Suddreth, originally from Altamont, Utah, graduated from Colorado State University in 2009 with a bachelor’s degree in equine science and agricultural business. Suddreth started at the ORC on Feed Crew, and then came back after graduation working as an animal care technician. Jen joined the ORC full time as Barn Manager and Volunteer Coordinator in June 2010.

**Administrative Staff**

Paula Vanderlinden, Program Coordinator

Paula joined the ORC in March 2007 as Program Coordinator and as Dr. McIlwraith’s personal assistant. Paula manages the Annual Stallion Auction, publishing of the annual newsletter and bi-annual lab report. Prior to working at CSU, Paula worked in the pharmaceutical industry.

Candice Hastings, Accounting Manager

Candice is the Accounting Manager for the Department of Clinical Sciences and in May 2011 began managing the accounting activity for the ORC.
Orthopaedic Research Program
Areas of Expertise of Personnel

Core Faculty

College of Veterinary Medicine and Biomedical Sciences

C. Wayne McIlwraith, B.V.Sc., Ph.D., D.Sc., FRCVS, Diplomate ACVS
University Distinguished Professor
Clinical Orthopaedics
Joint Pathobiology
Gene Therapy
Medical and Surgical Treatment
Rehabilitation
Cartilage Healing

David D. Frisbie, D.V.M., Ph.D., Diplomate ACVS
Cartilage Healing
Biochemistry
Molecular Biology
Gene Therapy
Clinical Orthopaedics

Laurie Goodrich, D.V.M./Ph.D., Diplomate ACVS
Clinical Orthopedics
Gene Therapy
Vector Development
Cartilage Healing

Kevin Haussler, D.V.M., D.C., Ph.D.
Complementary (Integrative Medicine)
Rehabilitation
Spinal and Sacroiliac Disorders
Anatomy
Biomechanics

Christopher E. Kawcak, D.V.M., Ph.D., Diplomate ACVS
Pathogenesis of Subchondral Bone Disease and Traumatic Joint Injury
Histomorphometry
Biomechanics
Clinical Orthopaedics

John Kisiday M.S., Ph.D.
Mechanobiology
Cartilage Healing
Biomechanical Characterization

Natasha Werpy D.V.M.
Orthopaedic Imaging including Radiology, Computerized Tomography, MRI, and Ultrasonography

Collaborating Faculty

College of Veterinary Medicine and Biomedical Sciences

Gary M. Baxter, VMD, M.S., Diplomate ACVS
Clinical Orthopaedics
Medical and Surgical Treatment
Vascular Physiology

Nicole Ehrhart, D.V.M., M.S., Diplomate ACVS
Orthopaedic Oncology
Gene Delivery and Tissue Engineering

Thomas R. (Tod) Hansen, B.S., M.S., Ph.D.
Gene Chip Technology

Ashley Hill, D.V.M./Ph.D.
Epidemiology
Experimental Design

Robert Norrdin, D.V.M., Ph.D., Diplomate ACVP
Orthopaedic Pathology
Bone Histomorphometry

Richard D. Park, D.V.M., Ph.D., Diplomate ACVR
Orthopaedic Imaging including Radiology, Computerized Tomography and MRI

College of Engineering

Susan P. James, Ph.D.
Biomechanics

Ketul Popat, Ph.D., Assistant Professor, Department of Mechanical Engineering, School of Biomedical Engineering

Christian Puttlitz, Ph.D.
Orthopaedic Biomechanics

College of Agricultural Sciences

Jason Bruemmer, Ph.D.
Gene Chip Technology

College of Natural Sciences

Hariharan K. Iyer, B.S., M.S., Ph.D.

Ann Hess, Ph.D.

College of Applied Human Science

Raoul F. Reiser II, Ph.D.
Musculoskeletal Biomechanics
Custom Equipment/Instrumentation
Student Hourly Assistants at the ORC 2010-2011

Alyssa Ball
Kaylan Campbell
Annaliese Catlin
Casey Cooper
Lauren Farrington
Sarah Johnson

Stephanie Lowe
Lauren Luedke
Whitney McMillan
Cassie Powers
Jami Reed
Lindsay Richardson

Jordan Schimming
Ashlee Shelly
Jen Suddreth
Meghan Tumlinson

Volunteers at the ORC 2010-2011

Carly Brown
Liz Carazo
Jack Conner
Jenn Hartman

Nick Lemmel
Kalie Petefish
Maggie Rollert
Amy Scott

Mason Vickerman
Haley Wilson

[Images of people]
<table>
<thead>
<tr>
<th>Student</th>
<th>Degree</th>
<th>Date Graduated</th>
<th>Current Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fahd Al-Sobayil</td>
<td>M.S.</td>
<td>1997</td>
<td>Assistant Professor, King Saud University, Riyadh, Saudi Arabia</td>
</tr>
<tr>
<td>Abigail Dimock</td>
<td>M.S.</td>
<td>1997</td>
<td>Currently a Ph.D. student, Equine Nutrition (Orthopaedic Related), Rutgers University</td>
</tr>
<tr>
<td>Becky Woodward</td>
<td>M.S.</td>
<td>1998</td>
<td>Graduate Researcher on S-V Dagon Research Vessel, University of British Columbia</td>
</tr>
<tr>
<td>Tina Anderson</td>
<td>Ph.D.</td>
<td>1998</td>
<td>Director of Marketing</td>
</tr>
<tr>
<td>Louise Southwood Perante</td>
<td>M.S.</td>
<td>1998/2002</td>
<td>Associate Professor, University of Pennsylvania School of Veterinary Medicine</td>
</tr>
<tr>
<td>Charles Hubbeling</td>
<td>Ph.D.</td>
<td>1999</td>
<td>Private consulting</td>
</tr>
<tr>
<td>Guy Beauregard</td>
<td>Ph.D.</td>
<td>1999</td>
<td>Senior scientist/researcher for private industry</td>
</tr>
<tr>
<td>Andrew Green</td>
<td>M.S.</td>
<td>1999</td>
<td>Engineering manager for private industry</td>
</tr>
<tr>
<td>Elisha Rentfrow</td>
<td>M.S.</td>
<td>1999</td>
<td>Private consulting</td>
</tr>
<tr>
<td>Tara Ruttley</td>
<td>M.S.</td>
<td>2000</td>
<td>Engineer for NASA</td>
</tr>
<tr>
<td>Carson Shellenberger</td>
<td>M.S.</td>
<td>2000</td>
<td>Engineer for private industry</td>
</tr>
<tr>
<td>Al Kane</td>
<td>Post-Doc</td>
<td>2000</td>
<td>Analytic Epidemiologist, USDA; Affiliate Faculty for Colorado State University's Center of Veterinary Epidemiology and Animal Disease Surveillance Systems</td>
</tr>
<tr>
<td>Julie Dechant</td>
<td>M.S.</td>
<td>2000</td>
<td>Assistant Professor, University of California Davis</td>
</tr>
<tr>
<td>Troy Trumble</td>
<td>M.S.</td>
<td>2000, 2004</td>
<td>Associate Professor, University of Minnesota</td>
</tr>
<tr>
<td>Chengcheng Lui</td>
<td>M.S.</td>
<td>2001</td>
<td>Continuing in school</td>
</tr>
<tr>
<td>Jana Read</td>
<td>M.S.</td>
<td>2001</td>
<td>Employed in quality control</td>
</tr>
<tr>
<td>Erin Peterson</td>
<td>M.S.</td>
<td>2001</td>
<td>Faculty Member, Department of Animal Science, University of Maryland</td>
</tr>
<tr>
<td>Anne DePalma</td>
<td>M.S.</td>
<td>2002</td>
<td></td>
</tr>
<tr>
<td>Joel Millets</td>
<td>M.S.</td>
<td>2002</td>
<td>Employed at Osteotech, Allograft Company</td>
</tr>
<tr>
<td>Carolyn Skurla</td>
<td>Ph.D.</td>
<td>2002</td>
<td>Assistant Professor, Baylor University</td>
</tr>
<tr>
<td>Louise Southwood Perante</td>
<td>Ph.D.</td>
<td>2002</td>
<td>Faculty Member, University of Pennsylvania School of Veterinary Medicine</td>
</tr>
<tr>
<td>Awad Al-Zaben</td>
<td>Ph.D.</td>
<td>2003</td>
<td>Faculty Member, Electronics Engineering Department, Yarmouk University, Irbid, Jordan</td>
</tr>
</tbody>
</table>
## Graduate Students – Placement Since Inception

<table>
<thead>
<tr>
<th>Student</th>
<th>Degree</th>
<th>Date Graduated</th>
<th>Current Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sophie Morisset</td>
<td>Ph.D.</td>
<td>2003</td>
<td>Assistant Professor, Department of Clinical Sciences, Université de Montréal</td>
</tr>
<tr>
<td>Thomas Young</td>
<td>M.S.</td>
<td>2003</td>
<td>Currently job searching</td>
</tr>
<tr>
<td>Colin Scruten</td>
<td>M.S.</td>
<td>2004</td>
<td>Private practice, Alberta, Canada</td>
</tr>
<tr>
<td>Lea Rempel</td>
<td>Ph.D.</td>
<td>2004</td>
<td>Post-Doctoral Fellow, University of Kansas Medical School, Currently, Research Scientist, United States Meat Animal Research Center, Clay Center, Neb.</td>
</tr>
<tr>
<td>Chris Sorensen</td>
<td>Ph.D.</td>
<td>2004</td>
<td>Post-Doctoral, National Mass Spectrometry Facility, Environmental Molecular Sciences Laboratory and Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Wash.</td>
</tr>
<tr>
<td>Brandon Santoni</td>
<td>Ph.D.</td>
<td>2006</td>
<td>Postdoctoral Research Fellow, ORBL, Colorado State University</td>
</tr>
<tr>
<td>Katja Duesterdieck</td>
<td>Ph.D.</td>
<td>2006</td>
<td>Assistant Professor, Oregon State University</td>
</tr>
<tr>
<td>M. Shearin</td>
<td>D.V.M./Ph.D.</td>
<td>2006</td>
<td>Assistant Doctoral Fellow, University of Tennessee</td>
</tr>
<tr>
<td>Valerie Perino</td>
<td>M.S., Ph.D.</td>
<td>2007</td>
<td>Completed Ph.D., Equine Orthopaedic Research, Colorado State University</td>
</tr>
<tr>
<td>Sam Hendrix</td>
<td>M.S.</td>
<td>2008</td>
<td>Equine practice, Utah</td>
</tr>
<tr>
<td>Ty Wallis</td>
<td>M.S.</td>
<td>2008</td>
<td>Equine specialty practice</td>
</tr>
<tr>
<td>Erin Contino</td>
<td>M.S.</td>
<td>2009</td>
<td>Final year D.V.M. student</td>
</tr>
<tr>
<td>Ryan Carpenter</td>
<td>M.S.</td>
<td>2009</td>
<td>Equine practice, Southern California</td>
</tr>
<tr>
<td>Jennifer Antonnici</td>
<td>Ph.D.</td>
<td>2010</td>
<td>University of California</td>
</tr>
<tr>
<td>Christina Lee</td>
<td>Post-Doc</td>
<td>2010</td>
<td>Lab Manager, Orthopaedic Research Center</td>
</tr>
<tr>
<td>Myra Barrett</td>
<td>M.S.</td>
<td>2010</td>
<td>Assistant Professor CVMBS, CSU</td>
</tr>
<tr>
<td>Carrie Adrian</td>
<td>Ph.D.</td>
<td>2011</td>
<td>Director of Rehabilitation Services, VCA Animal Hospitals</td>
</tr>
<tr>
<td>Katrina Easton</td>
<td>D.V.M./Ph.D.</td>
<td>2011</td>
<td>University of Sydney</td>
</tr>
<tr>
<td>Melissa King</td>
<td>Ph.D.</td>
<td>2011</td>
<td>Staff Veterinarian, Orthopaedic Research Center, Clinical Instructor Sports Medicine and Rehabilitation Service, CSU</td>
</tr>
</tbody>
</table>
## Surgery Residents Supervised (and Outcome)

<table>
<thead>
<tr>
<th>Resident</th>
<th>Years of Residency</th>
<th>Date Achieved Board Certification in the American College of Veterinary Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>J.V. Yovich</td>
<td>1983-1986</td>
<td>1987</td>
</tr>
<tr>
<td>M.J. Reeves</td>
<td>1986-1989</td>
<td>1990</td>
</tr>
<tr>
<td>T. Trumble</td>
<td>1996-1999</td>
<td>2000</td>
</tr>
<tr>
<td>J. Dechant</td>
<td>1997-2000</td>
<td>2001</td>
</tr>
<tr>
<td>J. Alldredge</td>
<td>2000-2003</td>
<td>2004</td>
</tr>
<tr>
<td>C. Scruton</td>
<td>2001-2004</td>
<td>2004</td>
</tr>
<tr>
<td>E. Farstvedt</td>
<td>2002-2005</td>
<td>2005</td>
</tr>
<tr>
<td>S. Hendrix</td>
<td>2003-2006</td>
<td>2006</td>
</tr>
<tr>
<td>T. Wallace</td>
<td>2006-2008</td>
<td>2008</td>
</tr>
<tr>
<td>R. Carpenter</td>
<td>2007-2009</td>
<td>2010</td>
</tr>
</tbody>
</table>
1. Musculoskeletal Tissue Healing

Until a few years ago we have principally addressed articular cartilage healing and will continue to do so, but we have enlarged the focus to include tendons, ligaments, and menisci. For instance, treatments of tendonitis including A-cell therapy, extracorporeal shock wave therapy (ESWT), and mesenchymal stem cell therapies have been assessed.

2. Early Diagnosis of Bone and Joint Disease

This area includes the development of novel imaging techniques (present and future), body fluid biomarkers, and also molecular monitoring. The uses of these early diagnostic techniques include a) Evaluation of the pathogenesis of musculoskeletal disease, b) Early detection of disease processes, c) Monitoring of therapy, with the long term goal of preventing severe osteoarthritis or failure of joints, tendons, ligaments, and menisci.

3. Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease

Catastrophic injury is a major problem in the equine athletic industry and we, as well as researchers elsewhere, have demonstrated that the severe fractures and injuries start as microfractures in the subchondral bone. Our ongoing mission is to develop methods of detecting this damage in the clinical patient before it becomes severe, irreversible damage. Exercising horses have been followed with imaging techniques including computed tomography (CT) and MRI, nuclear scintigraphy, defined sentinels of early damage, and fluid biomarkers as a means of identifying horses at risk studied with promising results. Recently, biomechanical and modeling studies have been done to monitor early events in bone disease. Modeling has been used to look at the pathogenesis of condylar fractures and other disease processes as well as mapping of pressure distribution and articular cartilage thickness in equine joints. Other factors that can potentially contribute to traumatic musculoskeletal injury including race track surface and conformation have also been part of this research focus.

Program Synopsis

History

The Orthopaedic Research Center (ORC) began as a multidisciplinary equine program dedicated to finding methods to treat and prevent equine musculoskeletal disease and injury. Prior to 1984, the program’s research was primarily clinical. During this time, many of the techniques for arthroscopic surgery currently used to treat joint problems more effectively and to enable continued athletic function were developed at CSU. We also identified and defined a number of new clinical conditions and documented some of the best methods for diagnosis and treatment. A major goal of the program has always been to find solutions to musculoskeletal problems, especially joint injuries and arthritis. The researchers strive to offer the best possible treatment of clinical cases with continual and critical assessment of the results, which are then used to modify treatments and direct the research toward disease prevention. The program’s goals are to use state-of-the-art research techniques to find new methods to rehabilitate damaged joints, to prevent or decrease the occurrence of joint disease and musculoskeletal injuries, find methods of early detection and develop better treatments to prevent permanent damage to injured joints and validate manual therapies and rehabilitation techniques. Significant collaboration with the College of Engineering, School of Bioengineering and the Orthopaedic Bioengineering Research Laboratory (OBRL) as well as the Department of Health and Exercise Sciences has added considerably to our research strengths. In recent years considerable human-based funding (Foundation, NIH and corporate) has been added to ORC and OBRL support.

Research Activities

The following are the research focuses of the Orthopaedic Research Center. Details of recent and current projects can be found on pages 105-182.
Program Synopsis

4. Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse

Objective evaluation of currently available pharmaceutical agents as well as new potential ones have been a significant focus of our work. These evaluations also include examination of specific biological inhibitors including gene therapy, novel protein therapies, and mesenchymal stem cell therapies. These newer therapies offer the potential of inhibiting the disease process sufficiently early so that the need for palliative drugs currently used is decreased.

5. Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease

This is a newer focus that includes objective assessment of integrative therapies including physical manipulation and acupuncture for management of musculoskeletal disease and pain as well as rehabilitative techniques of swimming under water treadmill and hyperbaric therapy. This area also includes study of the pathogenesis of musculoskeletal problems biomechanically and using gait analysis (kinetics, kinematics) and electromyography (EMG), as well as novel methods of pain detection.

In recent years, the Orthopaedic Research Center has acquired the personnel and technical abilities to do more sophisticated orthopaedic research and to address critical questions at a more basic level. Development of this expertise has allowed us to use the horse as a model to resolve problems in human arthritis where conditions are comparable to those in horses. This has led to collaborations with human health researchers, foundations, and industry.

Impact

As a preeminent equine orthopaedic research program, both nationally and internationally, the Orthopaedic Research Center provides critical new findings of significant clinical impact and has been able to attract talented students who wish to pursue careers in orthopaedic research. Students choose this program because of its excellent reputation and because of the opportunities they have to be involved in research during their undergraduate and pre-veterinary programs. Many pre-veterinary students have served as volunteers in the equine orthopaedic research program over the past 10 years; this allows students to develop a high level of research expertise during this undergraduate experience. This involvement encourages students to pursue advanced degrees and ultimately research careers rather than traditional private veterinary practice. Our program also impacts undergraduate and pre-veterinary education by applying findings from research studies to clinical veterinary medicine.

The breadth of dissemination of information from the Orthopaedic Research Center is extensive, with information distributed to graduate and undergraduate students in eight Departments within five Colleges at Colorado State University. Many faculty members from these five Colleges who are participants in the Orthopaedic Research Program are internationally recognized; they are therefore able to share research findings worldwide to academia, the equine industry, the scientific community, and private biomedical industry. The Orthopaedic Research Center’s extensive collaboration with the Steadman Philippon Sports Medicine Foundation and biotechnology companies has significantly impacted the treatment of humans with orthopaedic injuries and osteoarthritis. Human medicine, as well as veterinary medicine, has been positively affected by the dissemination of the Orthopaedic Research Center’s findings.

Program Trends

Over the last 10 years, funding for our orthopaedic research and specialized personnel availability has increased dramatically. Until 1994, orthopaedic research was being performed by faculty members within the Department of Clinical Sciences. Since that time, the Orthopaedic Research Center has acquired seven full-time faculty senior scientists and also has two Bioengineering Faculty in our Center. To
support the work of the Faculty Researchers, we now have eight research associates. We have had 10 Ph.D. students and seven M.S. students in the program the past two years. Current funding is around $4 million annually. Thanks to generous private donors, the construction of a new Orthopaedic Research Center facility and the remodeling of the existing laboratory have been completed. In addition, a state-of-the-art equine MRI facility has been in operation for five years, and this has also been funded by private donations. We have also received three $3 million University Endowed Chairs from Barbara Cox Anthony, Iron Rose Ranch, and Abigail K. Kawananakoa. We have also acquired a $1.5 million Chair in Musculoskeletal Imaging from the estate of Kenneth and Virginia Atkinson. We continue to pursue endowed funding to make all of our positions permanent. In addition, the Orthopaedic Bioengineering Laboratory has had two full-time faculty senior scientists, five Ph.D. students and 12 M.S. students in the past two years.

Program Goals

Goals Accomplished 2010-2011

1. Construction of Equine Gait Analysis Building. This building has been completed and been critical in the completion of two major Ph.D. projects: 1) The assessment of underwater treadmilling in an experimental model of osteoarthritis by Dr. Melissa King in which kinetic and kinematic evaluations enabled us to show that underwater treadmilling not only decreased the amount of osteoarthritis developing but also improved proprioception and postural balance in these patients and 2) The evaluation of electromyographic and kinematic changes following cruciate ligament injury and rupture in the dog by Dr. Carrie Adrian. Dr. King remains at the Orthopaedic Research Center as a clinical instructor and in addition to being the supervisor of the Gait Analysis Center, will also be the ORC staff veterinarian and is playing a pivotal role in the new Sports Medicine Program.

2. Achieve Extramural Research Funding to Continue Quality Orthopaedic Research. The NIH Program grant in collaboration with MIT (Dr. Frisbie PI of sub-contract) has been completed. The NIH KO8 training grant of Dr. Laurie Goodrich completed its second and third years with excellent progress in developing an adenoassociated viral gene vector. In addition, Dr. Goodrich (PI Sub-contract) and Dr. McIlwraith collaborated in an NIH RO1 grant with Dr. Connie Chu at the University of Pittsburgh in which we did a 12-month study evaluating the value of bone marrow derived mesenchymal stem cells (BMSC) in diluted fibrin to repair articular cartilage. This project also involves Dr. Bob Sah and we have added a number of critical biomechanical and imaging parameters to evaluate outcomes and results will be forthcoming. Last but not least, McIlwraith and Frisbie are Co-PIs on a sub-contract with Dr. Steve Trippel of Indiana University on another NIH RO1 grant evaluating gene therapy and cartilage repair. It is expected that the 12-month equine study that is part of this grant will commence at the beginning of 2012.

3. Development of an Equine Ambulatory Sports Medicine Service. An equine ambulatory sports medicine service has been developed over the period of this report by Dr. Chris Kawcak which is an extension of the work that Dr. Kawcak was doing with research associate Jodi Callison in providing service to some of our major donors. There is increasing demand from equine clients for this service offering state of the art expertise in equine musculoskeletal problems in athletic horses. Dr. Melissa King has been retained to work with Dr. Kawcak and Jodi as well as our equine sports medicine residents. This service commenced in 2011 and has exceeded our expectations in demand.

4. Establishment of Equine Sports Medicine and Rehabilitation Residencies. A new American veterinary specialty, The American College of Veterinary Sports Medicine and Rehabilitation has been developed and was accredited by the American Veterinary Medical Association in May 2010. There are 27 Charter Diplomates established
by a nomination and Delphi election system. Four of our faculty, Drs. McIlwraith, Haussler, Kawcak, and Frisbie, were made Charter Diplomates of the new College. We have established an equine sports medicine and rehabilitation residency program to train future specialists. Our first resident, Dr. Dora Ferris commenced in July 2010 followed by our second resident, Dr. Erin Contino starting in July 2011. At the moment, we have the only equine sports medicine residency program in the U.S. and the College is using our program as a template.

5. Unrestricted Funding from Donors and Foundations: The period 2010-2011 has been one of continuing to function without any loss of faculty and staff in these recessionary times. In 2008-2009, the corpuses of our four endowed chairs decreased markedly. Fortunately, thanks to the generosity of Herbert Allen, Jim Kennedy (The Cox Family Foundation), Gail Holmes, and Abigail Kawananakoa, we have been able to make up for necessary operating expenses and continue to fund new cutting edge projects. In the 2010-2011 period we have made up some of the deficit with increase in corpus by 6.25% in FY10 and 16.75% in FY11. As mentioned before, we have been able to maintain all our positions thanks to support with operating expense deficits.

6. Promotion of Orthopaedic Research Center Faculty in 2011. Both Drs. John Kisiday and Laurie Goodrich were promoted to Associate Professor and gained tenure and Dr. Chris Kawcak was promoted to Full Professor. In 2010, Dr. Christian Puttlitz, the Director of OBRL, was promoted to Associate Professor with tenure and in 2011, was made a Monfort Chair. This is a two year position with supplementary funding and is only given to two faculty members in the whole university.

Current Goals

1. Continue to achieve adequate funding from Federal Grant Agencies, industry, and private funding.

2. Identify funding for construction of a building to house offices for faculty and graduate students for both the Orthopaedic Research Center and the Orthopaedic Research Bioengineering Laboratory.

3. Create endowed funding for two staff positions, one post-doctoral fellow and scholarships for graduate students.

4. Provide quality education to Undergraduate PVM and Graduate Students.

5. Continue to do State-of-the-Art Research within the Orthopaedic Research Center’s Research Focuses.

Research Goals Achieved 2010-2011

1. Focus 1 Musculoskeletal Tissue Healing

We continued to explore the use of mesenchymal stem cells (MSCs) for repair of articular cartilage and other tissues in the joint and how the cells can be optimally manipulated. Current practices for the preparation of bone marrow mesenchymal stem cells (BMSCs) for equine musculoskeletal injuries involve culture-expansion to obtain millions of cells for single treatment. While tissue culture plastic is the standard surface on which BMSCs are culture-expanded, we reported that coating tissue coated plastic with fibrinogen precipitated from blood plasma increases BMSC proliferation without effecting differentiation potential. Fibrinogen harvested from autologous blood is an inexpensive means of creating a growth surface that is superior to tissue culture plastic.

The comparison of the sternum and ilium as a source of BMSCs was evaluated. It was found that both sternum and ilium offer a rich supply of BMSCs that have similar growth rates. It was also shown that the highest concentration of BMSCs is in the first 5 mls of bone marrow aspirate. In a second related study it was found that the cells acquired from equine sternum and ilium were also similar in their differentiation capacity in vitro. In a third study, we showed that
BMSCs from the ilium were superior in chondrogenic potential (ability to grow new cartilage) compared to BMSCs from the sternum.

The basic science of subchondral bone microfracture in articular cartilage repair in the horse (and how this information can be extrapolated to human cartilage repair) was reviewed by Drs. Frisbie and McIlwraith and published in the journal *Cartilage*. In addition, Drs. McIlwraith and Frisbie did a collaborative review with Drs. Fortier and Alan Nixon from Cornell University on the use of equine cartilage repair models to evaluate the best technique for horses and humans. This involved excellent discussion as to the comparison of results between the two research groups and what as the best way forward in the use of the equine model that has become widely accepted as a human pre-clinical model. This review has also been recently published in the journal *Cartilage*.

Another pivotal study that was completed in 2011 was a 12-month study evaluating the effect of bone marrow derived mesenchymal stem cells (BMSCs) administered intra-articularly four weeks after creation of full thickness subchondral microfractured defects on the medial femoral condyle. There was superior firmness of the repair tissue in the BMSC treated groups as well as enhancement of aggrecan content (a critical component that is typically very deficient in repair studies done thus far). This study was published in *Arthroscopy* in 2011.

Another study headed up by Dr. Frisbie evaluated the effects of clinically relevant autologous conditioned blood products (IRAPII™, ACP™, and various other PRP products) on the anabolic properties equine digital flexor tenocytes and suspensory ligament fibroblasts to examine these products on tendon healing. This was recently presented at the AAEP meeting and is being submitted for publication.

2. Focus 2 Early Diagnosis of Bone and Joint Disease

Work has continued in the development of a wireless gait analysis system for horses to enable us to measure three dimensional forces on the hoof at fast exercise. This project is the Ph.D. project of Dr. Valerie Moorman, supervised by Drs. Chris Kawcak and Raoul Reiser. The sensor developed by EquySys has been evaluated in comparison to the Gold Standard of force plate analysis and although promising, some inadequacies found. This work is in press in the *American Journal of Veterinary Research*. Work is continuing on a modified system of an inertial measurement unit (IMU) in collaboration with Dr. Mick Peterson at the University of Maine (as well as a strain gauge system in collaboration with Dr. Peterson and Dr. Jeff Thomason).

Dr. Lacy Kamm, a large animal surgery resident (working with Drs. Goodrich and McIlwraith), has also done a detailed descriptive study of the equine proximal interphalangeal joint (paster joint) (PIP) using magnetic resonance imaging, contrast arthrography, and arthroscopic examination which has defined completely our ability to diagnose and treat problems in the dorsal and palmar pouches of the PIP joint. It was found arthroscopic approaches allow adequate access to the proximal interphalangeal joint for diagnosis and anatomy surrounding the joint is described. There are limitations with a surgical approach to certain areas.

The study on radiographic changes in yearling cutting horses has progressed from a detailed evaluation of the incidence of lesions of looking at the significance of those changes with regard to soundness/lameness and cutting performance. The initial study was performed by Dr. Erin Contino (and is in press in *Equine Veterinary Journal*) and the latter study by Dr. Barrett (see research reports) is in submission at *Equine Veterinary Journal*.

Dr. Werpy has also done studies on a novel technique for ultrasound examination of the suspensory ligament, the pioneering comparative study of MRI changes compared to histologic changes of the navicular region in the horse. Working with Dr. Frisbie and Lauren Farrington, a pre-veterinary student, she also developed better techniques for radiographic-guided needle placement into the collateral ligaments of the distal interphalangeal joint. These were presented at AAEP and are included in the abstracts.
3. Focus 3 Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease

Dr. Kawcak, working with student Chelsea Zimmerman, showed in previous work that horses that suffered from third metacarpal condylar fractures had a significant difference in the shape of their third metacarpal bones compared to those horses that did not fracture. In order to determine how abnormal shape influences the stresses across the joint, Dr. Katrina Easton, a recent Ph.D. graduate from the ORC, recently completed a finite element model of the fetlock joint and showed that the abnormal shape pattern found in horses that fractured can lead to a significant reduction in loading at the site of fracture, leading to the conclusion that those bones may not be properly conditioned for racing due to this shape.

Two additional studies have been recently completed as part of the Global Equine Research Alliance (GERA) in New Zealand. Drs. Kawcak and McIlwraith with Dr. Elwyn Firth at Massey University investigated the effects of early exercise on the metacarpophalangeal (front fetlock) joints assessing bone density, distribution using computed tomography (CT) as well as assessing articular cartilage metabolism and histologic assessment of synovial membrane, articular cartilage, and subchondral bone. Horses that were exercised since near birth had fewer gross lesions in the joints, greater bone fraction in the dorsal lateral aspect of the distal metacarpal condyle and higher bone formation rate compared to non-exercised horses. This paper has been published in *American Journal of Veterinary Research*, 2010.

A second study continuing GERA work was done by Drs. Firth and Neil Broom at Auckland University in New Zealand with Drs. Kawcak and McIlwraith looking at severity of articular lesions in the mid carpal joints between exercised and non-exercised horses as well as quantifying swelling behavior of the articular cartilage extracellular matrix. The investigators found a wide range of defects in the joint surfaces but there were no significant differences in the number or severity of lesions between the two groups. There were also no significant differences in material properties of the articular cartilage between both groups with regard to swelling behavior and the conclusion was that early conditioning had no negative effects of the articular cartilage on the mid carpal joints. Previous work had shown beneficial effect on the chondrocytes in the articular cartilage of the metacarpophalangeal joints.

Dr. Christina Lee, working with Drs. Frisbie and McIlwraith has been developing a reproducible model of cartilage injury that can be done in a dish in the laboratory. Mechanical load is applied to rapidly compressed cartilage explants to 60% of the total thickness and success was demonstrated at inducing histologic changes in cartilage that mimic injury induced OA that we see clinically. Using co-culture models of cartilage with synoviocytes under load we hope to be able to screen molecular based therapies including gene therapy to alter the progression of OA in response to injury and minimize the use of testing in live horses. This research has been accepted for publication and is hoped that it will be a useful *in vitro* model (avoiding any sacrificing of live animals) in evaluating putative therapies for OA.

4. Focus 4 Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

An *in vitro* study evaluating two different platelet rich plasma (PRP) formulations on anabolic and catabolic activities in equine cartilage and meniscal implants was led by Drs. Kisiday, working with Drs. McIlwraith and Frisbie in collaboration with Drs. Rodkey and Steadman of the Steadman Philippon Research Institute. Various proclamations have been made regarding the various formulations and the importance of platelet numbers and cells. Single spin technique with relatively low platelet counts was shown to be associated with higher protein and proteoglycan synthesis then a traditional double spin PRP technique. In addition, gene expression of the proteoglycan catabolic enzyme (ADAMTS-4 expression) was lowest for single spin PRP and suggest that single spin PRP preparation may be the
most advantage for intra-articular applications and double spin systems (despite higher platelet counts) should be considered with caution.

In another study, mesenchymal stem cell proliferation in expression of growth factors in response to shockwave treatment was evaluated in vitro. Although using proliferation cultures of stem cells, the first application of shockwave treatment decreased growth relative to unshocked MSCs but subsequent treatments did not affect MSC proliferation. This result suggests that MSCs are capable of acclimating to shockwave therapy. The conclusion was that no immediate benefit of shockwave therapy was observed when stem cells were administered but it seems that multiple shockwave treatments can be administered to defects without harming the repair response subsequent to MSC injection.

In addition, a second study on shockwave therapy in our in vivo equine OA model showed positive results in the subchondral bone (and no harmful side effects) in addition to the symptom modifying effects in the articular cartilage as previously reported.

Considerable work has continued with the adenoassociated viral vector that Dr. Goodrich has been working with Dr. Jude Samulski. The study done by Nikki Phillips (research associate in the lab) in collaboration with Drs. Goodrich, Samulski and McIlwraith showed that age does not appear to significantly influence the efficacy of gene transduction using a self-complimentary adeno-associated viral vectors (scAAV) in synoviocytes and chondrocytes in horses. Because the adult population may be more prone to receiving gene therapy then neonatal or young animals this is valuable information.

Another study headed up by Dr. Goodrich showed that the scAAVIL-1ra vector injected into metacarpophalangeal and middle carpal joints of horses produced IL-1ra protein for 23 and 183 days, respectively. There was no evidence of intra-articular toxicity which has been a concern with previous regimens and the horses remained sound for the duration of the testing period. This work is continuing with higher numbers in order to evaluate the ideal dose to be used in osteoarthritis. The length of expression is particularly exciting.

Another study on scAAV transduction efficiencies in joint tissue monolayer and explant cultures and the effects of synovial fluid neutralization was done by Dr. Goodrich’s Ph.D. student, Daniel Hemphill, working with Drs. Goodrich, McIlwraith and Samulski. We’ve shown that gene transduction of chondrocyte and synovial monolayers significantly different than cartilage synovial explants and this study highlights the necessity to test gene therapeutic tissue in situ. Neutralizing antibodies were found to exist in both the synovial fluid and the serum which could reduce efficient gene transduction. It is important to determine which serotypes have antibodies that exist in the horse. A pivotal in vitro study was done looking at gene and protein expression with autologous conditioned plasma (ACP™) and comparing the newer IRAPII™ to the earlier product IRAPI™. This study has recently been published in the Equine Veterinary Journal and showed superior IL-1ra protein production and more particularly, significantly improved IL-1ra/IL-1 ratios with the IRAPII™ system compared to the IRAPI™. In addition, the concentrations of a harmful cytokine, TNF-α were higher in the IRAPII™ system.

5. Focus 5 Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease

The last two years have seen the completion of the pivotal underwater treadmilling study in horses. Dr. Melissa King completed her Ph.D. working with Drs. Kawcak, Haussler, Reiser, and McIlwraith and showed marked therapeutic effects of underwater treadmilling in decreasing symptom and disease effects in equine experimental osteoarthritis in the knee. In addition, the underwater treadmilled horses showed considerable improvement in proprioception parameters. This is the first scientific evaluation of underwater treadmilling in horses and reinforces the positive clinical results obtained. A randomized controlled study in clinical cases after arthroscopic surgery showed improvement in functional parameters.
Program Synopsis

surgery in a study at Pegasus Training Center in Seattle by Drs. McIlwraith and Haussler working with Drs. Jim Bryant and Mark Dedomenico is ongoing.

Another project under Focus 5 was the use of an equine back profiling system for objectively measuring dorsal trunk contours as it relates to saddle fitting. The equine back profiling system (EBPS) was able to reliably capture a wide variety of dorsal trunk contours and provides a significant advancement as we are now able to better communicate findings or changes in dorsal trunk contours related to saddle fit to colleagues, owners, and trainers.

Details of these projects above are in the Research Summaries.

Future and Current Research at the ORC

The 2010-2011 years have been challenging but exciting times for the Orthopaedic Research Center. The scientists have continued to achieve considerable extramural funding in the last two years, including long-term funding to offset the economic difficulties associated with endowed funding.

The research projects continue to revolve around the programs five main focuses.

1. Focus 1 Joint Tissue Healing

Another study headed up by Dr. Frisbie is evaluating the effects of clinically relevant autologous conditioned blood products (IRAPIT™, ACP™, and various other PRP products) on the anabolic properties equine digital flexor tenocytes and suspensory ligament fibroblasts to examine these products on tendon healing.

A 12-month study to evaluate the effect of implantation of the novel chondroprogenitor cells produced from the superficial layers of articular cartilage is under way. Earlier work by Dr. Helen McCarthy, working with Professor Charlie Archer at the University of Cardiff, has shown superiority in in vitro production of cartilage tissue and avoidance of terminal differentiation of the repair tissue into bone. The technique is now being evaluated in a 12-month study with full thickness defects on the medial trochlear ridge of the femur with the novel chondroprogenitor cells implanted in fibrin.

An eight-month equine study evaluating bone marrow derived stem cells in a fibrin/PRP scaffold has been completed. This project has been led by Dr. Laurie Goodrich (with Dr. McIlwraith) as part of a sub-contract for an NIH RO1 grant with Dr. Connie Chu at the University of Pittsburgh. Dr. Bob Sah at UC San Diego, and Dr. Lisa Fortier at Cornell University, are also collaborators.

A long-term study evaluating a new model of tendonitis is being led by Dr. Dave Frisbie working with Drs. Alex Valdez and Wayne McIlwraith. We are using a traumatically induced model previously described by investigators at Utrecht University in Holland. This 12-month study is comparing imaging of the lesions with ultrasound compared to contrast CT and contrast MRI. It is hoped that a better system of evaluating therapies for tendonitis will be the result of this work and the plan is to incorporate preliminary finding into a critical study on a novel stem cell technique. In conjunction with this project, Dr. Melissa King is collecting kinematic and kinetic data from this group of horses to investigate the changes in forelimb biomechanics associated with acute tendon injury and repair. This portion of the study is expected to be a noninvasive method for determining the biomechanical extent of the repair process and may be used in future studies to evaluate the efficacy of various treatment options for tendon injury.

2. Focus 2 Early Diagnosis of Bone and Joint Disease

Dr. Kawcak is leading two studies at this time that focus on the use of computed tomography for diagnosis of stifle and suspensory ligament injuries. The goal is to develop a rapid scanning technique that can be used for these problems.
We continue to pursue validation of synovial fluid and serum biomarkers for musculoskeletal disease in horses. Analysis of the biomarkers from the three-year GERA study has been completed with the help of Dr. John Cockrem at Massey University. These biomarkers are currently being analyzed but will show changes from birth to the end of the three-year-old year of racing Thoroughbreds.

The study where gene chip microarray was used to find novel markers in our experimental OA model has finally been analyzed and a manuscript submitted. This work has been done by Dr. Lacy Kamm with Drs. Frisbie and McIlwraith.

Also we are embarking on exploration of other biomarkers in collaboration with Dr. Peter Clegg at the University of Liverpool as well as examining potential tendon biomarkers with Dr. Dick Heinegård of the University of Lund in Sweden.

A long-term goal of this work is identifying biomarkers that may predict exercise-induced tendinopathy.

3. Focus 3 Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease

Work continues with finite element modeling to understand the pathogenesis of traumatically induced osteochondral disease and fractures in the equine athlete. This work is headed by Dr. Kawcak.

4. Focus 4 Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse

Work continues with the evaluation of intra-articular PRP, IRAP™ as well as mesenchymal stem cells (MSCs) as intra-articular therapies for equine traumatic arthritis and OA.

Dr. Laurie Goodrich is continuing work on gene therapy vectors, specifically in an adenoassociated virus (AAv) to deliver important genes to cells of joint tissues such as cartilage, synovium and mesenchymal stem cells. The collaboration with Dr. Jude Samulski at The Gene Therapy Center at UNC has already resulted in a paper published in the journal Human Gene Therapy Journal and describes the best serotypes of these vectors in transvection to synovial membrane and cartilage after intra-articular injection as identified by green fluorescent protein expression. Currently *in vivo* dose titration studies are being done and this will lead to testing an AAv-IL-1ra in our equine osteoarthritis model. It appears that these vectors will safely and efficiently deliver important gene sequences to the cells of the normal or injured joint and result in long-term protein expression. This work was initially supported by an NIH KO8 grant obtained by Dr. Goodrich (with Dr. Jude Samulski of the University of North Carolina and Dr. McIlwraith as co-mentors) and the development of vector costs for the initial study as well as of *in vivo* dose titration study has been supported by funds donated by Herbert Allen of Allen & Company for cutting edge techniques. These funds will also support the study of AAv-IL-1ra in our equine osteoarthritis model.

In addition to assessment of these new therapies, our pursuit of better biological therapies continues. The use of bone marrow-derived mesenchymal stem cell therapies has been used in a clinical study of soft tissue healing in joints has been submitted for publication.

A 12-month-long term study with the traumatically induced tendonitis model is evaluating intralesional bone marrow-derived MSCs for tendonitis. This 12-month study is also using novel imaging techniques of contrast CT and contrast MRI to evaluate the healing and compare it to tendon strength at the end of twelve months.

Dr. Kisiday is also assessing the influence of dynamic loading on mesenchymal stem cells and their activity.

5. Focus 5 Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease

We are currently applying rehabilitation techniques through the Equine Sports Medicine service. Dr. Melissa King is leading this effort and applying the results from her graduate work to this endeavor. Dr.
Program Synopsis

King submitted two manuscripts on her Ph.D. work in underwater treadmill exercise in horses.

Carrie Adrian is in the process of finalizing the first manuscript reporting EMG changes after canine cruciate ligament injury and rupture for submission. Dr. Adrian will also be involved in a new collaboration on clinical canine rehabilitation.

The collaborative studies with Pegasus Rehabilitation on carpal chip rehabilitation and SDFT rehabilitation with hyperbaric oxygen therapy, underwater treadmill exercise, swimming, and a progressive exercise program in Thoroughbred racehorses is ongoing. It has been very difficult getting sufficient cases for this randomized controlled study, but over 50 percent of the horses have been treated and it is hoped that this study will be completed in 2012.

With the development of the new clinical Sports Medicine Program as well as offering rehabilitation to patients, it is hoped to extend our database regarding rehabilitation and this work will be done along with our two Sports Medicine and Rehabilitation residents, Drs. Ferris and Contino.

Dr. Haussler is collaborating on a NASA grant with Dr. Puttlitz investigating in vivo bone healing in unweighted space conditions and the role of physical therapy modalities to stimulate bone healing in this environment. Low intensity pulsed ultrasound will be used in pilot studies to assess its effect on bone healing in this animal model during treadmill locomotion.

Dr. Haussler is also collaborating with Dr. Puttlitz investigating a biological microelectromechanical system (Bio-Mems) for in vivo application for measuring tendon strain and healing in response to physical therapy in a sheep model. Passive joint range of motion will be used in pilot studies to assess its effect on tendon healing in this animal model.
The Orthopaedic Research Center at Colorado State University is a comprehensive research facility predominantly focusing on the prevention and repair of orthopedic disease in humans and animals. In addition to protein biomarker analysis and development, this program is supported by several molecular biology applications such as antibody purification, real-time PCR assay development and gene expression analysis, cell and tissue culture techniques, adenoviral construction and cloning, gene chip microarray, biomechanical testing, and histological procedures. As the support structure for biomedical research continues to expand with modern medical discoveries and advances, the Orthopaedic Research Center will continue to provide ground-breaking research for the future.

Below is a brief list of the laboratory applications and services provided by the ORC.

1. Biomarker Analysis

Fully equipped to run any commercially available absorbance or fluorescence biomarker immunoassay in 96 or 384-well plate format, using Molecular Devices SpectraMax 384 plus, microplate absorbance/transmittance reader, as well as a Gemini-XS Fluorometer.

Extensive experience with the following biomarker assays:

- Detection of Cartilage Markers:
  - Alcian Blue: Standardize measurement of 35S labeled proteoglycan complexes.
  - C1,C2: An assay to standardize the measurement of Types I and II collagen degradation.
  - CPII: An assay to measure type II collagen carboxy propeptide (C-propeptide).
  - Eq. Col 2 ¾ (CEQ): An assay to quantify equine specific Type II collagen, which has also been proven to work with canine fluid.
  - GAG DMBB: An assay for standardized measurement of glycosaminoglycans in biological fluids and/or tissues.
  - Prolagen-C: Measurement of C-Terminal propeptide Type-I collagen.
  - Pyd Assay: An assay to standardize measurement of pyridinoline crosslinks in serum and urine.
  - Pyrlinks-D: To standardize measurement of deoxypyridinoline crosslinks in urine.
  - TCA: Assay to measure 3H content in media or cartilage digested samples.

- Detection of Bone Markers:
  - C1,2C: An assay to standardize measurement of Type I and II collagens (378 assay, MMP1 and MMP13).
  - Metra™ BAP: Quantification of bone-specific alkaline phosphatase in serum and synovial fluid samples.
  - Metra™ Osteocalcin EIA: An enzyme immunoassay for the quantification of intact (de novo) osteocalcin.
  - Serum Cross Laps™ (CTX): Assay for the quantification of degradation products of C-terminal telopeptides of Type-I collagen in serum and plasma.

- Cytokine Assays:
  - HIL-1ra: To standardize the measurement of interleukin 1 receptor antagonist concentrations in cell culture supernatant, serum and plasma.
  - IGF: To standardize the measurement of Insulin-like Growth Factor in Serum, Cell culture and plasma.
  - TGF-α: An assay to quantify measurement of Transforming Growth Factor-beta in serum, cell culture supernatant, plasma, and urine.
  - TNF-alpha: An assay to quantify levels of Tumor Necrosis Factor-alpha in serum, plasma, synovial fluid, and cell culture supernatant.
  - IL-10: An assay to quantify levels of Interleukin-10 in serum, plasma, and cell culture supernatant.
Research Techniques Available at the Orthopaedic Research Center

- **PDGF-BB**: An assay to quantify levels of Platelet-Derived Growth Factor-BB subunit in serum, plasma, and cell culture supernatant.
- **PGE2**: An assay to quantify levels of Prostaglandin E2 in serum, plasma, synovial fluid, cell culture supernatant, and urine.

- **Pre-assay sample processing including**: papain, hyaluronidase, and collagenase digestion, as well as chromatography extraction of synovial fluid, serum, and tissues.

- **Western, Southern, and Northern Blotting**
- **Many other assays available. Please inquire.**
  - PDGF-BB: An assay to quantify levels of Platelet-Derived Growth Factor-BB subunit in serum, plasma, and cell culture supernatant.
  - PGE2: An assay to quantify levels of Prostaglandin E2 in serum, plasma, synovial fluid, cell culture supernatant, and urine.

2. **Biomechanical Testing**

- Displacement control testing for compressive, tension, and shear material properties
- Tissue explants or cell-seeded scaffolds
- Light to moderate load cells are suitable for testing small tissue explants or cell-seeded scaffolds

3. **Molecular Biology**

- Evaluation of metabolic activity in living tissues
  - Radiolabel protocols available

- **GeneChip® Microarray Analysis**
  - Complete Affymetrix GeneChip® 3000 scanner, fluidics 450, and hybridization system

- **Real Time PCR Analysis**
  - ABI Prism® 7000 Sequence Detection System
  - Optimization of PCR Primers

- **RNA/DNA Exctrations/Isolations**
  - cDNA synthesis from RNA
  - RNA from cells, tissue, or whole blood
  - Primer and probe design
  - Gel extraction and purification
  - Purification of plasmid DNA
  - PCR amplification

- **Isolation of Synoviocytes, Chondrocytes, and Tenocytes**
  - Cell culture expansion of freshly collected cells

- **Culturing of Mesenchymal Stem Cells (bone-marrow derived or fat-derived)**
  - Cell culture expansion of bone-marrow derived or adipose-derived cells, including three-dimensional culturing for clinical use

- **Adenoviral Vector construction and cell transfection**
  - The development of adenoviral vectors for the delivery of genes into cells

4. **Histology Services**

- **Decalcified tissue histology**
- **Immunohistochemistry**
- **Paraffin and frozen Sectioning and staining of paraffin embedded samples**
- **Histomorphometric analysis**
The Orthopaedic Bioengineering Research Laboratory (OBRL) is an interdisciplinary research and educational effort bringing together engineers, clinicians, biologists, and scientists all over campus. The goal of the laboratory is to provide an environment for undergraduate and graduate education in Biomedical Engineering while advancing treatment and/or prevention of muscular, neuromuscular or skeletal injury and/or disease. The primary research focuses include:

1. **Computational Simulation of Orthopaedic Conditions and Treatments**
   a. Finite element analysis
   b. Cadaver and animal experiments to validate and augment the computational models

2. **Biomaterials Development**
   a. Enhancing wear resistance of polymeric orthopaedic implant bearing materials
   b. Biopolymer derivative synthesis and characterization
   c. Bioactive and osteoinductive bone graft materials

3. **Engineering and Growth Factor Therapy for Cartilage and Bone Repair**
   a. In vitro cell culture assessment
   b. Animal models to evaluate repair
   c. In vitro micro-assessment of mechanics of regenerated and normal tissue
   d. Development and assessment of biomaterial carriers

4. **Retrieval Analysis for Failure Assessment, Design Improvement, and Tissue Interface**
   a. Orthopaedic implants
   b. Allograft bone composites
   c. Synthetic bone graft materials

5. **Biocompatibility and Biomaterial/Tissue Interface**
   a. Interface biomechanics
   b. Tissue response to biomaterials

6. **Comparative Orthopaedics and Animal Models**
   a. Animal model development and validation
   b. Comparison of human and other animal disease mechanisms and treatment efficacy

7. **Biomechanical Analysis**
   Equipment available includes: minibionix MTS machine, standard MTS, spine tester, biaxial tester
   a. Range of motion/kinematics
   b. Materials testing for shear strength
   c. Tension and compression analysis

8. **Hard Tissue Structural Analysis**
   a. MicroComputedTomography (µCT) – High resolution imaging of bone to determine bone volume and morphology
   b. Non-decalcified hard tissue histology
   c. Histomorphometric analysis

---

Research Techniques Available at the Orthopaedic Bioengineering Research Laboratory
Scientific Publications and Presentations

Textbook Chapters
2010


Textbook Chapters
2011


Scientific Publications and Presentations


Scientific Publications and Presentations


Scientific Publications and Presentations


Refereed Publications

2010


Almodovar J., Bacon S., Gogolski J., Kisiday J., Kipper M. Polysaccharide-based polyelectrolyte multilayer surface coatings can enhance mesenchymal stem cell response to adsorbed growth factors. Biomacromolecules, 2010;11:2629-239.


Scientific Publications and Presentations

Carpenter R.S., Goodrich L.R., Frisbie D.D., Kisiday J.D., Carbone B., McIlwraith C.W., Centeno C.J., Hidaka C. Osteoblastic differentiation of human and equine adult bone marrow-derived mesenchymal stem cells when BMP-2 or BMP-7 homodimer genetic modification is compared to BMP-2/7 heterodimer genetic modification in the presence and absence of dexamethasone. *J Orthop Res* 2010;28:1330-1337.


**Scientific Publications and Presentations**


Werpy N.M., Ho C.P., Kawcak C.E. Magic angle effect in normal collateral ligaments of the distal interphalangeal joint in horses imaged with a high-field magnetic resonance imaging system. *Vet Radiol Ultrasound* 2010;51:2-10.

Scientific Publications and Presentations


**Refereed Publications**

**2011**


Scientific Publications and Presentations


Scientific Publications and Presentations


**Scientific Publications and Presentations**


Woldtvedt D.J., Womack W., Gadomski B.C., Schuldt D., Puttlitz C.M. Finite element lumbar spine facet contact parameter predictions are affected by the cartilage thickness distribution and initial joint gap size. *J Biomech Eng* 2011;133:061009.


Zoppa A.L., Santoni B., Puttlitz C.M., Cochran K., Hendrickson D.A. Arthrodesis of the equine proximal interphalangeal joint: A biomechanical comparison of three-hole 4.5 mm locking compression plate and three-hole 4.5 mm narrow dynamic compression plate with two oblique 5.5 mm cortex screws. *Vet Surg* 2011;40:253-9.

**Published Abstracts/Proceedings**

2010


Scientific Publications and Presentations


Goodrich L.R. Correlations of stifle arthroscopy and ultrasound. American College of Veterinary Surgeons Symposium, Seattle, Wash. 2010.


Scientific Publications and Presentations


Scientific Publications and Presentations


Scientific Publications and Presentations


Scientific Publications and Presentations


Werpy N.M., Ho C.P., Kawcak C.E. Magic angle effect in normal collateral ligaments of the distal interphalangeal joint in horses imaged with a high-field magnetic resonance imaging system. *Vet Radiol Ultrasound* 2010;51:2-10.


Published Abstracts/Proceedings

2011


Scientific Publications and Presentations


Scientific Publications and Presentations


Scientific Publications and Presentations

Oral Presentations
2010


Frisbie D.D. Defining stem cells, what is out there, their clinical use in joints and tendons. Northwest Equine Practitioner’s Association, Bend, Ore., March 12-14, 2010.

Frisbie D.D. Defining shockwave therapy, what is out there, its clinical use on tendons and joints. Northwest Equine Practitioner’s Association, Bend, Ore., March 12-14, 2010.
Scientific Publications and Presentations


Haussler K.K. 6th International Association of Veterinary Rehabilitation and Physical Therapy Symposium, Auburn University, College of Veterinary Medicine, Auburn, Ala., 2010.


Haussler K.K. 71st Annual Conference for Veterinarians, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colo., January 2010.


Haussler K.K. Colorado Veterinary Medical Association Annual Convention, Loveland, Colo., September 2010.

Haussler K.K. The DeeDee Arrisone Holistic and Integrative Wellness Seminar Series. College of Veterinary Medicine, Cornell University, N.Y., October 2010.

Haussler K.K. Diagnosis & Treatment of Lameness in Horses, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colo., February 2010.


Haussler K.K. Student Chapters of the American Association of Equine Practitioners and the Pain Management Club, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colo., October 2010.


Scientific Publications and Presentations


McIlwraith C.W. AO North America, Equine Principles of Fracture Management course, Faculty member: 3 lectures and 3 two hour laboratories, Columbus, Ohio., April 22-25, 2010.


McIlwraith C.W. Basic arthroscopic surgery course, Muenster, Germany. Three 1-hour lectures and three 2-hour laboratories, May 28-29, 2010.

McIlwraith C.W. Basic arthroscopic surgery course, Colorado State University, Fort Collins, Colo. Four hours of lecture and four hours of laboratory, June 10, 2010.

McIlwraith C.W. Advanced arthroscopic surgery course, Colorado State University, Fort Collins, Colo. Eight hours of lecture and four hours of laboratory, June 11-12, 2010.


McIlwraith C.W. FEI Congress on NSAIDs usage in the Equine Athlete, Lausanne, Switzerland. Two invited lectures, “What are NSAIDs used for in equine practice?” “How effective are NSAIDs at pain control in horses?” Chaired another session, August 16-17, 2010.


McIlwraith C.W. International Advanced Course in Arthroscopic Surgery, Muenster, Germany. Six hours of lecture and three hours of laboratory, October 15-16, 2010.


McIlwraith C.W. November 11-12, 2010 – AONA Challenges in Fracture Care across Disciplines, Phoenix, Ariz. Invited lecture, “Applied basic science research: cartilage repair as it relates to articular fracture, injury and joint function.”


Oral Presentations

2011


Scientific Publications and Presentations


McIlwraith C.W. Colorado State University Delegation to visit UADY Merida, Mexico. “A one health approach to addressing arthritic and joint diseases of humans and animals,” January 17, 2011.


McIlwraith C.W. Havemeyer Conference on Regenerative Medicine, Sagauro Lake Ranch, Ariz. “Equine joint models” and 4 days discussion, May 2-5, 2011.

McIlwraith C.W. Basic Equine Arthroscopic Surgery course, Berlin, Germany. 4 hours lecture and three 4-hour laboratories, May 27-28, 2011.

McIlwraith C.W. University of Liverpool, Department of Musculoskeletal Biology Annual Science Day. Keynote lecture, “Attempts at cartilage resurfacing: studies in equine models,” June 8, 2011.


McIlwraith C.W. Basic Equine Arthroscopic Surgery Course, Colorado State University, Fort Collins, Colo. 4 hours of lecture and 4 hours laboratory, August 4, 2011.

McIlwraith C.W. Advanced Arthroscopic Surgery Course, Colorado State University, Fort Collins, Colo. 8 hours lecture and 4 hours laboratory, August 5-6, 2011.


McIlwraith C.W. Advanced Arthroscopic Surgery of the Stifle course, Cornell University, Ithaca, New York. 5 lectures and 2 laboratories (2-day course), September 16-17, 2011.


McIlwraith C.W. 57th Annual Convention American Association of Equine Practitioners, San Antonio, Texas. Lecture, “The use of corticosteroids” and participation in panel, Choosing joint therapies for the best results. Two Table Topics (1.5 hrs each), “The FDA and drug compounding” (with Jeff Berke, Lynn Oliver & Scott Stanley) and “The American College of Veterinary Sports Medicine and Rehabilitation: What is it about and how might one qualify?” (with Chris Kawcak), November 19-22, 2011.
Scientific Publications and Presentations


## Funded Research Projects

<table>
<thead>
<tr>
<th>Title</th>
<th>Investigators</th>
<th>Sponsor</th>
<th>Project Period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Track Banking and the Asymmetry of Hoof Loading</td>
<td>J.J. Thomason (PI) University of Guelph; C. Wayne McIlwraith (Co-I)-1678</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>2010-2011</td>
<td>$36,761.00</td>
</tr>
<tr>
<td>Incidence of Nonfatal Injuries in Racing Thoroughbreds</td>
<td>C. Wayne McIlwraith (Primary PI)-1678</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>2009-2010</td>
<td>$44,397.00</td>
</tr>
<tr>
<td>Performance Parameters for Engineering Track Management</td>
<td>C. Wayne McIlwraith (Primary PI)-1678</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>2008-2010</td>
<td>$43,838.00</td>
</tr>
<tr>
<td>Evaluation of Intra-Articular Polyglycan Versus Intravenous Polyglycan or Saline (0.9%NaCl) for Osteoarthritis Using an Equine Model</td>
<td>C. Wayne McIlwraith (Primary PI)-1678; Christopher E Kawcak (Co-PI)-1678; David D Frisbie (Co-PI)-1678</td>
<td>ArthroDynamic Technologies, Inc.</td>
<td>2007-2011</td>
<td>$644,832.00</td>
</tr>
<tr>
<td>Effect of Rehabilitation on Carpal Osteoarthritis</td>
<td>Melissa King (PI)-1678; C Wayne McIlwraith (Co-I)-1678</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>2009-2010</td>
<td>$19,994.00</td>
</tr>
<tr>
<td>Gene Transfer Treatment of Articular Cartilage Damage</td>
<td>David D. Frisbie, C. Wayne McIlwraith (Co-PIs)-1678; Steve Trippel (PI) University of Indiana</td>
<td>NIH R01AR047702-07A1</td>
<td>2011-2014</td>
<td>$516,060.00</td>
</tr>
<tr>
<td>Effects of Clinically Relevant Autologous Conditioned Blood Products (ACBP) on the Anabolic Properties of Equine Digital Flexor Tenocytes and Suspensory Ligament Fibroblasts</td>
<td>David D. Frisbie (Primary PI)-1678; C. Wayne McIlwraith (Co-PI)-1678; Thomas Howard Hraha (Co-PI)-1678</td>
<td>AQHA-American Quarter Horse Assoc.</td>
<td>2009-2010</td>
<td>$19,560.00</td>
</tr>
<tr>
<td>Self-Assembling Peptide for Tissue Engineering</td>
<td>David D. Frisbie (PI of subcontract)-1678; C. Wayne McIlwraith (Co-PI)-1678; with Dr. Alan Grodzinsky (MIT)</td>
<td>HHS-HIH (NIH MIT subaward amendment) (5-R01-EB003805-03 5710002213)</td>
<td>2007-2010</td>
<td>$590,205.00</td>
</tr>
<tr>
<td>Evaluation of Intra-Articular Polysulfated Glycosaminoglycan (Adequan) Versus Intra-Articular Hyaluronate Sodium (Hylavisc) or Saline (0.9% NaCl) for Osteoarthritis</td>
<td>David D. Frisbie (Primary PI)-1678; C. Wayne McIlwraith (Co-PI)-1678; Christopher E. Kawcak (Co-PI)-1678</td>
<td>Luitpold Pharmaceuticals</td>
<td>2007-2008</td>
<td>$357,601.00</td>
</tr>
<tr>
<td>Evaluation of Intra-Articular Polysulfated Glycosaminoglycan (Adequan) and Amikacin, Versus Intra-Articular Polysulfated Glycosaminoglycan (Adequan) and Triamcinolone Acetonide with Amikacin or Saline (0.9% NaCl) with Amikacin for Osteoarthritis Using an Equine Model</td>
<td>David D. Frisbie (Primary PI)-1678; C. Wayne McIlwraith (Co-PI)-1678; Christopher E. Kawcak (Co-PI)-1678</td>
<td>Luitpold Pharmaceuticals</td>
<td>2009-2010</td>
<td>$357,602.00</td>
</tr>
<tr>
<td>ARRA: Multicenter Cartilage Repair Preclinical Trial in Horses</td>
<td>Laurie R. Goodrich (PI subcontract)-1678; C. Wayne McIlwraith (Co-I)-1678; John D. Kisiday (Co-I)-1678; Connie Chu (PI) University of Pittsburg</td>
<td>NIH ARRA (5327810)</td>
<td>2009-2011</td>
<td>$459,989.00</td>
</tr>
<tr>
<td>ARRA: Gene Therapeutic Approaches to Cartilage Repair</td>
<td>Laurie R. Goodrich (Primary PI)-1678; C. Wayne McIlwraith (Co-mentor); Jude Samulski (Co-mentor) (University of North Carolina)</td>
<td>HHS-NIH-National Institutes of Health</td>
<td>2009-2011</td>
<td>$108,000.00</td>
</tr>
</tbody>
</table>
### Funded Research Projects

<table>
<thead>
<tr>
<th>Title</th>
<th>Investigators</th>
<th>Sponsor</th>
<th>Project Period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAV-IRAP Gene Therapy to Prevent Osteoarthritis</td>
<td>Laurie R. Goodrich (Primary PI)-1678; David D. Frisbie (Co-PI)-1678</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>2011-2013</td>
<td>$134,757.00</td>
</tr>
<tr>
<td>Orthokine Protocol to Assess Serum Protein Factors</td>
<td>Frisbie D.D., McIlwraith C.W., Reardon K.F., Carbone B.A.</td>
<td>Arthrex</td>
<td>11/1/2006-10/31/2008</td>
<td>$49,307.00</td>
</tr>
<tr>
<td>Evaluating Reduction in Lameness or Prevention of Pathological Bone Changes Following Application of Dynamix Shoes</td>
<td>Frisbie D.D., Kawcak C.E.</td>
<td>Dynamix</td>
<td>1/1/2001-6/30/2009</td>
<td>$432,174.00</td>
</tr>
<tr>
<td>Pilot Study to Assess the Short Term Effects of Chondrofix in Equine Model #18,000.01</td>
<td>Frisbie D.D., McIlwraith C.W.</td>
<td>Zimmer, Inc.</td>
<td>12/19/2005-6/30/2009</td>
<td>$296,061.20</td>
</tr>
<tr>
<td>Horse Gait Trials at CSU</td>
<td>Kawcak C.E., Frisbie D.D., Werpy N.M., McIlwraith C.W.</td>
<td>Sharp Foundation</td>
<td>11/1/2008-10/31/2009</td>
<td>$28,500.00</td>
</tr>
<tr>
<td>An Experimental Model for Tendon Strain Injury and Mesenchymal Stem Cell Interactions</td>
<td>Kisiday J.D., Frisbie D.D.</td>
<td>CRC Funding</td>
<td>7/1/2008-6/30/2009</td>
<td>$10,500.00</td>
</tr>
<tr>
<td>Colorado Racehorse Postmortem Evaluation Project</td>
<td>Kawcak C.E., Werpy N.M.</td>
<td>CRC Funding</td>
<td>7/1/2008-6/30/2009</td>
<td>$15,000.00</td>
</tr>
<tr>
<td>Mesenchymal Stem Cell Proliferation and Migration Out of Fibrin Scaffolds in Response to Shockwave Treatment</td>
<td>Kisiday J.D., Frisbie D.D., McIlwraith C.W.</td>
<td>Pulse Veterinary Technologies LLC</td>
<td>7/15/2009-7/31/2010</td>
<td>$20,420</td>
</tr>
<tr>
<td>Evaluation of Intrarticular Polysulfated Glycosaminoglycan (Adequan) and Amikacin, Versus Intrarticular Polysulfated Glycosaminoglycan (Adequan) and Triamcinolone Acetonide with Amikacin or Saline (0.9% NaCl) with Amikacin for Osteoarthritis Using an Equine Model</td>
<td>Frisbie D.D., McIlwraith C.W., Kawcak C.E.</td>
<td>Luitpold Pharmaceuticals</td>
<td>4/8/2009-4/7/2010</td>
<td>$357,601</td>
</tr>
<tr>
<td>Title</td>
<td>Investigators</td>
<td>Sponsor</td>
<td>Project Period</td>
<td>Amount</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Evaluation of Polyglycan (At a Single Dose Level and Three Time Dose Level) Versus Saline (0.9% NaCl) After Intraarticular Injection</td>
<td>Kawcak C.E., McIlwraith C.W., Frisbie D.D.</td>
<td>ArthoDynamic Technologies, Inc</td>
<td>6/1/2008 – 5/31/2009</td>
<td>$75,990</td>
</tr>
<tr>
<td>Gene Therapeutic Approaches to Cartilage Repair</td>
<td>Goodrich L.R., McIlwraith C.W.</td>
<td>NIH Mentored Clinical Scientist Research Career Development Award (K08)</td>
<td>6/01/2008-5/01/2013</td>
<td>$677,875</td>
</tr>
<tr>
<td>A Gene Therapy Approach to Cartilage Healing Utilizing Adenoassociated Viral Vectors in Bone Marrow-Derived Mesenchymal Stem Cells</td>
<td>Goodrich L.R., McIlwraith C.W.</td>
<td>College Research Council, Colorado State University</td>
<td>3/01/2008-3/01/2009</td>
<td>$26,000</td>
</tr>
<tr>
<td>The Effect of Adenovirus Mediated Co-expression of Combined Bone Morphogenetic Protein-2 and 7 on Osteoblastic Differentiation of Equine and Human Bone Marrow-Derived Mesenchymal Stem Cells</td>
<td>Goodrich L.R., McIlwraith C.W.</td>
<td>College Research Council, Colorado State University</td>
<td>3/01/2007-3/01/2008</td>
<td>$30,000</td>
</tr>
<tr>
<td>Effect of Rehabilitation on Carpal Osteoarthritis</td>
<td>King M.R., McIlwraith C.W.</td>
<td>Grayson-Jockey Club Research Foundation</td>
<td>4/1/2009-3/31/2010</td>
<td>$15,000.00</td>
</tr>
<tr>
<td>Collaborative Research: Nanostructured Titania for Orthopedic Biomaterials</td>
<td>Popat K.C.</td>
<td>NSF - National Science Foundation</td>
<td>9/1/2008-8/31/2011</td>
<td>$180,000.00</td>
</tr>
<tr>
<td>Fibrotic Effects and Regulation of MMP Proteins in Thrombus Resolution</td>
<td>Puttlitz C.M.</td>
<td>N. CA Inst. for Research and Education</td>
<td>5/12/2006-4/30/2009</td>
<td>$126,298.00</td>
</tr>
<tr>
<td>The Annual Symposium on Computational Methods in Orthopaedic Biomechanics</td>
<td>Puttlitz C.M.</td>
<td>HHS-NIH-Arthritis, Musculoskel, and Skin</td>
<td>2/20/2009-8/31/2009</td>
<td>$15,000.00</td>
</tr>
<tr>
<td>A Development Proposal for an Instrumented Cervical Intervertebral Disc Space Distractor</td>
<td>Puttlitz C.M.</td>
<td>CSURF-CSU Research Foundation</td>
<td>7/12/2007-12/31/2008</td>
<td>$107,285.00</td>
</tr>
<tr>
<td>Partial Joint Resurfacing with Biopoly™RS – A Hydrophilic Polymer</td>
<td>James S.P., Puttlitz C.M., Kisiday J.D.</td>
<td>Schwartz Biomedical, LLC</td>
<td>12/1/2006-12/31/2008</td>
<td>$400,000.00</td>
</tr>
<tr>
<td>Augmentation of a Bone Tendon Reattachment with a PDGF Soaked Collagen Matrix in a Sheep Model</td>
<td>Puttlitz C.M.</td>
<td>Biomimetic Therapeutics, Inc.</td>
<td>11/1/2008-7/1/2009</td>
<td>$66,371.00</td>
</tr>
</tbody>
</table>
## Funded Research Projects

<table>
<thead>
<tr>
<th>Title</th>
<th>Investigators</th>
<th>Sponsor</th>
<th>Project Period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Vivo and In Vitro Measurements of Human Cervical Stress Relaxation during ACD</td>
<td>Puttlitz C.M.</td>
<td>Synthes</td>
<td>1/1/2007-3/31/2009</td>
<td>$39,000</td>
</tr>
<tr>
<td>STS/GCD Ovine Histology</td>
<td>Puttlitz C.M.</td>
<td>NuVasive, Inc.</td>
<td>7/1/2007-7/1/2008</td>
<td>$53,071</td>
</tr>
<tr>
<td>Comparison of Bone Cements in Sheep</td>
<td>Puttlitz C.M.</td>
<td>Medronic Spine LLC</td>
<td>3/17/2008-8/30/2008</td>
<td>$8,842</td>
</tr>
<tr>
<td>Triple Damper System Chronic Sheep Study: Biomechanical and Histomorphometric Evaluation of Sheep Lumbar Region</td>
<td>Puttlitz C.M.</td>
<td>Blackstone Medical, Inc.</td>
<td>5/2/2008-11/30/2008</td>
<td>$134,180</td>
</tr>
<tr>
<td>Evaluation of Bone Void Filler Resistance to Bleeding and Irrigation and Correlation with New Bone Formation in ...</td>
<td>Puttlitz C.M.</td>
<td>Kuros Biosurgery AG</td>
<td>5/1/2008-5/1/2009</td>
<td>$73,961</td>
</tr>
<tr>
<td>Title</td>
<td>Investigators</td>
<td>Sponsor</td>
<td>Project Period</td>
<td>Amount</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Evaluation of Polyglycan (At a Single Dose Level and Three Times Dose Level) Versus Saline (0.9% NaCl) After ...</td>
<td>Kawcak C.E., Frisbie D.D., McIlwraith C.W.</td>
<td>ArthroDynamic Technologies, Inc.</td>
<td>6/1/2008-5/31/2009</td>
<td>$75,990</td>
</tr>
<tr>
<td>Failed Spinal Fusion Analysis</td>
<td>Puttlitz C.M.</td>
<td>NuVasive, Inc.</td>
<td>6/17/2008-7/31/2008</td>
<td>$784</td>
</tr>
<tr>
<td>Long Term Implantation Effects of Flexion Limiting Device in an Ovine Model</td>
<td>Puttlitz C.M.</td>
<td>Simpirica Spine</td>
<td>12/1/2008-12/1/2009</td>
<td>$130,784</td>
</tr>
<tr>
<td>Screw Insertion Device Torque Assessment</td>
<td>Puttlitz C.M.</td>
<td>High Plains Technology Group LLC</td>
<td>6/15/2008-1/15/2009</td>
<td>$744</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>$8,125,573</strong></td>
</tr>
</tbody>
</table>
### Revenue and Expense, FY10 to FY11

<table>
<thead>
<tr>
<th>Donations – 64 Accounts</th>
<th>FY 11 07/01/10 to 06/30/11</th>
<th>FY 10 07/01/09 to 06/30/10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Donations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hargett, Carla</td>
<td>5,000</td>
<td>Employee's Community Fund Heidi Gordon on behalf Denise Steensland 65</td>
</tr>
<tr>
<td>(Raymond James Char. Endowment Fund)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Armstrong, Elizabeth</td>
<td>50</td>
<td>Emery, Jaynn 50,000</td>
</tr>
<tr>
<td>Powers, James</td>
<td>50</td>
<td>Equusys Incorporated 50,000</td>
</tr>
<tr>
<td>Carpenter, Cathy</td>
<td>13,000</td>
<td>Ochsner, Michael R. 100</td>
</tr>
<tr>
<td>(Dea Family Foundation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>William T. O'Donnell</td>
<td>500</td>
<td>American Quarter Horse 4,011</td>
</tr>
<tr>
<td>(for Lezlie Rehagen)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey S. Matthews</td>
<td>3,750</td>
<td>Walton Family Foundation (Alice Walton) 10,000</td>
</tr>
<tr>
<td>– Franklin Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partners</td>
<td></td>
<td></td>
</tr>
<tr>
<td>James M. Cox Jr.</td>
<td>250,000</td>
<td>Mill Creek Veterinary (James Latham) 250</td>
</tr>
<tr>
<td>Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Leigh Ann Launius)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ms. Gail Holmes, Double</td>
<td>52,663</td>
<td>Allen, Herbert A. (Allen &amp; Co.) 250,000</td>
</tr>
<tr>
<td>Dove Ranch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>McIlwraith</td>
<td>20,000</td>
<td>McKelvie, David K. and Linda 150</td>
</tr>
<tr>
<td>Allen &amp; Company, Kim</td>
<td>250,000</td>
<td>Elsevier Inc 67</td>
</tr>
<tr>
<td>Wieland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro Sports Club – on</td>
<td>50,000</td>
<td>Pro Sports Club – Domenico 50,000</td>
</tr>
<tr>
<td>Behalf of Mark Domenico</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. George Dewell D.V.M.</td>
<td>2,000</td>
<td>Community Foundation of Greater Memphis – Lee and Melanie Taylor 3,000</td>
</tr>
<tr>
<td>Mace Siegel</td>
<td>10,000</td>
<td></td>
</tr>
<tr>
<td>Wildenstein Family, LLC</td>
<td>2,500</td>
<td>McIlwraith, Wayne and Nancy Goodman McIlwraith 20,000</td>
</tr>
<tr>
<td>Voth, Roy H.</td>
<td>25</td>
<td>Simonds, William Jo 25</td>
</tr>
<tr>
<td>Ms. Cynthia Chesnutt</td>
<td>40</td>
<td>Oak Tree 1,667</td>
</tr>
<tr>
<td>Marilyn Dammon – King’s</td>
<td>150</td>
<td>Rood and Riddle 20,000</td>
</tr>
<tr>
<td>Hill Stables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cauleen Glass – in</td>
<td>350</td>
<td>Community Fund Boehing 60</td>
</tr>
<tr>
<td>memory of Denison P.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glass</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community Fund Boehing</td>
<td>95</td>
<td>Piper, Cynthia 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kuzyk, Zory (Oak Creek Ranch) 5,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Voth, Marlyn S. 25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ketch, R.J. (RJ Ketch Equine Inc) 75</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kawananakoa Foundation (Abigail) 35,100</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shideler, Robert K., D.V.M. 1,000</td>
</tr>
</tbody>
</table>

**Total Donations** 660,173 502,361
## Revenue and Expense, FY10 to FY11

<table>
<thead>
<tr>
<th></th>
<th>FY 11 07/01/10 to 06/30/11</th>
<th>FY 10 07/01/09 to 06/30/10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interest on Endowments</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wayne and Nancy McIlwraith Scholarship</td>
<td>5,602</td>
<td>McIlwraith Scholarship</td>
</tr>
<tr>
<td>Cox Anthony Chair</td>
<td>125,819</td>
<td>Cox Anthony Chair</td>
</tr>
<tr>
<td>Iron Rose Ranch Chair</td>
<td>111,457</td>
<td>Iron Rose Ranch Chair</td>
</tr>
<tr>
<td>Atkinson Chair</td>
<td>48,048</td>
<td>Atkinson Chair</td>
</tr>
<tr>
<td>Kawanananaka Chair</td>
<td>97,510</td>
<td>Kawanananaka Chair</td>
</tr>
<tr>
<td><strong>Total Interest</strong></td>
<td>388,437</td>
<td>365,173</td>
</tr>
<tr>
<td><strong>Medical Center Clinical Services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digital Xrays</td>
<td>2,178</td>
<td>Digital Xrays</td>
</tr>
<tr>
<td>Outpatient</td>
<td>19,104</td>
<td>Outpatient</td>
</tr>
<tr>
<td>MRI</td>
<td>47,544</td>
<td>MRI</td>
</tr>
<tr>
<td>Shockwave</td>
<td>26,323</td>
<td>Shockwave</td>
</tr>
<tr>
<td>Surgery</td>
<td>13,946</td>
<td>Surgery</td>
</tr>
<tr>
<td><strong>Client Services Total</strong></td>
<td>109,096</td>
<td>55,756</td>
</tr>
<tr>
<td><strong>ORC Ambulatory</strong></td>
<td>77,648</td>
<td>73,365</td>
</tr>
<tr>
<td><strong>ORC CORE Lab Revenue – 22 Account</strong></td>
<td>18,723</td>
<td>30,868</td>
</tr>
<tr>
<td><strong>Research Projects – 53 Accounts</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AQHA</td>
<td>22,200</td>
<td>Arthro</td>
</tr>
<tr>
<td>HHS-NIH ARRA</td>
<td>189,659</td>
<td>MIT</td>
</tr>
<tr>
<td>Grayson AAV-IRAP</td>
<td>63,566</td>
<td>AQHA</td>
</tr>
<tr>
<td>HHS-NIH Gene</td>
<td>122,364</td>
<td>Pulse</td>
</tr>
<tr>
<td>PITT ARRA</td>
<td>304,822</td>
<td>HHS-NIH Gene</td>
</tr>
<tr>
<td>HHS-NIH ARRA</td>
<td>108,000</td>
<td>AQHA – Pilot</td>
</tr>
<tr>
<td>Grayson – King</td>
<td>15,000</td>
<td>Grayson – King</td>
</tr>
<tr>
<td><strong>Research Accounts Total</strong></td>
<td>397,789</td>
<td>1,034,137</td>
</tr>
<tr>
<td><strong>Stallion Auction</strong></td>
<td>31,175</td>
<td>74,264</td>
</tr>
<tr>
<td><strong>State Funds – Various 14 and 16 Accounts</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frisbie Salary Savings</td>
<td>173</td>
<td>CWM Salary Savings</td>
</tr>
<tr>
<td>Goodrich Salary Savings</td>
<td>74,952</td>
<td>Frisbie Salary Savings</td>
</tr>
<tr>
<td>Haussler/Kisiday Start up</td>
<td>33,333</td>
<td>Goodrich Salary Savings</td>
</tr>
<tr>
<td>ICR Return</td>
<td>14,760</td>
<td>Haussler/Kisiday Start up</td>
</tr>
<tr>
<td>Kawcak CRC Grant</td>
<td>15,000</td>
<td>ICR Return</td>
</tr>
<tr>
<td>Kisiday CRC Grant</td>
<td>10,000</td>
<td>Kisiday CRC Grant</td>
</tr>
<tr>
<td>Haussler CRC Grant</td>
<td>16,000</td>
<td>PRSE Grant</td>
</tr>
<tr>
<td>PRSE Grant</td>
<td>20,182</td>
<td>PRSE Grant</td>
</tr>
<tr>
<td><strong>State Funds Total</strong></td>
<td>184,400</td>
<td>301,375</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>1,867,441</td>
<td>2,437,299</td>
</tr>
</tbody>
</table>
## Revenue and Expense, FY10 to FY11

<table>
<thead>
<tr>
<th></th>
<th>FY 11</th>
<th>FY 10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07/01/10 to 06/30/11</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EXPENSE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Salaries</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Faculty Salaries</td>
<td>575,515</td>
<td>756,388</td>
</tr>
<tr>
<td>Research Associate Salaries</td>
<td>356,472</td>
<td>361,964</td>
</tr>
<tr>
<td>Administrative Salaries</td>
<td>118,822</td>
<td>123,335</td>
</tr>
<tr>
<td>Graduate Student Salaries</td>
<td>68,975</td>
<td>119,949</td>
</tr>
<tr>
<td>Hourly EORC students</td>
<td>99,848</td>
<td>114,421</td>
</tr>
<tr>
<td><strong>Total Salaries</strong></td>
<td>1,219,634</td>
<td>1,476,058</td>
</tr>
<tr>
<td>Faculty Travel</td>
<td>36,014</td>
<td>37,662</td>
</tr>
<tr>
<td>Materials and Supplies</td>
<td>311,020</td>
<td>505,130</td>
</tr>
<tr>
<td>Other Direct</td>
<td>540,556</td>
<td>852,063</td>
</tr>
<tr>
<td>Equipment</td>
<td>77,378</td>
<td>–</td>
</tr>
<tr>
<td><strong>Expense Subtotal</strong></td>
<td>2,184,600</td>
<td>2,870,912</td>
</tr>
<tr>
<td>Facility and Administrative Overhead Costs</td>
<td>181,497</td>
<td>254,258</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td>2,366,097</td>
<td>3,125,170</td>
</tr>
<tr>
<td><strong>ACCOUNT BALANCE</strong></td>
<td>(498,657)</td>
<td>(687,871)</td>
</tr>
</tbody>
</table>
Honors and Awards

McIlwraith, C.W. Dr. med. vet. (honoris causa), Royal Veterinary College, University of London, 2010; Life Member, New Zealand Equine Veterinary Association, 2011.


Frisbie, D.D. AAEP President’s Award, 2011.

Goodrich, L.R. NIH Mentored Clinical Scientist Development Award, 2008-2013.


Puttlitz, C.M. Monfort Professor, Colorado State University, 2011.


Puttlitz, C.M. Editor’s Choice: one of the highest impact papers in Anesthesiology in 2009, 2010.


Reiser, R.F. Most Productive Mentor, Rocky Mountain Chapter, American College of Sports Medicine, 2010.
Editorial and Scientific Advisory Boards 2010-2011

Baxter, G.M.
- American Journal of Veterinary Research
- The Compendium for Continuing Education, Practicing Veterinarian

Frisbie, D.D.
- Journal of Sports Medicine & Doping Studies

McIlwraith, C.W.
- Equine Veterinary Journal Advisory Board
- Journal of Equine Veterinary Science
- Equine Veterinary Education Assistant Editor
- Steadman-Hawkins Foundation Scientific Advisory Board
- Cartilage Editorial Board
- AO Vet Advisory Committee
- New Zealand Equine Trust Board of Trustees
- American Association Equine Practitioners (AAEP) Foundation Advisory Committee
- European College of Veterinary Surgeons, Foundation Committee

Puttlitz, C.M.
- Computational Methods in Ortho Biomechanics
- Open Spine Journal

Reiser, R.F.
- Strength and Conditioning Journal Review Board
**Baxter, G.M.**
American College of Veterinary Surgeons
American Veterinary Medical Association
American Association of Equine Practitioners
Veterinary Orthopaedic Society
American Association of Veterinary Clinicians
Colorado Veterinary Medical Association
Phi Zeta
Phi Kappa Phi

**Frisbie, D.D.**
International Cartilage Research Society
Orthopaedic Research Society
American College of Veterinary Surgeons
American Association of Equine Practitioners
Osteoarthritis Research Society International
American Veterinary Medical Association
Veterinary Orthopaedic Society
American College of Veterinary Sports Medicine and Rehabilitation

**Goodrich, L.R.**
Veterinary AO Society
International Cartilage Repair Society
American Society of Gene Therapy
Orthopaedic Research Society
American College of Veterinary Surgeons
Veterinary Orthopaedic Society
California Veterinary Medical Association
American Veterinary Medical Association

**Haussler, K.K.**
American Veterinary Medical Association
American College of Veterinary Sports Medicine and Rehabilitation
American Association Equine Practitioners
Colorado Veterinary Medical Association
International Veterinary Academy of Pain Management
Phi Zeta National Honor Society

**James, S.P.**
Society of Women Engineers
American Society of Mechanical Engineers
Society for Biomaterials

**Kawcak, C.E.**
American Veterinary Medical Association
American Association of Equine Practitioners
American College of Veterinary Surgeons
American College of Veterinary Sports Medicine and Rehabilitation
Osteoarthritis Research Society International
Orthopaedic Research Society
Veterinary Orthopaedic Society

**Kisiday, J.D.**
Orthopaedic Research Society

**McIlwraith, C.W.**
Royal College of Veterinary Surgeons (Fellow)
American College of Veterinary Surgeons (Diplomate)
American Association of Equine Practitioners
American Veterinary Medical Association
Phi Zeta Veterinary Honor Society
Gamma Sigma Delta Honor Society of Agriculture
Colorado Veterinary Medical Association
Orthopaedic Research Society
Veterinary Orthopaedic Society
American Association of Veterinary Clinicians
European College of Veterinary Surgeons (Diplomate)
International Society of Arthroscopy and Knee Surgery
International Cartilage Research Society (ICRS) (Fellow)
American Academy of Orthopaedic Surgeons (AAOS) (Associate Member)
American College of Veterinary Sports Medicine and Rehabilitation
Professional Associations 2010-2011

Puttlitz, C.M.
Orthopaedic Research Society
Cervical Spine Research Society
American Society of Biomechanics
American Society of Mechanical Engineers
International Society of Biomechanics
Spine Arthroplasty Association
North American Spine Society

Reiser, R.F.
National Strength and Conditioning Association (NSCA)

International Society of Biomechanics in Sports (ISBS)
American College of Sports Medicine (ACSM)
International Sport Engineering Association (ISEA)

Werpy, N.M.
American Veterinary Medical Association
American Association of Equine Practitioners
American College of Veterinary Radiology
Large Animal Diagnostic Imaging Society
Gail E. Holmes  
Quarter Horse Owner and Breeder

John Andreini  
Racing Quarter Horse Owner  
and Breeder,  
Oxbow Ranch

Rick Arthur, D.V.M.  
Racetrack Veterinarian, California  
Past-president, American  
Association of Equine  
Practitioners

Thomas Bailey  
Cutting Horse Owner and Breeder,  
Iron Rose Ranch

Larry Bramlage, D.V.M.  
Specialist Equine Surgeon,  
Rood & Riddle Equine  
Hospital

Lindy Burch  
Hall of Fame/Cutting Horse  
Trainer and Breeder,  
Oxbow Ranch

Mark Dedomenico, M.D.  
Thoroughbred Owner and Breeder

Ron Ellis  
Thoroughbred Racehorse Trainer

John Halley, MVB (D.V.M.)  
Veterinarian for Coolmore and  
Ballydoyle, Ireland

Bobby Lewis, D.V.M.  
Elgin Veterinary Hospital  
Past-president, American  
Association of Equine  
Practitioners

Richard Mandella  
Racing Thoroughbred Trainer,  
Racing Hall of Fame

Dr. Wayne McIlwraith, BVSc  
(D.V.M.), Ph.D.  
Director Orthopaedic Research  
Center, Colorado State  
University

Maria Niarchos-Gouazé  
Thoroughbred Owner, Europe

Dan Rosenberg  
Rosenberg Thoroughbred  
Consulting

Dr. Barry Simon  
Thorn Bioscience, LLC

Melanie (Smith) Taylor  
Olympic Gold Medalist Show  
Jumping

Martin Wygod  
Thoroughbred Owner, California
Our Donors
With grateful acknowledgment to those who are so critical to the continued success of our program.

### Platinum Level

<table>
<thead>
<tr>
<th>Amount</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1,000,000+</td>
<td>Barbara Cox Anthony, James M. Cox, Jr. Foundation</td>
</tr>
<tr>
<td></td>
<td>Thomas Bailey</td>
</tr>
<tr>
<td></td>
<td>Abigail Kawanakao, Kawanakao Foundation</td>
</tr>
<tr>
<td></td>
<td>Herbert A. Allen, Allen &amp; Co.</td>
</tr>
<tr>
<td></td>
<td>Ken and Virginia Atkinson* , Ken and Virginia Atkinson Estate</td>
</tr>
<tr>
<td></td>
<td>Steadman Philippon Research Institute</td>
</tr>
<tr>
<td></td>
<td>Alice Walton, Walton Family Foundation</td>
</tr>
</tbody>
</table>

### Gold Level

<table>
<thead>
<tr>
<th>Amount</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100,000-999,999</td>
<td>AAEP Foundation, Inc</td>
</tr>
<tr>
<td></td>
<td>American Cutting Horse Association</td>
</tr>
<tr>
<td></td>
<td>Coolmore Stud</td>
</tr>
<tr>
<td></td>
<td>Mark P. Dedomenico, Pro Sports Club</td>
</tr>
<tr>
<td></td>
<td>Jaynn Emery</td>
</tr>
<tr>
<td></td>
<td>Ms. Gail Holmes, Double Dove Ranch</td>
</tr>
<tr>
<td></td>
<td>IDEXX Laboratories, Inc</td>
</tr>
<tr>
<td></td>
<td>Robert B.* and Beverly J. Lewis</td>
</tr>
<tr>
<td></td>
<td>Dan Lufkin, Lufkin Family Foundation</td>
</tr>
</tbody>
</table>

### Silver Level

<table>
<thead>
<tr>
<th>Amount</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25,000-99,999</td>
<td>American Quarter Horse Association</td>
</tr>
<tr>
<td></td>
<td>John Andreini, Andreini &amp; Company</td>
</tr>
<tr>
<td></td>
<td>Bayer, Inc.</td>
</tr>
<tr>
<td></td>
<td>Cathy Carpenter Dea and Peter Dea, Dea Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Walter and Jaynn Emery</td>
</tr>
<tr>
<td></td>
<td>EquuSys</td>
</tr>
<tr>
<td></td>
<td>Gooding Family Foundation</td>
</tr>
<tr>
<td></td>
<td>Iron Rose Ranch</td>
</tr>
<tr>
<td></td>
<td>Zory Kuzyk</td>
</tr>
<tr>
<td></td>
<td>Oaktree Charitable Foundation</td>
</tr>
<tr>
<td></td>
<td>Pavillard Scholarship</td>
</tr>
<tr>
<td></td>
<td>Progenteq</td>
</tr>
<tr>
<td></td>
<td>Rosenthal Ranch Trust</td>
</tr>
</tbody>
</table>

### Bronze Level

<table>
<thead>
<tr>
<th>Amount</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10,000-24,999</td>
<td>Susan Allen</td>
</tr>
<tr>
<td></td>
<td>Arthro Dynamic Technologies, Inc.</td>
</tr>
<tr>
<td></td>
<td>Vincent A. Baker</td>
</tr>
<tr>
<td></td>
<td>California Authority of Racing Fairs</td>
</tr>
<tr>
<td></td>
<td>Del Mar Thoroughbred Charities</td>
</tr>
<tr>
<td></td>
<td>Hollywood Park Racetrack</td>
</tr>
<tr>
<td></td>
<td>Los Angeles Turn Club, Inc.</td>
</tr>
<tr>
<td></td>
<td>Luipold Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Nutramax Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>The Pidgeon Company</td>
</tr>
<tr>
<td></td>
<td>Rocky Mountain LAE</td>
</tr>
<tr>
<td></td>
<td>Rod Richards</td>
</tr>
<tr>
<td></td>
<td>Rood and Riddle</td>
</tr>
<tr>
<td></td>
<td>Bob Rosenthal</td>
</tr>
<tr>
<td></td>
<td>Barry W. Simon, D.V.M. and Kari H. Simon</td>
</tr>
</tbody>
</table>

* Deceased
Our Donors

With grateful acknowledgment to those who are so critical to the continued success of our program.

Thorn BioScience
Thoroughbred Owners of California
Zell/Peppet

Blue Level
$1,000-9,999
American Livestock Insurance
Animal Health Options-ProMotion Studies
Joerg A. Auer
Bartlett and Ann Baker
Dr. Chip Beckett
J. Mark Beverly, D.V.M.
Dr. Edward and Darci Black
Sharmin E. Bock
Charles Boles
Britt Land & Cattle Company
Maynard M. Brittan
Brokaw Family Foundation
California Thoroughbred Breeders Association
R.A. and Farall Canning
Care Research
Celavie Biosciences, LLC
James J. Corbett
Ron Crockett
Brad R. Jackman and A. Lindsay Croom
C. George Dewell, D.V.M.
Kim Ellis
Equine Trust Foundation
Gene and Marylynn Fischer
Fossil Creek Veterinary
David F. Frisbie
Carla Hargett (Raymond James Charitable Endowment Fund)
Dorothy Russell Havemeyer Foundation, Inc.
R. James Charitable Trust
Jenkins Veterinary Services
William J. Keller
Land 'O Lakes Farmland Feed
Drs. James M. and Patricia D. Latham, Mill Creek Veterinary Service
Midge Leitch
John and Susan Magnier
Tommy Manion, Inc.
George S. Martin
Jeffrey S. Matthews – Franklin Street Partners
Maggie McHugh
Manfred Menzi

Dr. James P. Morehead
Neil J. Mulholland
Norris Foundation
North American Specialty Insurance Company
New Zealand Equestrian Foundation
Oak Tree Racing Association
Bonnie O’Neil
Denish Opdahl
R&P Medical
Rancho Petersen
Lezlie Rehagen
Joelle Rogers
Dan and Linda Sauders
Robert K Shideler, D.V.M.
Fahd Al-Sobayil
Sulzer Biologics
Dr. Terry Swanson
Robert L. and Melanie Taylor II
Transoceanic Marine, Inc.
Trefethen Vineyard Winery, Inc.
Gayle and Judith Trotter
Valley Oak Ranch
Wildenstein Family, LLC
Worldwide Medical, Inc.
Our Donors

With grateful acknowledgment to those who are so critical to the continued success of our program.

Green Level
$100-999

Rick Abbot
Alamo Pintado Equine Clinic
Alamogordo Animal Hospital
Dennis and Kerrie Allen
Elizabeth Armstrong
Ashford Stud
Atlantic Mutual Companies
Bend Equine Medical Center
Marilyn Berg-Voth
Bishben Cutting Horses
Blue Castle Racing
Dennis Bogott
Boehing Community Fund
Tom Bohanon, Glenwood Vet Clinic
Fernando Canonici
Joe and Terri Carter
Ms. Cynthia Chesnutt
Cherry Creek Clinic
Clover Valley Veterinary Hospital
Columbia Equine Hospital
Contract Veterinary Sales
Vaughn Cook
Claire Cox

Marilynn Dammon, King's Hill Stables
Cecil and Hatie Davis
David C. Davis
Dearborn Stables
Denali Stud
Double JK Ranch
Joy Dreier
Lorna and Shannon Dueck
Mike and May Edwards, Edwards Quarter Horses
Ron Ellis Racing Stable
Equine Sports Medicine and Surgery, Inc.
Falcon Seaboard, Snaffle Bit Ranch
Pierre Famille Inc
Fenton International
Dr. James P. and Amy J Foley
G.W. Ranch
Melissa Lyons Gardner
Loni D. Gattinger
Kate A. Gaughan
Barrie and Brenda Gerolamy
Cauleen Glass – In memory of Denison P. Glass
Goff (Lon) Custom Homes
Martha Goodrich

Steven and Cynthia Gregory
Paul L. Grimm Law Offices
Cindy Guagenti
Heidi Gordon on behalf Denise Steensland, Employee's Community Fund
Hagyard Equine Medical Institute
Ed Halpern
Harrington Equine Hospital
Heidi J. Hamlen
Cynthia Hamton
Carolyn J. Hannaford
Harris Veterinary Clinic
John M. Harris, Jr.
Alex Harthill
Bryan K. Hobson
Hong Kong Jockey Club
Lawrence Horan
Connie Inglish
James Irving
J Diamond 3
Robert A. Jackson
Jane M. Jennings
John W. Kaufman
RJ Ketch, RJ Ketch Equine, Inc.
Gerard Kelly
Our Donors

With grateful acknowledgment to those who are so critical to the continued success of our program.

James F. Kelly
Jessica A. Kidd
LaSalle Veterinary Clinic
Lazy E Ranch, LLC
Mrs. Alysa Tothill Levine
Mary B. Lint
Susan Locke
London Equine Hospital Professional Corp.
Paul Loomis
Londonerry Equine Clinic
Dennis A. Luedke D.V.M., Glenwood Veterinary Clinic
Lois and Joan Luft
Richard E. Mandella
John V. and Neola J. Martz
Gretchen Mathes
Marc R. McCall, D.V.M. Cherry Creek Animal Clinic
David K. and Linda McKelvie
Brit and Sharon McLine
Jud E. and Catherine Miller
Richard Mosier
Edward Murray
Napa Valley Veterinary Hospital
Michael Ochsner

Okotoks Animal Clinic
Virginia L. Pabst
Lester Pedicord
Joe Petalino
Robert and Anita Edmondson
Pexton
Jean Pierre
Cynthia Piper
Placer County 4-H
George W. Platt
James Power
Gary Praytor
Rauscher (Dain) Foundation
Steve Rael
Ranch and Coast Equine
Rosewood Hanoverians
John D. Roven
The Ruffian Stables
Edgar R. Sander
Scarmardo Enterprises
James C. Shircliff
Karen and Charles Scoggin
Pamela Silverman
Simon Development and Construction Company
William Jo Simonds

Joseph M. Singer
Wallace Souza
John R. Steele and Associates
Stillwater Veterinary Clinic
Donald N. and Judith M. Stone Family
Gary and Yvette Croteau Striker
Studio and TV Hire
Summer Hills Veterinary Hospital
Dr. William and Sandra Sutter
Dorothy L. Thielen
Three Chimneys Farm
Kenneth and Elizabeth Thomazin
Tiffany Farms and Stables
Traub-Brittan Family Foundation
United Way of Kitsap County
Von Hemel Racing Stable
Ute Vaske
Roy Voth
Treve Williams
James A. and Juanita B. Winn
Wisconsin Equine Clinic
Myron Yoknis
Patrick H. Young
Marshal and Anne Younglund
Summary of Research Projects 2010-2011
Take Home Message
Equine tendon injury accounts for a large number of days out of training/competition and/or retirement. There have been considerable advances in this field over the past 20 years and this consensus document draws conclusions from discussion of four key areas 1) severity grading, 2) genetics of tendon disease, 3) the design of clinical trials and, 4) rehabilitation programs.

Introduction
This recently published editorial written by Dr. Roger Smith of the Royal Veterinary College, London and Dr. Wayne McIlwraith of CSU ORC presents conclusions following the discussions at a three-day symposium in Iceland sponsored by the Dorothy Havemeyer Foundation in November 2007. It also provides recommendations for future research.

Terminology
‘Tendinitis’ is commonly used to describe a nontraumatic overstrain injury to a tendon. Although ‘tendinosis’ has been suggested in the human field, as many pathologic specimens from human patients show no evidence of traditional histological features of inflammation, it does not rule out components of the inflammatory cascade having some role and so more recently, the nonspecific terms ‘tendinopathy’ or ‘tendon disease’ have been adopted.

Severity Grading and Staging of Tendon Disease
Severity
- Criteria was proposed for severity grading for superficial digital flexor tendon injuries (Table 1)
- Staging – An accurate definition of the disease is vital for epidemiological and genetic studies (Table 2)
- Clinical definition – heat, pain, swelling reflecting stage (acute vs. chronic)
- Ultrasonographic definition – Ultrasonographic criteria of disease were originally correlated with broad histological parameters. However, more recently, more sophisticated computer-assisted analysis of the ultrasonographic image shows potential for defining and staging the disease through providing a more accurate determination of the nature of the tissue within the tendon.
- Magnetic resonance imaging definition – A more accurate and/or sensitive definition of disease may be provided by MRI, although to be practical, this should be performed using standing units.
- Histologic definition – Histological analysis could provide the most accurate definition of pathological change, although it is usually only appropriate post mortem because of the trauma created by biopsy techniques.

Genetics of Tendon Disease
Genetics have the potential to provide useful markers of susceptible individuals in disease mechanisms which will be beneficial in the future to help prevent injury.

The Design of Clinical Trials and Objective Outcome Parameters
There are many studies published in both the human and the equine literature on tendon disease that are underpowered. To assist in the design of future studies to compare outcomes between different treatments, a power calculation was performed to give the sizes of the groups required, assuming a P value of 0.05 (two-sided), 90% power and 1:1 treated: non-treated ratio – details in paper.

Rehabilitation Protocols
There is a need for a standardized rehabilitation protocol. At present, programs are empirical, but the variability of the disease makes scientific testing of these protocols impossible.

Recommendations for Future Research
The following were considered the most important directions for research into tendon disease in the horse in the immediate future.
- Biomechanics:
  - Evaluation of ‘microklutziness’ in the horse.
• Relationship of biomechanics to risk of injury, both in terms of ‘macrobiomechanics’ (i.e. of the limb) and biomechanics at a tissue level.
• Experimental models of tendon disease in the horse:
  • Validation of surgical models in the horse and sheep.
  • Development and validation of in vitro models to identify molecular processes of degradation.
• Diagnostic imaging (ultrasonography and MRI) of tendon injuries.
• More sensitive and specific correlation with histology.
• Genetics of tendon disease.
• The influence of genetics on tendon biology and risk of injury.
• Prevention of tendon disease:
  • Development of training regimes to prevent tendon disease in both young and mature horses.
  • Epidemiological studies to identify risk factors.
  • The influence of surface to tendon injury.
• Medication targets in tendons.
• Development of new drugs to reduce the apparent excessive remodeling in tendons.
• ‘Biological’ therapies:
  • Mechanism and evidence-based outcomes for platelet-rich plasma and other growth factor/cytokine-related therapies.
  • Mechanism and evidence-based outcomes for cell-based therapies.
• Clinical trials:
  • Need to be well controlled, with an adequate number of horses per group (see power calculation above).
  • Need for randomized controlled trials, although this may not be possible/practical in the equine industry.
• Rehabilitation programs

Acknowledgments
The organizers (the authors) would like to acknowledge the considerable financial assistance that was given to hold this meeting primarily from the Dorothy Havemeyer Foundation but also from Luitpold Pharmaceuticals, and the Orthopaedic Research Center, Colorado State University.

Participants:
Stephen Arnoczky, Michigan State University, USA
Matthew Binns, Royal Veterinary College, UK
Helen Birch, University College London, UK
Bruce Caterson, Cardiff University, UK
Peter Clegg, Liverpool University, UK
Jay Dudhia, Royal Veterinary College, UK
Elwyn Firth, Massey University, New Zealand
Karl Kadler, University of Manchester, UK
Chris Kawcak, Colorado State University, USA
Michael Kjaer, Copenhagen University, Denmark
Chris Little, University of Sydney, Australia
Wayne McIlwraith, Colorado State University, USA
Alan Nixon, Cornell University, USA
Tim Parkin, Glasgow University, UK
Stuart Raleigh, University of Northampton, UK
Graham Riley, University of East Anglia, Norwich, UK
Michael Schramme, North Carolina State University, USA
Roger Smith, Royal Veterinary College, UK
Sue Stover, University of California Davis, USA
Gene Pranzo, President of Havemeyer Foundation, USA
Allyn Mann, Luitpold (Sponsor), USA

With additional input from:
Sue Dyson, Animal Health Trust, UK
Yoshinori Kasashima, Equine Research Institute, Japan Racing Association, Japan
Janet Patterson-Kane, Massey University, New Zealand
Rene vanWeeren, Utrecht University, The Netherlands
Natasha Werpy, Colorado State University, USA

References
**Summaries: Focus 1**  
*Musculoskeletal Tissue Healing*

Table 1. Proposed criteria for severity grading of superficial digital flexor tendon injuries (consensus includes previously proposed definitions).

<table>
<thead>
<tr>
<th>Proposed definitions</th>
<th>Havemeyer grade 1 (mild)</th>
<th>Havemeyer grade 2 (moderate)</th>
<th>Havemeyer grade 3 (severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAPten protocol</td>
<td>0-15% of tendon ‘volume’ affected</td>
<td>16-25% of tendon ‘volume’ affected</td>
<td>&gt;25% of tendon ‘volume’ affected</td>
</tr>
<tr>
<td>Lesion size at MIZ</td>
<td>0&lt;10%</td>
<td>10%-40%</td>
<td>&lt;40%</td>
</tr>
<tr>
<td>Maximum tendon CSA</td>
<td>&lt;2 cm²</td>
<td>2-5cm²</td>
<td>&gt;5 cm²</td>
</tr>
</tbody>
</table>

Table 2. Summary of the parameters used to define and stage tendon disease

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
<th>Normal</th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical findings</td>
<td>No heat, pain or swelling</td>
<td>Heat, pain or swelling on palpation</td>
<td>Enlargement only</td>
<td></td>
</tr>
<tr>
<td>Ultrasonography</td>
<td>Cross-sectional area 80-140 mm² for superficial digital flexor tendon at level 2B in Thoroughbreds; &lt;20% difference from contralateral limb</td>
<td>Enlargement of tendon</td>
<td>Enlargement of tendon</td>
<td></td>
</tr>
<tr>
<td>Echogenicity</td>
<td>Even and bright echogenicity</td>
<td>Reduction in echogenicity</td>
<td>Heterogeneous and variable echogenicity</td>
<td></td>
</tr>
<tr>
<td>Longitudinal pattern</td>
<td>Prominent striated pattern (dependent on tendon)</td>
<td>Reduction in longitudinal fibre pattern</td>
<td>‘Fibrotic’ longitudinal fibre pattern</td>
<td></td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>Homogeneous low signal intensity with normal size/shape</td>
<td>Enlargement of tendon with increased signal intensity</td>
<td>Enlargement of tendon with increased signal intensity; alternatively, enlarged with low signal intensity on all sequences</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>Sparse vasculature</td>
<td>Haemorrhage; increased vascularity</td>
<td>Neovascularisation; increased to normal vascularity</td>
<td></td>
</tr>
<tr>
<td>Fascicle organisation</td>
<td>Prominent fascicular pattern with linearly arranged fascicles</td>
<td>Fibre disruption, giving rise to a variation in crimp signifying partial rupture</td>
<td>Disorganised fascicular pattern Accumulation of proteoglycan between fascicles Cyst formation; fat necrosis</td>
<td></td>
</tr>
<tr>
<td>Cellular component</td>
<td>Sparse tenocyte population</td>
<td>Tenocyte necrosis</td>
<td>Increased cellularity with cell rounding Acellular areas</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acellular areas in old tendon</td>
<td>Inflammation and reparative cellular proliferation and fibroplasias; neutrophil and monocyte infiltration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Equine Bone Marrow-Derived Stem Cells: Comparing the Ilium and the Sternum**

**Take Home Message**
Both the sternum and ilium offer a rich supply of stem cells that have similar growth rates. The highest concentration of stem cells is in the first 5 ml of bone marrow aspirate.

**Introduction and Hypothesis**
Bone marrow-derived mesenchymal stem cells (BMDMSCs) have been shown to improve healing of cartilage, bone, and soft tissue defects in horses and other species. Many studies have shown the need for sufficient numbers of stem cells to optimize repair. Studies have also shown that the timing of stem cell implantation affects treatment outcome. Currently, stem cell processing techniques strive to produce a large number of pluripotent cells within a short time. However, there are no standards for stem cell processing in the horse, and processing techniques vary widely between laboratories. The two sites of BMDMSC harvest in the horse are the sternum and ilium, and site selection is based primarily on practitioner preference. Also, laboratories differ in their preferred volume of marrow to collect. Differences in stem cell quantity or growth characteristics between harvest sites or harvest volumes could significantly affect the outcome of stem cell therapy. The primary goal of this study performed by McKenzie Adams with Drs. Goodrich, Rao, Olea-Popelka, Kisiday and McIlwraith with Nikki Phillips at the ORC was to determine any differences in cell concentration or growth rates between the equine sternum and ilium. A secondary goal was to determine the affect of aspiration volume on stem cell quantity and rate of growth. We hypothesized that there would be a higher concentration of cells in the sternum compared to the ilium, and that the first 5-ml fraction of marrow from either site would yield the greatest concentration of cells compared to subsequent fractions. Furthermore, we hypothesized that growth rates of cells from each site would not differ.

**Materials/Methods**
Seven horses from the Equine Orthopaedic Research Center were sampled prior to euthanasia for another study. Horses ranged in age 2-5 years old. Two sequential 5-ml marrow samples were taken from the sternum and ilium of each horse. Nucleated cell counts were obtained for all samples pre and post marrow processing. Cells were expanded in culture for three passages and cell counts were obtained at each passage. Nucleated cell count concentrations between sites pre and post marrow processing were evaluated using a Signed Rank Test for non-parametric paired t-test. Differences in growth rates for cells in all comparisons were evaluated using a multivariable linear regression analysis. The data on number of nucleated cells (in millions) was checked for assumptions of linear regression analysis. If not met, the data was log transformed for analysis purposes. A p-value of 0.05 was used for determining statistical significance.

**Results**
There was no significant difference (p>0.05) between the nucleated cell counts of the first sternum aspirate and first ilium aspirate, both pre and post marrow processing (Figures 1 and 2). However, the nucleated cell counts of the first 5-ml aspirate were significantly higher than the second 5-ml aspirate for both sites, both pre and post marrow processing (p<0.05) (Figures 1 and 2). There was no significant difference between growth rates for any of the groups (p>0.05) (Figure 3).

**Discussions/Conclusions**
These data should give practitioners confidence that cell numbers and growth rate characteristics do not vary between sternal and ilial sites and that the first 5 ml aspirate yields the highest concentration of stem cells for both sites. Depending on clinician preference both sites offer a rich supply of BMDMSCs that have similar growth rate characteristics. Further studies will reveal the importance of marrow volume in regard to cell counts and growth rate characteristics.
Summaries: Focus 1
Musculoskeletal Tissue Healing

References:

Figure 1. Pre-marrow-processing numbers of nucleated cells. Vertical bars extend for the entire range of values, and boxes encompass all values between the first and third quartile. Horizontal bars represent median values.

Figure 2. Post-marrow-processing median numbers of nucleated cells. Vertical bars extend for the entire range of values, and boxes encompass all values between the first and third quartile. Horizontal bars represent median values.

Figure 3. Growth of all stem cells in culture over time. Day 0 represents first passage of cells out of colony at 800 cells/cm² (60,000 cells/1-T75 flask). ST = sternum, IL = ilium 1 and 2 represent the first or second sample from each site.
Equine Mesenchymal Stem Cells in Vitro Differentiation Capacity: Differences Between Sternum and Ilium

Take Home Message
Cells acquired from both equine sternum and ilium are similar in their differentiation capacity in vitro. Clinicians can draw marrow from either site without concern that one is superior to another.

Introduction
Equine bone-marrow mesenchymal stem cells (BMDMSCs) have been a primary focus for tissue regeneration, primarily in relation to joint injuries. The two sites of marrow aspiration in the horse are the sternum and wing of the ilium. Each site has been shown to offer a rich supply of BMDMSCs that have similar growth rate characteristics in vitro. This study was done by Karla Penman and Jennifer Phillips with Drs. Goodrich, Kisiday, and McIlwraith of the ORC. The next step in guiding practitioners in their aspirate choice involves investigating the capacity of BMDMSCs to differentiate into chondrocytes, osteocytes and adipocytes in vitro. We hypothesized that BMDMSCs acquired from the sternum and wing of the ilium in horses will have a similar capacity to undergo chondrogenic, osteogenic, and adipogenic differentiation regardless of their aspiration location.

Materials and Methods
Bone Marrow Aspiration and Cell Culture
Five horses, between 3-5 years of age, had sternum and ilium aspirates performed using sterile technique. Aspirates were then spun down and plasma collected. Cells were cultured with alpha-MEM supplemented with FGF and grown to 80 percent confluency. Cells were passaged three times, were then cryopreserved, and stored for future use in liquid nitrogen. Cells from the third passage were chosen since these are the cells most commonly used clinically.

Tri-Lineage Differentiation
Cells were removed from cryopreservation and recovered at passage 3. Cells were then plated in 12 well plates at a density of 50,000 cells per cm² and treated with osteogenic and adipogenic media. After 14 days under osteogenic and adipogenic conditions cells stained. Osteogenic cells were lifted for quantification assays. Chondrogenic differentiation was conducted in 2% agarose gel with a concentration of 10 million cells per mL of agarose, surrounded with chondrogenic media. After 14 days the gels were sliced for stains and digested for total GAG accumulation.

Take Home Message
Cells acquired from both equine sternum and ilium are similar in their differentiation capacity in vitro. Clinicians can draw marrow from either site without concern that one is superior to another.

Introduction
Equine bone-marrow mesenchymal stem cells (BMDMSCs) have been a primary focus for tissue regeneration, primarily in relation to joint injuries. The two sites of marrow aspiration in the horse are the sternum and wing of the ilium. Each site has been shown to offer a rich supply of BMDMSCs that have similar growth rate characteristics in vitro. This study was done by Karla Penman and Jennifer Phillips with Drs. Goodrich, Kisiday, and McIlwraith of the ORC. The next step in guiding practitioners in their aspirate choice involves investigating the capacity of BMDMSCs to differentiate into chondrocytes, osteocytes and adipocytes in vitro. We hypothesized that BMDMSCs acquired from the sternum and wing of the ilium in horses will have a similar capacity to undergo chondrogenic, osteogenic, and adipogenic differentiation regardless of their aspiration location.

Materials and Methods
Bone Marrow Aspiration and Cell Culture
Five horses, between 3-5 years of age, had sternum and ilium aspirates performed using sterile technique. Aspirates were then spun down and plasma collected. Cells were cultured with alpha-MEM supplemented with FGF and grown to 80 percent confluency. Cells were passaged three times, were then cryopreserved, and stored for future use in liquid nitrogen. Cells from the third passage were chosen since these are the cells most commonly used clinically.

Tri-Lineage Differentiation
Cells were removed from cryopreservation and recovered at passage 3. Cells were then plated in 12 well plates at a density of 50,000 cells per cm² and treated with osteogenic and adipogenic media. After 14 days under osteogenic and adipogenic conditions cells stained. Osteogenic cells were lifted for quantification assays. Chondrogenic differentiation was conducted in 2% agarose gel with a concentration of 10 million cells per mL of agarose, surrounded with chondrogenic media. After 14 days the gels were sliced for stains and digested for total GAG accumulation.

Take Home Message
Cells acquired from both equine sternum and ilium are similar in their differentiation capacity in vitro. Clinicians can draw marrow from either site without concern that one is superior to another.

Introduction
Equine bone-marrow mesenchymal stem cells (BMDMSCs) have been a primary focus for tissue regeneration, primarily in relation to joint injuries. The two sites of marrow aspiration in the horse are the sternum and wing of the ilium. Each site has been shown to offer a rich supply of BMDMSCs that have similar growth rate characteristics in vitro. This study was done by Karla Penman and Jennifer Phillips with Drs. Goodrich, Kisiday, and McIlwraith of the ORC. The next step in guiding practitioners in their aspirate choice involves investigating the capacity of BMDMSCs to differentiate into chondrocytes, osteocytes and adipocytes in vitro. We hypothesized that BMDMSCs acquired from the sternum and wing of the ilium in horses will have a similar capacity to undergo chondrogenic, osteogenic, and adipogenic differentiation regardless of their aspiration location.

Materials and Methods
Bone Marrow Aspiration and Cell Culture
Five horses, between 3-5 years of age, had sternum and ilium aspirates performed using sterile technique. Aspirates were then spun down and plasma collected. Cells were cultured with alpha-MEM supplemented with FGF and grown to 80 percent confluency. Cells were passaged three times, were then cryopreserved, and stored for future use in liquid nitrogen. Cells from the third passage were chosen since these are the cells most commonly used clinically.

Tri-Lineage Differentiation
Cells were removed from cryopreservation and recovered at passage 3. Cells were then plated in 12 well plates at a density of 50,000 cells per cm² and treated with osteogenic and adipogenic media. After 14 days under osteogenic and adipogenic conditions cells stained. Osteogenic cells were lifted for quantification assays. Chondrogenic differentiation was conducted in 2% agarose gel with a concentration of 10 million cells per mL of agarose, surrounded with chondrogenic media. After 14 days the gels were sliced for stains and digested for total GAG accumulation.

Figure 1: Total GAG Accumulation
![Figure 1: Total GAG Accumulation](image)

Statistical Analysis
Osteogenic and Chondrogenic data results were analyzed using Statistical Analysis Software and a paired t-test was performed on each.

Results
Differentiation assays (adipogenic, osteogenic and chondrogenic) yielded BMDMSCs with morphologic changes consistent with the desired assays. These results confirmed that BMDMSCs from both sternum and ilium were capable of tri-lineage differentiation. Chondrogenic and osteogenic propensity were not found to be significantly different between the two aspirate locations (P<0.05).
**Summaries: Focus 1**
*Musculoskeletal Tissue Healing*

**Discussion**
The results of this study indicate that there is no difference between the aspiration location on the cells' differentiation capacity in vitro. This supports previous work that demonstrated that there is no significant difference between the nucleated cell counts between aspiration locations. This confirms the multipotency of BMDMSCs regardless of their aspirate location. This is consistent with previous EORC studies evaluating in vitro differentiation capacity of BMDMSCs. This data illustrates that clinicians can draw from either sternum or ilium when attempts at regenerative therapy are pursued without concern that one site would be superior to the other.

**Future Studies**
Evaluating which aspirate location is preferable necessitates testing cells from each location for 'stem cell' criteria. The standards for evaluation include monolayer expansion and tri-lineage differentiation, which have been explored in this study; however, the next step in this investigation is to examine cell surface markers on cells cultured from both aspirate location. Research is currently underway to evaluate cell surface markers to indicate cell quality of BMDMSCs from both sternum and ilium.

**Acknowledgments**
Funding provided by PVM student grant.

**References**
Equine Models of Articular Cartilage Repair

Take Home Message
This article is a review of equine chondral defect models that have recently been recognized as having specific advantages for translation into human articular cartilage regeneration co-authored by Drs. McIlwraith and Frisbie at CSU and Drs. Lisa Fortier and Alan Nixon of Cornell University. The defect models in the femoropatellar and femorotibial joints of the horse provide the closest approximation to humans in terms of articular cartilage and subchondral bone thickness. It is possible to selectively remove calcified cartilage, create defects, and do manipulations arthroscopically. Large sized defects allow for more tissue for evaluation, and there is the ability to have controlled exercise and test the ability of the repair tissue to cope with athletic exercise. Rehabilitation regimens can be followed as well.

Introduction
Articular cartilage injuries of the knee are common, and a number of different methods have been developed recently in an attempt to improve this repair. In one review of 31,516 knee arthroscopies, 53,569 hyaline cartilage lesions were documented in 19,827 patients. From a clinical point of view there are two distinct goals of cartilage repair: 1) restoration of joint function, which includes pain relief, and 2) prevention of or at least delay of the onset of osteoarthritis. Methods of assessing putative repair techniques have not been developed in vitro and therefore screening of potential procedures for human clinical use is done by pre-clinical studies using animal models of articular cartilage defects.

Articular cartilage lesions encountered within the human joint typically arise as a consequence of trauma (usually a sports injury) or during the course of diseases such as osteoarthritis (OA) and osteochondritis dissecans (OCD), and it is common for them to not encroach significantly beyond the cartilage-bone interface into the subchondral bone compartments. Repair strategy should focus on reestablishing the articular cartilage compartment rather than the bony one, but it is recognized that augmentation of bone is sometimes necessary.

Recent Equine Models of Cartilage Repair
Currently, the joints of horses with anatomically equivalence to the human knee and ankle are used for cartilage repair studies. The use of the femoropatellar and femorotibial joints (collectively known as the stifle) which are the anatomic equivalent of the human knee. Equine models for cartilage repair have been performed using the medial femoral condyle (MFC), the lateral trochlear ridge (LTR) of the femur, and the medial trochlear ridge (MTR) of the femur. Compared to other animal models, articular cartilage thickness in the stifle of the horse most closely approximates that of the human knee. Histological measurements of the thickness of noncalcified and calcified cartilage, as well as the subchondral bone plate, were made in three locations on the femoral trochlea and two locations on the MFCs of the species used in pre-clinical studies of articular cartilage and compared to those of the human knee. Species included human, horse, goat, dog, sheep, and rabbit. Average articular cartilage thickness over five locations was 2.2 to 2.5 mm for human, 0.3 mm for rabbit, 0.4 to 0.5 mm for sheep, 0.6 to 1.3 mm for dog, 0.7 to 1.5 mm for goat, and 1.5 to 2.0 mm for horse.

Critical size defects have been tested on both the MFC and the trochlea. An MFC model was initially developed to evaluate the effect of subchondral bone microfracture on articular cartilage repair. It has since been used to look at early events in cartilage repair after subchondral bone microfracture as well as the effective removal or retention of calcified cartilage and the value of augmented gene therapy in the repair of full-thickness defect treated with microfracture. Results have been published as indicated by the references.
Summaries: Focus 1
Musculoskeletal Tissue Healing

Use of the LTR in the horse as a model of articular cartilage repair was developed by Alan Nixon. This model was first reported as a 12-mm-diameter defect in 1994\(^{10}\) and a modified 15-mm defect creation reported in 1995\(^{11}\). The LTR model has been used to evaluate technologies that require suturing of a membrane\(^{12}\). The LTR has been recently used to evaluate osteochondral repair with a biphasic construct\(^{13}\) and a device developed by Dr. Fortier with Kensey Nash.

In initial work at Colorado State University, the MTR of the femur was used to create five, 4-mm defects for gathering of pilot data. Presently creation of two, 15-mm defects on the MTR of the femur is the standard for test cartilage transplantation techniques to ensure that critical defect size is achieved\(^{14,15}\). In this model with two, 15-mm defects on the MTR has been used to evaluate both an autologous chondrocyte implantation (ACI) technique\(^{14}\) and an autologous fragment transplantation system (CAIS)\(^{15}\).

Postoperative Care and Exercise
All of the procedures are performed arthroscopically so postoperative care is straightforward. At CSU, an exercise regimen of two minutes trot, two minutes gallop and two minutes trot on a high-speed treadmill was implemented at four months and continues out to 12 months. This technique is considered useful to test for durability of tissue. In other studies at Cornell, free exercise is used as a less expensive alternative to high-speed treadmill exercise and typically those studies have gone out two tight months rather than 12 months.

Advantages of Equine Femoropatellar and Femorotibial Models
Based on the studies presented in this review article and summarized here, the horse provides the closest approximation to humans in terms of articular cartilage and subchondral bone thickness, it is possible to selectively leave the entire calcified cartilage or on the other hand, completely remove it with certainty. The MFC model illustrates that it is possible to emulate MFC lesions in humans. One potential disadvantage of the MFC model is that if the subchondral bone plate is violated, a subchondral bone cyst can potentially develop which might confound the result, but this has not been a problem in the recorded study. Both the MTR and LTR locations can be used to generate one or two critically sized cartilage or osteochondral defects.

Other advantages of the equine model include and ability to use the arthroscope to create lesions and to perform second-look arthroscopies. The advantages over other species also include more repair tissue for analysis, the ability to monitor patients clinically, as well as with diagnostic imaging, thereby allowing practical assessment of clinical response to repair techniques. Horses also get similar orthopaedic clinical diseases as humans so clinical evaluation in naturally occurring disease can be additive to the preclinical research studies and both horses and humans can benefit from these studies. It is also the opinion of the authors that the ability to have controlled exercise with horses is an advantage both in the early rehabilitation stage and later to test the ability of the repair tissue to cope with athletic exercise.

Acknowledgments
This project was funded by the Steadman Philippon Research Institute.

References


Evaluation of Intra-Articular Mesenchymal Stem Cells to Augment Healing of Microfractured Chondral Defects

Take Home Message
Studies confirmed that the intra-articular injection of 20x10^6 bone marrow-derived mesenchymal stem cells (BMSCs) four weeks after creation of full-thickness defects on the central weight-bearing area of the medial femoral condyle in the equine stifle caused enhanced cartilage repair quality with increased aggrecan content and increased firmness of the repair tissue.

Introduction
Microfracture technique was developed to enhance chondral resurfacing by taking advantage of the body’s own healing capability and is the most frequently used technique for first-line treatment of symptomatic lesions in the articular cartilage in the knee. Study microfracture enlargement, full-thickness articular cartilage defects in a controlled manner, an equine model was developed to mimic lesions often observed in human patients. Full-thickness chondral defects are made arthroscopically in the weight-bearing portion of the medial femoral condyle. This model obviates a noted flaw in many studies where the full-thickness defect penetrated deep into the subchondral bone.

Early work using labeled mesenchymal stem cells has shown that they have an affinity for damaged joint tissue with the ability to localize and participate in repair of damaged joint structures including the cruciate ligaments and menisci, as well as cartilage lesions (if administered in sufficient quantities). Most studies have focused on meniscal repair by either direct injection or intra-articular injection of MSCs into the joint stimulated meniscal regeneration in a caprine model of osteoarthritis and this led to the question of potential value in cartilage repair. A recent equine study showed early benefits of MSCs in a fibrin matrix, but no significant difference was noted when MSCs plus fibrin compared with fibrin alone at eight months.

The purpose of this study was to test the potential of bone marrow-derived mesenchymal stem cells (BMSCs) to enhance the healing response of full-thickness cartilage defects that had been microfractured. We hypothesized that the intra-articular injections of BMSCs would augment healing with microfracture compared with microfracture alone. This study has just been published in *Arthroscopy: The Journal of Arthroscopic and Related Surgery* in 2011 and was done by Drs. McIlwraith, Frisbie, Kisiday, Werpy, and Kawcak at the ORC in collaboration with Drs. Bill Rodkey and Richard Steadman of the Steadman Philippon Research Institute.

Methods
Ten skeletally mature horses free of musculoskeletal abnormalities were entered into this 12-month study. We performed a power calculation based on a previous study with microfractured defects, an n=10 provided a power of 81% based on the previous study. Defects measuring 1cm^2 were arthroscopically created on the medial femoral condyle of both medial femorotibial joints in the stifle (analogous to the human knee) as previously described. Defects were debrided through the calcified cartilage layer down to the level of subchondral bone and both defects were subjective to standard subchondral...
bone microfracture (Figure 1). One month after defect creation, each horse had one joint randomly treated by intra-articular injection of BMSCs with 22 mg of HA (hyvisc) (hyaluronate sodium) 3 x 10^6 Da; Anika Therapeutics, Woburn, M.A. (BMSC plus HA) whereas the opposite joint received 22 mg of HA alone (OHA). A routine post-operative rehabilitation protocol was followed and the horses were subjected to a strenuous treadmill exercise protocol.

Other details of methods are described in the referred manuscript that has just been published.11

Results
At the termination of the study BMSC plus HA compared with OHA joints had significantly firmer repair tissue, whereas no difference existed at the six–month second-look arthroscopy (Figure 2). No deterioration in firmness was noted in the BMSC plus HA-treated joints from 6-12 months but the OHA-treated repair tissue became significantly softer compared with the surrounding cartilage in the same comparison. There was no significant difference with treatment on lameness (very mild) (in both cases), the degree of synovial effusion (again minor) and the response to joint flexion.

Evaluation of the MRI imaging yielded no significant treatment differences between groups and there were no differences in histologic analysis of articular cartilage. However, immunohistochemical evaluation of repair tissue and surrounding tissue significantly (P=0.02) greater aggrecan staining in the repair tissue of BMSC plus HA-treated joints (75.2% ± 8%) compared with OHA-treated joints (57% ± 8%).

Discussion
Microfracture has been previously shown to enhance the amount of repair tissue in full-thickness articular cartilage defects of the medial femoral condyle in the horse and Type II collagen content is significantly increased.1,4 It is also been shown that removal of calcified cartilage with retention of the subchondral bone plate in microfractured defects increased the overall amount of repair tissue as assessed by arthroscopic (four months) and gross evaluation (12 months); furthermore, there was improved attachment of the repair tissue to the underlying subchondral bone and the adjacent normal cartilage.5 Our study showed improvement in aggrecan content in microfractured defects that received intra-articular MSCs, a critical part of achieving cartilage repair. Previous work in evaluating defects treated with microfracture at 12 months showed good content in staining for Type II collagen but inadequate content in staining for aggrecan.3,5 This finding is consistent with the findings of enhanced firmness of repair tissue as aggrecan is the critical component to provided compressive stiffness in articular cartilage.

Acknowledgments
This study was funded by the Steadman Philippon Research Institute, Vail, Colo.

References
Summaries: Focus 1
Musculoskeletal Tissue Healing


Expansion of Adult Equine Bone Marrow Mesenchymal Stem Cells on Fibrinogen-Rich Protein Surfaces Derived From Blood Plasma

Take Home Message
Current practices for the preparation of bone marrow mesenchymal stem cells (MSCs) for equine musculoskeletal injuries involve culture-expansion to obtain millions of cells for a single treatment. While tissue culture plastic is the standard surface on which MSCs are culture-expanded, we report that coating tissue culture plastic with fibrinogen precipitated from blood plasma increases MSC proliferation without affecting differentiation potential. Fibrinogen harvested from autologous blood is an inexpensive means of creating a growth surface that is superior to tissue culture plastic.

Introduction
The low density of mesenchymal stem cells (MSCs) in bone marrow requires culture expansion to obtain sufficient numbers for many proposed therapies. Extensive research has focused on conditions for rapid and sustained MSC growth on tissue culture plastic; however, few studies have explored whether other growth substrates could better support MSC expansion. As an alternative to plastic, Drs. Kisiday, Lee, McIlwraith, and Frisbie with Ben Hale of CSU evaluated MSC proliferation on surfaces coated with a fibrinogen-rich precipitate (FRP) from blood plasma, a material that can be inexpensively obtained and processed using routine clinical and lab equipment and techniques. Chondrogenic and osteogenic cultures were conducted to determine the effect on expansion conditions on differentiation potential.

Materials and Methods
Bone marrow harvest and MSC isolation: 10 ml of bone marrow was harvested from the iliac crest of 2-5 year old horses. The nucleated cells were seeded into low glucose DMEM + 10% fetal bovine serum (FBS) at 0.25 x 10^6 cells/cm^2. Adherent MSC colonies were trypsinized after 6-10 days. FRP surfaces: Plasma was obtained from venous blood drawn into CPDA. Plasma proteins were precipitated by mixing 880 µl of 100% ethanol with 5 ml plasma. Precipitated proteins were concentrated by centrifugation, and then resuspended in an equal volume of plasma (200 µl). FRP solution was diluted 1:100 in sterile deionized water and added to flasks at 100 ul/cm^2. The next day, FRP solution was aspirated, and the flasks were rinsed once with water and dried. For Experiment 1, a subset of FRP surfaces was activated with thrombin (110 NIHU/mL in 40 mM CaCl₂, diluted 1:20 in water) to convert the bound fibrinogen to fibrin.

Expansion of MSCs: Cultures were conducted in medium consisting of αMEM + 10% FBS that had not been screened for stimulating high rates of MSC growth. In some cultures, the medium was supplemented with 2 ng/ml fibroblast growth factor 2 (FGF2). Expansion cultures were established by seeding at high (10x10^3 cells/cm²) or low (0.5x10^3) density. Agarose hydrogel chondrogenesis: MSCs were encapsulated in 2% (w/v) agarose at 10x10^6 cells/ml and cultured in high glucose DMEM, 1% ITS+, 0.1 mM dexamethasone, 37.5 µg/ml ascorbate-2-phosphate, and 10 ng/ml rhTGFβ-3. After 15 days, samples were digested in proteinase K, and the total accumulated sulfated glycosaminoglycan (GAG) content was measured via DMMB dye binding assay. Selected samples were evaluated for type II accumulation via immunohistochemistry. Osteogenesis: For Experiment 3, MSCs were seeded in monolayer cultures at 4 x 10^4 cells/cm² in high glucose DMEM plus 10% FBS, 5 mM β-glycerol phosphate, 0.01 mM dexamethasone, and 37.5 µg/ml ascorbate-2-phosphate. After 10 days, cultures were fixed in 2% formalin and stained with 0.5% Alizarin Red to identify mineralization. Statistical Analysis: Data was analyzed using a mixed model analysis of variance, with donor animal used as a random effect. Individual comparisons were made using least square means procedure. For each experiment, MSCs were tested from five donor horses.

Results
Experiment 1: Effect of thrombin activation of FRP on MSC proliferation – MSCs were seeded on FRP, with and without thrombin activation, at high density and cultured for five passages in FGF2 medium.
Control MSCs cultured on uncoated tissue culture plastic in FGF2 averaged a population doubling (PD) every 24.5 hours. Cumulative PDs on FRP and FRP/Thrombin were greater than uncoated cultures beyond the first passage (Fig. 1A, p<0.05). By Passage 5, growth in FRP and FRP/Thrombin cultures had exceeded uncoated tissue culture plastic by 1.2 and 1.5 PDs, respectively. Cumulative PDs were not significantly different for FRP and FRP/Thrombin surfaces (p=0.73-0.93). In chondrogenic cultures, GAG accumulation was not significantly different among surfaces after two and five passages (Fig. 1B, p=0.13-0.86). For uncoated and FRP cultures, GAG accumulation at Passage 5 was 72% of Passage 2 (p<0.05). For FRP/Thrombin, GAG accumulation at Passage 5 was 82% of Passage 2, although this difference was not significant (p=0.08). Type II collagen – Type II collagen was detected in all samples (data not shown). At Passage 2 and Passage 5, the intensity of staining was qualitatively similar among culture expansion conditions. The intensity of staining in Passage 5 samples was moderately lower than Passage 2.

PDs in uncoated/FGF2- were less than uncoated/FGF2+ at each passage (Fig. 2A, p<0.05). In FRP/FGF2- cultures, cumulative PDs were greater than uncoated/FGF2- conditions beyond the first passage (p<0.05). Cumulative PDs in FRP/FGF2- was less than uncoated/FGF2+ beyond the second passage (p<0.05). By Passage 5, FRP/FGF2- cultures had experienced 3.7 more PDs than uncoated/FGF2- cultures but 1.5 fewer than uncoated/FGF2+. Chondrogenesis: After two and five passages, GAG accumulation in MSC-seeded agarose was not significantly different among conditions (p=0.46-0.85, Fig. 2B). After five passages, GAG accumulation in uncoated/FGF2- and FRP/FGF2- cultures decreased to 69% and 67% of Passage 2 values, respectively (p<0.05). In uncoated/FGF2+ samples, Passage 5 GAG accumulation was 77% of Passage 2 values; however, this change was not significant (p=0.09).

Experiment 2: Effect of FRP on MSC proliferation in the absence of FGF2 – MSC expansion was evaluated on FRP, without thrombin activation, at high density and in the absence of FGF2. Uncoated control cultures, in the presence and absence of FGF2, were maintained at high density. Cumulative GAG accumulation in chondrogenic cultures after 15 days of culture. 'a' and 'b' denote a significant difference between groups (p<0.05).

Experiment 3: Effect of FRP on MSC proliferation in low density culture – MSCs in high density TCP cultures experienced at least two population doublings per passage, with an average of 10.9 cumulative population doublings at the end of the 10 day culture period (Fig. 3A). Low density TCP cultures experienced an average of 6.7 and 6.5 population doublings for the first and second passages, respectively. Low density FRP cultures...
Summaries: Focus 1
Musculoskeletal Tissue Healing

supported an average of 7.1 population doublings at each passage. At the end of the culture period, the cumulative number of population doublings among all conditions was significantly different (p<0.05). Low density FRP cultures experienced 1.0 and 3.2 additional population doublings relative to low and high density TCP cultures, respectively. GAG accumulation in chondrogenic cultures – GAG accumulation in MSC-seeded agarose ranged between 2.2-2.1 µg/mg wet weight, with no differences among the three conditions (p=0.61-0.82, Fig. 3B). Alizarin red staining in osteogenic cultures – All cultures accumulated mineralized matrix (Fig. 3C-E). Subjectively, the area and intensity of staining appeared similar among conditions.

Discussion
The continued advancement of MSC-based regenerative strategies will necessitate clinical expansion techniques that generate a consistent yield of MSCs. Variability among patient populations, such as MSC yield from bone marrow, proliferation rates, and differentiation capacity that can change with age2-5 may challenge expansion consistency and slow enthusiasm for clinical implementation. Given the ability of FRP surfaces to stimulate MSC proliferation without affecting chondrogenesis or osteogenesis, FRP surfaces represent a simple autologous method for enhancing proliferation in both rapid (FGF+) and slow (FGF-) growing MSCs. Expansion of MSCs in FGF2 at low density appears more promising than high density cultures.

Acknowledgments
Funded by a Colorado State University College Research Council grant.

References
Take Home Message
In a large population of young cutting horses there was a high prevalence of radiographic lesions, especially in the tarsi and stifles, on pre-sale survey radiographs. Notably, nearly 90% of the 458 included horses had at least one radiographic finding recorded. Changes in the medial femoral condyle (188/454, 41.4%) and osteophytes in the distal tarsus (201/438, 45.9%) were the most common findings.

Background
Radiographic repositories were first established at the Keeneland Thoroughbred yearling sales and due to the success, the National Cutting Horse Association (NCHA) followed suit at the 2005 NCHA Futurity Sales in Fort Worth, Texas. Studies of repository and survey radiographs have reported the prevalence of radiographic changes in various populations, most notably in Thoroughbreds\(^1\)\(^2\) and Standardbreds\(^3\)\(^5\). A veterinarian’s role is to identify abnormal radiographic changes and correlate them to future performance\(^1\)\(^6\) which can be challenging without knowledge, or in the absence, of clinical signs\(^6\). This problem has been addressed in Thoroughbred and Standardbred populations by studies that correlate radiographic changes with performance\(^7\)\(^10\). There are no such published studies in Quarter Horses. The objective of this study was to quantify the radiographic changes in survey radiographs of yearling and 2-year-old Quarter Horses intended for cutting. This study has recently been published in the *Equine Vet Journal* and was done by Drs. Erin Contino, Richard Park and Wayne McIlwraith.

Materials and Methods
Digital radiographs of yearling and 2-year-old horses were obtained from the Western Bloodstock Radiograph Repository at NCHA sales between December 2005 and December 2006. Routine survey radiographs of yearling Quarter Horses foaled between 2003 and 2006 at a private cutting horse farm were also included. One view of each carpus, two views of each fetlock, four views of each tarsus, and two views of each stifle were evaluated. Following categorization of radiographic lesions, the frequency of each lesion was statistically analyzed by limb, by horse, and by age. The prevalence of radiographic lesions between yearlings and 2-year-olds was compared.

Grading of the stifle: In the stifle, the medial femoral condyle (MFC) was classified as convex in contour (grade 0), flattened without evidence of subchondral bone changes (grade 1), a small defect or change in, without extension through, the subchondral bone (grade 2), a shallow, crescent shaped subchondral lucency that is confluent with the joint surface (grade 3) or a well-defined radiolucency in the middle of the MFC that communicates with the joint (grade 4) (Fig. 1). Abnormalities of the trochlear ridges, trochlear groove and patella were also recorded.

Grading of the carpus, tarsus, and fetlocks: The carpus was evaluated for the presence of osteophytes, bony fragments, and fractures of the accessory carpal bone. The fetlocks were evaluated for the presence of bony fragments, radiographic evidence of osteochondritis dissecans, palmar/plantar supracondylar lysis, abnormalities of the proximal sesamoid bones, and thickening of the dorsal proximal cortical surface of the middle phalanx (P2). The tarsocrural joint was evaluated for changes of the medial malleolus, distal intermediate ridge of the tibia (DIRT), and the trochlear ridges. The distal tarsal joints were evaluated for radiographic signs consistent with osteoarthritis (OA) including osteophytes, lysis, sclerosis, joint space narrowing, and tarsal bone malformation.

Results
The study included 8,857 radiographs of 3,900 joints in 458 horses (278 yearlings and 180 2-year-olds) of which 408 (89.1%) had at least one radiographic change recorded.

Stifle: Of the 454 horses with stifle radiographs, 202 (44.5%) had a radiographic change, the majority of which (188, 41.4%) were due to changes of the
MFC. Of these, 98 (52.1%) were categorized as grade 1, 37 (19.7%) as grade 2, 30 (16%) as grade 3 and 23 (12.2%) as grade 4. The right MFC (157, 34.6%) was affected significantly more than the left MFC (128, 28.2%) (p<0.0001). Six (1.3%) horses had an osteophyte on the medial proximal tibia; all were 2-year-olds which was a significant difference when compared to yearlings (p=0.0033). Of the 433 horses in which evaluation of the femoropatellar joint was possible, 14 (3.2%) had radiographic changes that most commonly involved the lateral trochlear ridge.

Tarsus: Of 438 horses with tarsal films, 304 (69.4%) had at least one finding recorded, most of which were in the distal tarsus. There were 201 (45.9%) horses with osteophytes, 76 (17.3%) with lysis, 30 (6.8%) with malformation, 29 (6.6%) with sclerosis, and 11 (2.5%) with joint space narrowing in the distal tarsus. In the tarsocrural joint, 54 horses (12.3%) had flattening of the medial trochlear ridge and 59 (13.5%) had changes of the DIRT. Two-year-olds had significantly more changes in the DIRT compared to yearlings (p=0.0107).

Fetlocks and Carpus: In the hind fetlocks, 155 of 355 horses (43.7%) had at least one radiographic change recorded. Changes of sagittal ridge were recorded in 69 (19.4%) horses and thickening of the dorsal cortex of P2 affected 49 (13.8%) horses. Osteophytes of the dorsal proximal aspect of P2 were recorded in 43 (12.1%) horses and were significantly more common in 2-year-olds than yearlings (p=0.0004). The front fetlocks were evaluated in 361 horses of which 131 (36.3%) had radiographic changes. In 54 (15%) horses, changes of the sagittal ridge were recorded. Palmar supracondylar lysis affected 47 (13.1%) horses, most of which (36, 76.6%) were categorized as mild. Only 27 of 342 (7.9%) horses had changes in the carpus making it the least affected joint examined.

Discussion
There was a high prevalence of MFC changes in this population. A recent study of Thoroughbred yearlings found that MFC lesions had a negative impact on the sale of a horse but did not negatively impact performance\(^1\). Flattening of the MFC affected over 20% of the horses in the study. There have been few studies on the prevalence or clinical relevance of this finding and further research is warranted in Quarter Horses to determine the extent to which changes to the MFC, including flattening, affect future performance.

In the fetlocks there was a relatively high prevalence of palmar supracondylar lysis which has been shown to decrease the likelihood of Thoroughbreds to start a race\(^2\). Thus, it may be a lesion that proves to negatively affect performance cutting horses. Dorsal cortical thickening of P2 in hind limbs has not been reported in the literature and may be unique to cutting horses. Yearlings were affected as frequently as 2-year-olds suggesting it does not develop in response to training. Osteophytes of P2 were significantly more common in 2-year-olds compared to yearlings suggesting they may form to stabilize the pastern joint in response to the biomechanical stresses of training.

There was a high prevalence of horses with radiographic signs of tarsal OA however, radiographic OA is not a reliable indicator of lameness\(^6\). It was interesting that there was no significant difference between the age groups since OA advances with age\(^12\). This indicates that training and discipline are clearly not the only factors contributing to the high prevalence of radiographic tarsal OA in this population of horses. Osteophytes, when seen independent of other changes, may be incidental although in Thoroughbreds, they have been associated with fewer race starts\(^7\).

This study establishes a baseline for what can be expected in the evaluation of pre-sale radiographs of young Quarter Horses. Work is ongoing to evaluate the clinical significance of these individual changes. This work was performed by Drs. Erin Contino, Richard Park, and Wayne McIlwraith.

Acknowledgments
This study was funded by the Colorado State University National Cutting Horses Association Stallion Auction Program with additional support from a Colorado State University Research and
Scholarly Excellence grant. We wish to thank Jim and Carolyn Ware and Western Bloodstock for facilitating the availability of radiographs.

References

Figure 1. Caudocranial radiographic projections of the femorotibial joint were used to evaluate the medial femoral condyle (MFC). A: The contour of the MFC is flat (Grade 1). B: There is a small defect in, but not extending through, the subchondral bone of the MFC (Grade 2). C: A shallow dome shaped lucency is seen extending through the subchondral bone in the MFC (Grade 3). D: A well defined subchondral bone cyst that communicates with the articular surface is evident in the MFC (Grade 4). Reproduced with permission from Contino et al. (2011).
A Descriptive Study of the Equine Proximal Interphalangeal Joint Using Magnetic Resonance Imaging, Contrast Arthrography, and Arthroscopy

Take Home Message
The dorsal and palmar pouches of the proximal interphalangeal joint are described in depth using MRI, contrast arthrography, and arthroscopy. Arthroscopic approaches allow adequate access to the proximal interphalangeal joint and anatomy surrounding the joint is described.

Introduction
The proximal interphalangeal (PIP) joint has the least amount of motion of all the joints of the equine distal limb and is challenging to access arthroscopically. The objective of this study was to assist in the treatment of diseases related to the PIP joint by describing its anatomy and outlining arthroscopic methods as there is very limited description of arthroscopy of the PIP joint in the current literature. This study done by Dr. Lacy Kamm together with Drs. Goodrich, Werpy, and McIlwraith described areas of the PIP joint that are arthroscopically accessible, defines the soft tissue structures that must be avoided during arthroscope and instrument placement, and investigates the differences between the fore and hind PIP joint.

Materials and Methods
Cadaver limbs were used to perform anatomic modeling, magnetic resonance imaging (MRI) with MRI-compatible needles, computed tomography (CT) with contrast arthrography, and arthroscopy of the PIP joint. CT contrast arthrography was performed on three fore and three hind limbs. Twenty-four limbs, 12 fore and 12 hind, were used for arthroscopy. Areas that could be viewed arthroscopically were measured, and two arthroscopic approaches to the dorsal joint pouch were compared.

Results
Imaging revealed that in order to prevent penetration of the axial palmar/plantar ligaments, abaxial palmar/ plantar ligaments, straight sesamoidean ligament, and the branches of the superficial digital flexor tendon, the palmar/plantar pouch instrument and arthroscope portals should be placed dorsal to the neurovascular bundle and just proximal to the epicondyles of the proximal phalanx.

No significant difference in the joint volume was found between the fore limb and the hind (p=0.137), though the mean volume was smaller in the fore limb than in the hind limb (8.89cm³±2.1 [std dev] vs. 10.76cm³±1.5, respectively). The only significant difference in visualization between the fore and the hind limb was the arthroscope portal in the proximal dorsal approach resulted in more visualization abaxially in the fore limb than in the hind (p=0.050) when visualizing the cartilage on the same side as the arthroscope portal.

There was no significant difference in the amount of joint viewed when using the more proximal or distal approach to the dorsal joint pouch (p=0.586). The average perimeter visualized was 224.62° when the proximal dorsal approach was used. This was only 62.4% of the total perimeter of the joint.

Conclusion
The dorsal and palmar/plantar joint pouches allowed for adequate arthroscopic visibility of the axial portions of the articular surface of the proximal and middle phalanx (P1 and P2). The abaxial portions of the articular surface were difficult to view due to the narrowing of the joint pouches abaxially. Palmar/plantar portals were placed dorsal to the neurovascular bundle to prevent injury of tendons and ligaments.

The one statistically significant difference between the fore and hind PIP joints was that the arthroscope could allow visualization more abaxial on the ipsilateral side of dorsal joint pouch in the fore limb compared to the hind limb. The cause for this is unknown as the soft tissues and bones of the PIP joint appeared very similar between the fore and hind on CT and MRI and the joint volumes were not significantly different on contrast arthrography CT. One possibility for the significant difference is that
the hind pastern is more likely to stay in flexion due to the stay apparatus. Flexion of the joint causes the dorsal aspect to be more restricted and may impede abaxial motion of the arthroscope.

Concerning the dorsal joint, no significant difference in visualization was found when the arthroscope was placed at the level of the PIP joint versus 1.5 cm proximal to the joint (p=0.586). The more proximal arthroscopic approach in this study was better to use as it allowed for easy visualization of the medial and lateral aspects of the joint and was not prone to the accidental exiting of the arthroscope or instruments that can happen with the distal approach when the ipsilateral side was visualized. It was found that if the arthroscope portal was placed too far proximally it can limit “the ability to view the joint space, because the arthroscope is held against the articular surface of the distal end of the proximal phalanx by the joint capsule.” Therefore, it is important to place the arthroscope up to 1.5 cm proximal to the joint surface, but no more proximal than this to allow for maximal manipulation of the arthroscope.

Acknowledgments
Funding for this study was provided by the John H. Venable Grant at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University.

References
1. Schneider et al. 1994
The Relationship Between Radiographic Changes and Performance Outcomes in Cutting Horses

Take Home Message
Radiographic repositories are commonly used as a predictor of future performance outcome. This study found that many radiographic changes were not correlated with performance outcomes. Of particular note, no radiographic changes of the medial femoral condyle of the stifle, including grade 4 subchondral cystic lesions, were associated with decreased performance outcome. However, some mild radiographic changes, most specifically mild osteophytosis of the distal tarsal joints, were associated with decreased performance outcomes.

Introduction
Radiographic repositories are becoming increasingly popular in multiple disciplines as a screening tool prior to sale. However, the importance of the radiographic findings must be objectively assessed relative to potential significance. While studies have been done to correlate survey radiographic findings with performance outcomes in Thoroughbreds, no such published study exists in Quarter Horses. This paper serves as part two of a study performed by Dr. Myra Barrett (as part of an M.S.) with Drs. Park and McIlwraith examining the relationship between radiographic changes in survey radiographs relative to objective performance outcomes in Quarter Horse cutting horses.

The goal of this study is to better clarify the potential significance of radiographic changes on repository radiographs relative to performance. This in turn will allow veterinarians and their clients to make more objective, informed decisions prior to purchase about the potential implications of various radiographic changes.

Methods: Radiographic changes of 436 Quarter Horses, which were quantified in a previous paper (Contino et al. 2011), were compared to objective performance outcome parameters. The parameters were: 1) likelihood of competing, 2) likelihood of earning money as a three year old, four year old, and as a three and four year old combined, 3) average amount of money earned as a three year old, four year old, and as a three and four year old combined. Mailed questionnaires and phone calls to owners of horses that did not earn money were used to try to determine why the horse had no recorded earnings.

Results
When the tarsometatarsal (TMT) and distal intertarsal (DIT) joints were examined together (Fig. 1), the presence of mild (grade 2) osteophytes, which affected 19% of the horses, was associated with reduced chance of competing, earning money and mean money earned. Very mild and mild osteophytes of the third and central tarsal bone assessed individually at the level of the TMT and DIT also have some significant effects in multiple performance outcome categories. The presence of thickening of the dorsal cortex of hind second phalanx as well as osteophytes at this location was associated with an increased likelihood of earning money. Several other potentially significant findings are reported but affect a relatively small number of the horses included in the study. Radiographic changes of the medial femoral condyle of the stifle were not significantly associated with performance outcome.

Conclusions
Many radiographic changes were not found to be significantly associated with performance outcome. However, some mild changes were associated with decreased performance. In addition, some radiographic changes were correlated with improved performance outcome. The findings of this study can be used to help veterinarians make more objective assessments of survey radiographic findings prior to sale. This research helps lay the groundwork for further investigations of the significance of survey radiographic findings in individual breeds and disciplines.

Acknowledgments
Thank you to Dr. Sangeeta Rao for her statistical analysis and to Taryn Yates for her assistance with data collection.
Summaries: Focus 2
Early Diagnosis of Bone and Joint Disease

References
Figure 1. Osteophytes in the tarsus were recorded by joint and bone involved and graded by size. A very small osteophyte (Grade 1) on the distolateral aspect of the central tarsal bone (A), a small osteophyte (Grade 2) on the proximal dorsolateral aspect of the third metatarsal bone (B), a medium osteophyte (Grade 3) on the distomedial aspect of the central tarsal bone (C) and a large osteophyte (Grade 4) on the proximal dorsolateral aspect of the third metatarsal bone (D) are shown with arrows. Reproduced with permission from Contino et al. (2011).
**Summaries: Focus 2**  
*Early Diagnosis of Bone and Joint Disease*

**Suspensory Ligament Ultrasound Using Oblique Incidence for Identification of Ligament Anatomy With Comparison to MRI**

Natasha M. Werpy, D.V.M., DACVR; Jean-Marie Denoix*, D.V.M., Ph.D., agrégé; C. Wayne McIlwraith, BVSc, Ph.D., DSc, FRCVS, DACVS

**Take Home Message**
Combining the standard ultrasound examination of the suspensory ligament with oblique incidence technique improves identification of the normal anatomic features of the suspensory ligament (SL).

Injury to the SL is a common condition affecting horses of different ages and disciplines. Lameness is often localized to the SL region using local infiltration of anesthetic solution around the ligament or perineural analgesia. Once injury of the SL is suspected based on the clinical examination and response to analgesia, diagnostic imaging of this region is often performed. Radiography can be used to evaluate the proximal palmar aspect (face) of the third metacarpal bone for evidence of sclerosis, lysis, proliferation or avulsion fracture at the attachment of the SL. However, examination of the ligament requires a modality that allows visualization of the soft tissue structures. Ultrasound has traditionally been the imaging modality of choice for diagnosis of SL injury. The technique has been describes the ultrasound probe being placed at the palmar surface of the limb with the beam oriented perpendicular to the longitudinal axis of the fibers. This technique has several limitations. The traditional technique for ultrasound of the SL creates an image which causes to the SL to appear as a rectangular shaped echogenic structure (Fig. 1).

However, the proximal aspect of the SL is a bilobed structure surrounded by connective tissue. The muscle and adipose tissue are most prominent in the central aspect of the each lobe and they are surrounded primarily by ligament fibers. Using the oblique incidence technique the SL is first imaged with the beam perpendicular to the long axis of the ligament creating an echogenic appearance (Fig. 2). The ultrasound beam is then angled obliquely relative to the long axis of the SL (Fig. 2). This causes the margins of the SL to become evident. The surround connective tissue remains bright. The ligament fibers become dark. The adipose tissue remains bright. The muscle becomes dark, but not as dark as the ligament fibers. Preliminary work suggested this technique produced images that provided anatomic information about the fiber versus adipose tissue/muscle distribution similar to MRI images and gross sections. This information was vastly different than what is obtained with the traditional technique (Fig. 2). We hypothesized that the combination of the standard ultrasound examination with additional imaging of the limb while flexed with the probe oriented oblique and perpendicular to the longitudinal axis of the fibers would provide the greatest amount of anatomic information about the SL. Furthermore this ultrasound technique would provide similar information about the distribution of ligament fibers versus adipose tissue/muscle distribution as can be determined with MR imaging.

**Methods and Materials**
Ultrasound examination, both with perpendicular and oblique beam orientation as well as MRI was performed on the forelimbs of 10 horses (age 2-5 years). Ultrasound examination was performed beginning at level of the carpometacarpal joint and ending at the level of the SL branches using a GE Logiq E (Carlsbad, Calif.) ultrasound machine with a 10 MHz linear probe. Transverse and longitudinal images were obtained with the ultrasound beam placed perpendicular to the ligament fibers with the limb in a weight-bearing position. Ultrasound and MR images were obtained at 2, 3, 4, 6, and 8 cm distal to the carpometacarpal joint. MR images (3 mm) were obtained post-mortem using proton density, T2-weighted fast spin echo and STIR sequences on a 1.0 Tesla OrthoOne ONI (Wilmington, Mass.).

Following MR imaging, the SL were harvested and sectioned. Gross evaluation of the sections and Masson’s trichrome stain was used to identify areas of ligament, muscle, and adipose. The circumferential area of the SL of the SL was measured on all
modalities. Flexed oblique incidence ultrasound and MR images of the right and left SLs were compared at each level and subjective evaluation for asymmetry of lobe size and shape as well as the fat and muscle distribution was performed.

**Results**

The standard ultrasound examination with probe placed perpendicular to the longitudinal axis of the SL did not allow accurate identification of the ligament margins relative to the surrounding connective tissue. In addition, this examination method did not allow visualization of the entire SL, specifically excluding the medial and lateral extent of the ligament. Examination with the limb in a non-weight bearing position with the carpus mildly flexed and the ultrasound beam perpendicular to the ligament fibers did allow visualization of the entire ligament. This was characterized by consistent identification of the axial margins of the second and fourth metacarpal bones. However, it did not consistently allow identification of the ligament margins and it did not allow differentiation between the ligament fibers versus areas of muscle and adipose tissue. Examination with the limb in a non-weight bearing position with the carpus mildly flexed and the ultrasound beam oblique to the longitudinal axis of the ligament allowed visualization of the ligament margins as well as identification of ligament fibers versus areas of adipose tissue and muscle.

In contrast to the MR images, which allowed areas of adipose tissue versus muscle to be easily distinguished, US images allowed identification of regions of adipose tissue and muscle but differentiation between the two tissue types was not reliably achieved (Fig. 3). Differences in the shape of the ligament margins or lobe size were well detected on the US images (Fig. 4). However, small areas of adipose tissue or muscle tracking through the ligament fibers were not well detected on US images.

In all 10 horses the lobes of the SL were asymmetrical in shape and size at least one level when comparing the right and left limbs (Fig. 4). In eight horses the ligament lobes joined to form a oval shape at approximately 6 cm distal to the carpometacarpal joint. In one horse this occurred at 5 cm in both forelimbs. This occurred in one horse at 5 cm in the left forelimb and 6 cm in the right forelimb.

The adipose tissue and muscle distribution was asymmetrical to varying degrees in all 10 horses at all levels when comparing the right and left limbs. The degree to which this occurred was variable, some horses only had slight differences when comparing the right and left forelimbs while others had marked differences.

There was a significant difference (P< 0.05) between the circumferential area of the different tissue types in the SL averaged over all measurement levels (Fig. 5). The ligament is composed primarily of ligament fibers, followed muscle tissue and then adipose tissue. The circumferential area of the ligament when measured on oblique incidence ultrasound images at 2 and 3 cm distal to the carpometacarpal joint was significantly different (P< 0.05) than when measured at the same levels on the MR images. The remaining levels were not significantly different when comparing oblique incidence ultrasound images and MR images.

There was no statistically significant difference between the cross sectional area of the SL in right and left forelimbs when comparing the measurement performed while the horse is standing with the ultrasound beam perpendicular to the ligament fibers to the flexed oblique incidence technique when averaged over the measurement distances. There was no statistically significant difference between the cross sectional area of the SL or the cross sectional area of fibers, muscle, or adipose tissue in the ligament when comparing the right and left forelimbs.

**Discussion**

The combination of multiple ultrasound techniques provides the most comprehensive examination of the SL. It will allow visualization of the entire ligament and a more accurate representation of the normal anatomy, both essential requirements for diagnosis of pathologic change. Although MR examination will still be required to diagnosis certain types or degrees of injury in the SL and will provide additional information, such as demonstrating the presence of
fluid in the third metacarpal bone at the ligament insertion, the more comprehensive examination will likely allow diagnosis of abnormalities not previous possible with US. This technique could facilitate diagnosis or monitoring of SL injury in multiple circumstances. It could allow a diagnosis to be obtained without MR examination. This is beneficial for owners who would like to avoid general anesthesia or for those who cannot afford the cost of advanced imaging. In addition it could allow monitoring of lesions over time following MR examination without additional general anesthesia.

Oblique incidence ultrasound provides a reliable method for measuring the circumferential area of the SL creating a detectable peripheral margin. The proximal extent of the ligament measured larger on MR images compared to ultrasound. This difference may originate from fibers extending from the fourth metacarpal bone as well as fibers in the palmar aspect of the medial and lateral interosseous spaces. These fibers are readily identified on MR images but are difficult to visualize on ultrasound images (Fig. 6). A convex probe would allow a beam angle that would make these fibers more echogenic and therefore better defined. However, this could potentially obscure other ligament margins still making it difficult to identify all the ligament fibers and measure the complete circumferential area in one image.

Although the circumferential area between the right and left front SLs is not significantly different, there was detectable difference in either lobe shape or fat and muscle distribution in all horses in the study (Fig. 4). These differences could be confusing when trying to detect injury using comparison to the opposite limb. However, more work showing the scope of normal anatomic variation and comparison to cases with confirmed pathologic change will provide criteria to allow more accurate identification of normal anatomic variation.

Conclusions
Although this comprehensive ultrasound technique has limitations, it provides additional and essential information not available with the traditional technique. It is currently part of our routine examination when assessing the SL for injury using ultrasound.

References

Acknowledgment
This study was funded by the College Research Council at Colorado State University. Sincere appreciation to Eric Garcia, D.V.M. for his assistance with this project.
Table 1. Circumferential area of the SL at different levels measured with oblique incidence ultrasound and MRI

<table>
<thead>
<tr>
<th>Distance (cm)</th>
<th>Modality</th>
<th>Oblique Incidence US</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>1.74* (+0.07)</td>
<td>2.15*(+0.07)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.76* (+0.07)</td>
<td>2.05* (+0.07)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1.57 (+0.07)</td>
<td>1.68 (+0.07)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1.52 (+0.07)</td>
<td>1.51 (+0.07)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1.58 (+0.07)</td>
<td>1.52 (+0.07)</td>
<td></td>
</tr>
</tbody>
</table>

Values with asterisks in the same row are significantly different (P < 0.05)

Distance is centimeters (cm) distal to carpometacarpal joint.

Figure 1. Transverse ultrasound image made using the current technique with ultrasound probe perpendicular to the ligament fibers in a weight-bearing limb. The suspensory ligament is demarcated by a white rectangle. This ligament appears as an echogenic rectangle shaped structure with hypoechoic areas. The palmar aspect of the third metacarpal bone is the white line just inside the bottom line of the rectangle. This technique causes the suspensory ligament to appear rectangular when in fact it is bilobed with rounded medial and lateral margins at this level.
Figure 2. Transverse ultrasound (A,B), MRI (C) and gross (D) images of the suspensory ligament (palmar is at the top and medial is to the left). The region of the ligament is demarcated by the white line, it does not exactly outline the ligament margins. Image A is made with the limbs in non-weight bearing position with the probe perpendicular to the ligament. The ligament is echogenic with the probe in this position. Image B is made at the same level as image A, but the probe is now oriented obliquely in a palmarodistal-dorsoproximal direction to the suspensory ligament. The ligament fibers are now hypoechoic. This horse has primarily muscle in the ligament lobes as opposed to other horses which have a combination of adipose tissue and muscle in the ligament. The muscle is echogenic compared to the ligament fibers with the probe oriented obliquely. The ultrasound image made with an oblique beam angle appears similar to the MR image, with a clear delineation of the ligament margins as well as the ligament fibers in contrast to Figure 1. These two images (B,C) correlate well with the gross image (D) and provide an accurate representation of the anatomy.
Figure 3. Corresponding US, MR and histology images of a limb 4 cm distal to the carpometacarpal joint (Dorsal is at the top and medial is to the right). The entire suspensory ligament is visible on the US image, and the size, shape and margins of the ligament are similar to the appearance on the MR images. The lateral lobe of the ligament (arrow) contains primarily adipose tissue (light gray on MR images) with a small area of muscle (dark gray on MR) within the axial aspect of the lobe. The medial lobe of the ligament (arrowhead) contains a mixture of adipose tissue and muscle. The differences between the fat and muscle distribution in the ligament lobes are clearly delineated on the MR image. However, the demarcation between muscle and adipose tissue is more difficult to identify on the US image. The histology slide (Masson’s trichrome) confirms the tissue distribution; ligament fibers are blue, adipose tissue is clear and muscle is red.
Figure 4. Paired US and MR images 4 cm distal to the carpometacarpal joint (Dorsal is at the top and medial is to the right). The suspensory ligament lobes of the left fore are symmetrical in size and shape. In contrast, the suspensory ligament lobes in the right fore are asymmetrical with a thinner longer medial lobe and a thicker shorter lateral lobe. The adipose tissue and muscle distribution is different when comparing the two limbs. The asymmetry of the right and left suspensory ligaments is not the result of pathologic change. It is a consequence of normal anatomic variation.
Figure 5. Circumferential area of the ligament and the different tissue types in the ligament averaged over the measurement levels. Circ area, circumferential area; tis, tissue type; 1 = circumferential area of the suspensory ligament, 2 = circumferential area of the muscle, 3 = circumferential area of the adipose tissue, 4 = circumferential area of the ligament fibers.

Figure 6. Paired MR and US image 2 cm distal to the carpometacarpal joint (dorsal is on the top and medial is to the left). There is a focal area of fibers extending from the fourth metacarpal bone (arrow). These fibers are located at the palmar extent of the interosseous space (arrowhead) and are difficult to identify on the US image. On the US image the lateral extent the suspensory ligament appears axial to its actual lateral margin which is apparent on the MR image. Therefore, the circumferential area measure less at this level on the US image compared to the MR image.
**A Technique for Performing Radiographic Guided Needle Placement Into the Collateral Ligaments of the DIP Joint**

**Take Home Message**
Radiographs can be used to guide needle placement in the distal aspect of the collateral ligaments of distal interphalangeal joints. If clinically indicated this technique can be used to facilitate intra-lesional therapy for treatment of collateral ligament injury.

**Introduction**
The diagnosis of abnormalities in the collateral ligaments of the distal interphalangeal (DIP) joint distal to the coronary band is occurring with increased frequency. This is due to use of magnetic resonance imaging (MRI) as a diagnostic tool in cases with foot lameness. Collateral ligament (CL) injury proximal and immediately distal to the coronary band can be diagnosed using ultrasound. Osseous lesions of the distal phalanx at the CL insertions can be diagnosed on radiographs. However, visualization of abnormalities in the collateral ligaments of the DIP joint at the level of the insertion on the distal phalanx can only be diagnosed with MRI or computed tomography (CT). Lesions identified in the collateral ligaments of the DIP joint diagnosed on MR images consist of core lesions with fiber disruption, diffuse injury without fiber disruption, margin tears, and complete ligament disruption.

Intralesional therapy, such as platelet rich plasma (PRP) and stem cells, is one of the possible treatment options in cases with a diagnosis of soft tissue injury. Imaging modalities can be used to facilitate needle placement for injection of therapeutic agents. Soft tissue is best visualized with MR and ultrasound (US). Therefore, these modalities are often selected to facilitate needle placement into soft tissue lesions. CT can be used in a soft tissue window in conjunction with osseous landmarks for needle placement into soft tissue injuries. MRI and CT require general anesthesia, while US and radiography can be performed in the standing horse. Radiography is commonly used to facilitate needle placement when reliable bony landmarks are available, such as injection of the navicular bursa using the navicular bone flexor surface as a landmark.

The collateral ligaments of the DIP joint insert on the fossae of the distal phalanx. The fossae of the distal phalanx can be reliably identified on radiographs and recognized on multiple views. A paper, which was presented at AAEP, was done by Drs. Werpy and Frisbie with Lauren Farrington to provide a description of how to use radiography to facilitate needle placement into the distal aspect of the collateral ligaments of the distal interphalangeal joint for injection of intra lesion therapy.

**Methods and Materials**
This technique is performed following diagnosis of a lesion in the distal aspect of the collateral ligaments of the DIP joint using high or low field MRI. The MR images are used to determine the desired site of needle placement based on relative distance from the margins of the fossa and whether the lesion is dorsal, palmar or centrally located within the ligament. A 3 ½ inch, 18-gauge needle placed into the fossa and can be performed with the horse standing or under general anesthesia. It can also be performed in conjunction with a MRI exam or other procedure. This report will provide a description of the procedure in a standing sedated horse, but can certainly be adapted to a patient under general anesthesia.

Prior to performing the procedure, an abaxial nerve block is performed and the hair is clipped from the injection site. During the procedure, sedation is used at the discretion of the veterinarian to prevent movement of the limbs. To approximate the location of the collateral ligaments for clipping, the coronary band can be palpated for areas of dense tissue at the 10 o’clock and 2 o’clock positions on the dorsal aspect of the foot. If the collateral ligaments are not palpable due to diffuse swelling, ultrasound can be used to locate them. A region of approximately 10 cm extending from the coronary band centered over the collateral ligament of interest is clipped. Properly placing a needle in the collateral ligament fossa is dependent on being able to identify the fossa margins.
on radiographs. Three radiographic views that are useful in locating the collateral ligament fossae include the lateromedial (LM), horizontal or weight-bearing dorsopalmar (DP), and dorso 60°proximal-palmarodistal (D60°P) views (Fig. 1). Therefore, the horse will need to be positioned with both front feet on foot blocks to allow proper radiographs to be taken once the needle is placed.

When taking radiographs it is important that proper safety precautions be taken and protective equipment is worn. In general, sequential radiographs are taken with continued needle advancement toward the fossa. We use a LM view followed by horizontal DP view and then a D60°P view. However, the sequence of radiographs could be adjusted as needed. When first learning this technique it is helpful to estimate the required proximal to distal angle of the needle prior to beginning needle placement. Before taking radiographs, a capped spinal needle can be positioned at the estimated proper angle and then held in place with tape (Fig. 2a). A lateral radiograph can be taken to view the needle placement in relation to the fossa. At this point, the capped needle can be adjusted accordingly until the person performing the procedure is confident it is properly angled. Once the appropriate angle is determined on a lateral radiograph this angle can be marked on the limb with correction fluid, pen or white tape so it can be repeated following sterile preparation of the injection site (Fig. 2b). Prior to removing the capped needle, a DP radiograph can be taken to approximate the medial to lateral angle needed to direct the needle towards the fossa. This initial process will reduce the need for repositioning the needle once it has been inserted through the skin. Once proficiency at this technique is obtained, initial marking of the limb for needle placement is often not necessary. However, this could depend on how exact the needle placement must be based on the size and shape of the lesion. The area of ligament injury is taken into account when positioning the needle. The lesion location in the ligament as identified on MR images should be taken into consideration when planning this procedure. The needle can be inserted dorsal, palmar, or peripheral (abaxial) to the proximal aspect of the collateral ligament. This will avoid passing the needle through the proximal aspect of the ligament and allow placement of needle in the affected area of the ligament.

Following sterile preparation of the injection site, the needle is inserted approximately 3 cm toward the fossa. Angles determined by the LM and horizontal DP radiographs, if previously obtained, are used to direct the needle (Fig. 3). Once the needle has been advanced approximately 3 cm, LM and horizontal DP radiographs should be taken to confirm that the needle is at the correct angle to enter the fossa. If needed, the needle can be readjusted by retracting it 1-2 cm and redirecting it (Fig. 4). If the angle and placement are correct, the needle should be advanced 1-2 cm and then a D60°P radiograph is taken to evaluate needle position. Once the correct angles have been obtained, the needle can be advanced until it contacts the fossa of the distal phalanx (Fig. 5). Once the spinal needle has reached the fossa, any additional views needed to confirm proper needle placement should be taken. Intralesional therapy is administered once correct needle placement has been confirmed. Once the needle is removed, the injection site is bandaged.

Results
This technique was performed initially on cadaver limbs using MRI compatible needles. The needle placement was confirmed on MR images. Subsequently, this technique was performed using spinal needles with contrast administration. The contrast agent was detectable on radiographs and MR images confirming placement of the contrast into the collateral ligaments. This technique has been used on 18 horses for administration of intralesional therapy following diagnosis of a collateral ligament lesion located in the distal aspect of the ligament. Lesions were diagnosed on MR studies from high and low field systems. No adverse effects from this technique have been observed. Stem cells and platelet rich plasma have been administered using this technique. Recheck examination six months following
treatment has been performed in three cases, which demonstrated clinical improvement as well as improvement in the appearance of the ligament on MR images.

**Discussion**
The technique provides a method for intralesional therapy of distal collateral ligament lesions with equipment commonly available in veterinary practice and without the use of general anesthesia. Proficiency can be achieved with knowledge of anatomy and radiographic technique as well as practice on a limited number of cadaver limbs. Using multiple radiographic views is necessary to ensure proper needle placement. Additional views, such as lateral oblique radiographs may also provide helpful landmarks. These views should be performed at the veterinarians discretion during the procedure such that needle placement is adequately confirmed. However, the needle could be consistently placed in the distal aspect of the collateral ligament using the three described views as was confirmed on MR images.

Fine tuning needle placement into specific areas identified on MR images, such as axial, abaxial, dorsal, or palmar aspects of the ligament can be achieved, but requires further practice (Fig. 6-7). Contrast can be used to confirm needle placement when practicing this technique on cadaver limbs. However, the effect of contrast material on most intralesional therapies is not known so contrast use is not recommended when performing this technique on clinical cases.

Axial lesions are the most challenging for needle placement, as they are in close proximity to the distal interphalangeal joint. The needle will enter the distal interphalangeal joint if it is placed axial to the ligament at the level of the joint or immediately distal to it. Often axial margin tears communicate with the distal interphalangeal joint. Furthermore, thinning of the ligament often occurs on the axial margin of the ligament. This space is often occupied by synovial membrane and fluid extending from the joint, increasing the possibility of needle placement in the joint. However, these characteristics of the lesion will be apparent on the MR images and can be considered when planning the needle path. In these cases placing the needle abaxial to the peripheral margin of the tear is necessary to prevent placing the needle into the joint.

**Conclusions**
Radiographic guided needle placement into the distal aspect of the collateral ligaments of the DIP joint can be used to facilitate injection of intra lesion therapy.

**References**
Figure 1. Lateromedial and DP radiographs of the bones of the distal limb with wire (arrow) marking the fossa of the distal phalanx at the insertion site of the medial collateral ligament of the distal interphalangeal joint. These landmarks are used for needle placement.

Figure 2. (a) External placement of a capped spinal needle secured with tape can be used when learning this technique. Radiographs are taken to determine the appropriate angle. (b) This angle is then marked with tape, or other method, and then used to guide needle placement.
Summaries: Focus 2
Early Diagnosis of Bone and Joint Disease

Figure 3. (a) Lateral radiograph showing initial needle placement. (b) The needle has been inserted approximately 3cm. The needle is correctly positioned and can be advanced toward the fossa. At this angle the needle will be placed in the dorsal aspect of the fossa.

Figure 4. Horizontal DP radiograph of initial needle placement. This view allows visualization of the medial to lateral angle of the needle. The distal aspect of the needle is angled too far axially or towards midline. Further advancement would place the needle in the DIP joint. The needle should be repositioned placing the hub closer to the limb, at an angle demonstrated by the arrow. This will allow advancement of the needle into the center of the fossa.
Figure 5. (a) Dorsopalmar and (b) D60°P views of the needle at the correct angle advanced into the center of the fossa.

Figure 6. Proton density transverse image at the proximal aspect of the distal phalanx. A focal area of fiber disruption is present in the palmar aspect of the medial collateral ligament of the distal interphalangeal joint (arrow) with an associated osseous cyst like lesion (arrowhead). Although abnormalities are present in the dorsal aspect of the ligament, the palmar aspect is most severely affected. Based on the MR image the needle would be directed into the palmar aspect of the ligament for administration of intralesional therapy.
Figure 7. Three radiographic views of needle placement into specific areas of the collateral ligament for injection of intralesional therapy in a lesion diagnosed on MR images. The location of the lesion was determined on MR images and the needle was placed in the region of injury. (a) The lateral view shows an additional angle which places the needle into the palmar aspect of the ligament. (b) A D60 °P view of the needle in the dorsal aspect of the ligament. (c) A D60 °P view of needle placed in the abaxial aspect of the ligament, just inside the margin of the fossa.
Development of an in Vitro Model of Injury Induced Osteoarthritis in Adult Equine Cartilage Using Single Impact Compressive Overload

Take Home Message
To develop an *in vitro* model of cartilage injury using adult full thickness equine tissue that can be used to simulate the *in vivo* disease and aid in therapeutic screening.

*Introduction:* *In vitro* models of cartilage injury enable the investigation of the cellular responses and structural changes of cartilage to traumatic injury in a highly controlled and reproducible manner. *In vitro* models also allow for high through-put and inexpensive preliminary testing of therapeutics to treat and prevent the progression of Osteoarthritis (OA). The purpose of the investigations presented here were to develop an *in vitro* model of cartilage injury using full thickness cartilage (containing the superficial, middle, and deep zones) extracted from cadaveric stifles from healthy adult horses. The project was a collaborative one done by Drs. Lee and Frisbie of the ORC and Dr. Alan Grodzinsky of MIT. Using a previously characterized computer controlled single impact model of unconfined compression samples were compressed to either 50, 60, 70, and 80% strain. Our objective was to determine which strain was sufficient to reproducibly induce pathologic change in cartilage that mimics the early stages of OA *in vivo*.

*Materials and Methods*
Cartilage explants were injured by single impact uniaxial compression to 50, 60, 70, or 80% strain at a rate of 100% strain/second, or left uninjured (control). Samples were subsequently cultured for twenty-eight days and evaluated histologically for characteristics of injury and early stages of osteoarthritis including: articular surface damage, chondrocyte cell death, focal cell loss, chondrocyte cluster formation, and loss of extracellular matrix molecules aggrecan, as well as types I and II collagen.

*Results*
Compared to controls, total proteoglycan content was significantly reduced in samples compressed to 60% strain (*p*<0.0002), and type II collagen content was significantly reduced in samples compressed to 60% strain (*p*<0.003). Compression to 60% strain or greater induced a significant increase in chondrocyte cell death, focal cell loss, and chondrocyte cluster formation compared to both controls and samples compressed to 50% strain. Independent of injury, severity of OA pathology differed significantly by region. Total proteoglycan content was most severely reduced in the superficial region (*p*<0.0008). Chondrocyte cell death was most severe in the superficial region (*p*<0.0020), while focal cell loss was most pronounced in both the superficial and deep regions (*p*<0.0009). Chondrocyte cluster formation was also most severe in the deep region (*p*<0.0001). Compression to all strain values induced some degree of pathologic changes seen in clinical equine OA *in situ*; however, only injury to 60% strain induced significant changes both morphologically and biochemically in the extracellular matrix (Figure 1).

*Discussion*
Injury to adult articular cartilage often leads to the degeneration of articular cartilage and the progression of OA. Previous research demonstrates mechanical injury induces matrix damage, chondrocyte death, and chondrocyte cluster formation, all of which are hallmark characteristics of OA. In this study full thickness adult equine cartilage explants were injured by single impact unconfined compression to 50, 60, 70, or 80% strain and evaluated after twenty-eight days in culture for histologic characteristics of OA. These data demonstrate the ability to produce histologic change consistent with previous cartilage injury models that are typical of OA *in vivo*. For adult full thickness equine cartilage it was necessary to compress explants by at least 60% strain, resulting in peak stresses greater than 14.68 (± 1.31) MPa, to induce significant pathologic change including proteoglycan loss, chondrocyte cell death, focal cell loss, and chondrocyte cluster formation.
**Conclusion**
This model of cartilage injury to 60% strain at 100% strain/second should allow more accurate study of pathophysiologic changes and therapeutic interventions for osteoarthritis.

**Acknowledgments**
This research was supported in part by the Colorado State University College Research Council.

**References**


**Figure 1.** Representative images of H&E stained sections from uninjured controls, or cartilage injured by 50, 60, 70, or 80% strain. The images at 10x resolution show tissue damage, such as fissures, in 60, 70, and 80% samples. Images at 20x resolution show cellular pathologies, such as chondrocyte cluster formation, in the 60 and 70% samples, and cell death in the superficial regions of the 60, 70, and 80% samples. Bar represents 100µm.
Effects of Early Exercise on Metacarpophalangeal Joints in Horses

Take Home Message
Exercising foals at an early age may help to improve their musculoskeletal tissue strength later in life, and in order to evaluate this theory, the investigators investigated the effects of early exercise on the metacarpophalangeal joints of horses. The results showed that the metacarpophalangeal joints of exercised horses were healthier and had denser subchondral bone than those horses that were not exercised.

Introduction
This study was a continuation of the collaboration between Drs. Kawcak and McIlwraith with Dr. Elwyn Firth at Massey University in New Zealand investigating the effects of early exercise on horses. The hypothesis was that early exercise of horses would lead to superior musculoskeletal tissues compared to horses that were reared in a pasture without additional exercise. The goal of this specific project was to provide a broad view of the effects of early exercise on the metacarpophalangeal joint of horses, including bone, articular cartilage, and synovial membrane.

Methods
Six horses that were conditioned from birth to 18 months of age were compared to six horses that had routine pasture turnout since birth. The metacarpophalangeal joints were evaluated for bone density distribution using computed tomography (CT), articular cartilage metabolism and histologic assessment of synovial membrane, articular cartilage, and subchondral bone (Fig. 1).

Results
Horses that were exercised since near birth had fewer gross lesions in the joints, greater bone fraction in the dorsolateral aspect of the condyle, and higher bone formation rate compared to non-exercised horses. However, there was less articular cartilage matrix staining in the dorsal aspect of the condyles in exercised horses.

Conclusions
It was concluded from this study that exercise at a young age may be protective to the metacarpophalangeal joint as demonstrated through fewer gross lesions and healthier bone. However, there is a concern about the fact that there was less articular cartilage matrix staining in exercised horses. Further investigation is needed to further characterize these changes. Overall, the results of this study support previous conclusions that early exercise has a net positive effect on joints and can be recommended for strengthening joint tissues in horses.

Acknowledgments
This project was funded by the Marilyn Simpson Trust, the Horse Racing Betty Levy Board, Utrecht University and the New Zealand Equine Partnership for Excellence, and the New Zealand Racing Board.

References
Take Home Message
Early conditioning of foals is thought to be needed in order to strengthen their musculoskeletal tissues for the rigors of exercise later in life. Through this study, the investigators found that there were no negative effects of early conditioning on the midcarpal joints of horses. In addition to previous work that showed a positive effect of early conditioning on chondrocytes, the authors concluded that early conditioning is safe and important for building early strong musculoskeletal systems.

Introduction
The investigators have worked for several years to determine the effects of early exercise on foals in the hopes of inducing stronger musculoskeletal tissues later in life. As a continuation of this project Drs. Kawcak and McIlwraith collaborated with Drs. Firth and Broom in New Zealand to determine the effects of early exercise on cartilage in the mid-carpal joint of horses. The purpose of this study was to specifically determine if exercise at an early age would lead to less gross lesions and better material properties of the articular cartilage in those joints.

Methods
Six horses that were conditioned from birth to 18 months of age were compared to six horses that had routine pasture turnout since birth. Midcarpal joints from each horse were evaluated, and gross defects were classified and mapped. Opposing surfaces of the radial carpal and third carpal bone surfaces were used to quantify swelling behavior of the articular cartilage extracellular matrix (Fig. 1).

Results
The investigators found that there was a wide range of gross defects on the joint surfaces, but that there were no significant differences in the number or severity of lesions in the midcarpal joint between the two groups. The investigators also found that there were no significant differences in material properties of the articular cartilage between both groups, as reflected by the swelling behavior of the cartilage extracellular matrix.

Conclusions
The investigators concluded from this study that early conditioning had no negative effects on the articular cartilage in the midcarpal joint. This is important, because in an earlier study which was a collaboration between Drs. Kawcak and McIlwraith and Dr. Elwyn Firth, they found that early conditioning exercise had a beneficial effect on the chondrocytes in the articular cartilage of the metacarpophalangeal joint. Therefore, based on this and previous studies the investigators have concluded that early conditioning is a positive influence on articular cartilage and is safe to use.

Acknowledgments
This project was funded by the Grayson-Jockey Club Research Foundation, the Marilyn Simpson Trust, the Horse Racing Betty Levy Board, Utrecht University, the New Zealand Equine Partnership for Excellence, and the New Zealand Racing Board.

References
**Summaries: Focus 3**

*Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease*

**Figure 1.** Map showing the orientation and collection of samples for assessment of articular cartilage swelling.
Take Home Message
Although optimization of surfaces alone will never eliminate catastrophic injuries, and may not even be a primary factor in most injuries, the absence of well-accepted characterization methods and basic science of racing surfaces is a significant obstacle to improve performance and safety. A critical aspect of the effort to improve surfaces is looking at the factors which control the performance of racing surfaces in the context of the relative biomechanics, the different types of surfaces, and potential testing and maintenance strategies.

Introduction
This white paper was drafted as a collection of published scientific papers and data. It is considered a work in progress and we update it as new scientific studies and track data become available. It is a collaborative effort between Dr. Mick Peterson and Miss Christy Mahaffey of the University of Maine, USA; Dr. Lars Roepstorff, Swedish University of Agricultural Sciences, Sweden; Dr. Jeffrey J. Thomason, University of Guelph, Canada; and Dr. Wayne McIlwraith at Colorado State University. The white paper is based on the recommendation of the Welfare Safety Summit (WSS) Racing Surface Sub-Committee supported by the Jockey Club. Its content has been reviewed by the WSS Racing Surface Committee. This white paper is available on line.

Preface
Racing surfaces have received a great deal of attention in the popular and fan coverage of horse racing. Additionally track surfaces have recently been a topic of discussion in the scientific literature. Three general areas of inquiry have emerged: (1) characterization of the interaction of the hoof and the ground, (2) in-situ testing of the surface and (3) specific characterization of the materials used in the racetrack. A general understanding of the hoof ground interaction has been facilitated by dynamic horseshoe studies over the last decade and loading of the ground and hoof has been reviewed.

Background
A safe surface is one for which the surface properties have been designed to prevent injury. Current evidence indicates that consistency of each surface and limited variability among surfaces seen by each horse are more important than the exact values of each property. Factors that have been considered include:

- **Horse-hoof-track interaction**
- **Loading on specific anatomical structures**
  - Energy from the shock of contact with the ground, and the forces owing to changing the momentum of the legs and body are transferred through the hoof loading on specific anatomical structures – the static and dynamic load on the legs stress the materials of each anatomical structure in the leg including each bone, muscle, tendon, and ligament
- **Causes of injury** – Injuries can principally occur in two different ways, either as a catastrophic injury due to acute overload or as degenerative changes due to repeated minor overload.
- **Features of injuries** – Accurate diagnosis of injuries, together with information on their location, severity, and frequency of occurrence, provide valuable information in combination with the categories of data described in the preceding 3 subsections.
• *Linking track properties to injury* – Achieving the goal of making a direct connection between track properties and specific injuries (not simply injuries in general) is a major step in minimizing the effect of the track on the occurrence of injury.

**Interaction of the Horse and Hoof With the Track**

At racing speeds reaching 38 mph (17 m/s), the hoof hits the track approximately 150 times a minute, remaining on the ground in the stance phase for a sixth of a second each time. The short duration of the stance hides from our eyes several stages that are distinctive in their mechanical characteristics (Fig. 2), there is primary impact when the hoof impacts the ground and a secondary impact as it slides and stops.

The resistance of the track to the impact and loading of the hoof determines the rate of loading of the leg and thus the acceleration and forces accounted in the joints of the horse. The track influences how quickly the foot is decelerated and then the stiffness of the track when the load is being applied. The rate of deceleration controls the strain which is transferred to the leg and results in higher peak loads for stiffer surfaces. It is reasonable to expect that above a critical strain and strain rate, there lies potential for propagation of damage to the bone. The horizontal response of the surface also plays a key role in loading of the leg. In addition to these mechanical properties, rough deformable surfaces increase the variance of vertical forces at the hoof and positioning of the load in the hoof.

**Types of Racing Surfaces**

To date, little formal discussion has been given to design of the racing surface. The design of surfaces is addressed in detail in this white paper.

**Testing of Racing Surfaces**

The characterization of the racing surface materials is the best understood and most common type of racing surface monitoring. While important to the overall performance of the surface, material is just one aspect of developing an appropriate racing or training surface. Tracks can be tested for composition and a racing testing and a surface testing laboratory has been set up for looking at the composition of both dirt tracks and synthetic tracks. However it is to be recognized that composition testing has a distinct limitation that it only describes the material not the results which occur from the composition of the material. In addition to this in-situ performance testing needed to describe the overall performance, the material when combined with the design of the track including shear strength, compaction, impact absorption and energy return and, moisture sensitivity.

**In-Situ Testing of Racetrack**

The first author of the white paper has designed a mechanism for in-situ testing. Outcome parameters include moisture content, depth, consistency, temperature, geometry, as well as in-situ performance testing. The equipment developed by the first author is a progression from previously used techniques including Clegg Hammer, dynamic penetrometer, agricultural penetrometer, and Going Stick. The Biomechanical Hoof Tester is a system that has been developed to make it possible to load the track at the rate and loads are applied by a horse at a gallop (Peterson, et al., 2008).

**Understanding Racing Surface Safety**

Beyond the tools needed for monitoring of racing surfaces, there is a need to understand what is done to the surface and how these surfaces are used. The condition of a racing or training surface is a result of maintenance, material, weather, and usage. A complete understanding of the surface can only be obtained if these factors are all included to understand the outcome in terms of the resulting surface performance.

Examination of climate and design, monitoring of the racing surface (composition, maintenance, weather and usage, performance) are critical and the authors of this white paper have been involved in a number of published studies looking at the various factors.

**Safety and the Epidemiological Literature**

The next step in this process is correlation of measurement and maintenance of track surface with epidemiologic database to define real world effectiveness. Correlation is critical in the assessment of engineered racing surfaces.
Summaries: Focus 3
Improvement in the Understanding of the Pathogenesis of Exercise-Induced Traumatic Disease

Acknowledgments
Funded by Grayson-Jockey Club Research Foundation.

References

Figure 1. A pathway from track properties as a risk factor to the desirable outcome of prevention of injury, via the postulated mechanical underpinnings of the causes of injury, and relevant feature of injuries once they occur.

Figure 2. Stages of the stance showing the differences in acceleration (red) and GRF (blue) among the stages. When the GRF arrow is tilted, that indicates that both vertical and horizontal components of GRF are present. The arrow shows the direction in which the ground is pushing the horse.
Effects of Platelet-Rich Plasma Composition on Anabolic and Catabolic Activities in Equine Cartilage and Meniscal Explants

Take Home Message
Clinical preparations of platelet-rich plasma (PRP) from autologous blood are created using commercial kits, of which there are numerous options that produce different platelet and growth factor doses. It is not known which PRP preparation is most appropriate for applications to cartilage and the meniscus. Therefore, we evaluated the response of equine cartilage and meniscal explants to single or double spin PRP preparations, the latter of which is necessary to obtain a high density of platelets. In general, protein and proteoglycan synthesis for single spin PRP was higher than double spin PRP. Gene expression of the proteoglycan catabolic enzyme ADAMTS-4 was lowest for single spin PRP. This study suggests that single-spin PRP preparations may be the most advantageous for intra-articular applications, and that double-spin systems should be considered with caution.

Introduction
Platelet-rich plasma represents an accessible and inexpensive source of growth factors that has received considerable attention for the treatment of musculoskeletal tissues, although few studies have evaluated the effect of PRP on articular cartilage and the meniscus (1). An important factor in determining the potential of PRP to heal joint tissues is the dose of platelets that best stimulates cartilage or meniscal growth. PRP containing less than a two-fold increase in platelet concentration relative to blood may be obtained by a single spin protocol (2). To further concentrate the platelets, a second higher force spin may be used (3). Given that higher platelet concentrations translate into a higher growth factor dose, we hypothesized that double spin PRP preparations will stimulate higher extracellular matrix synthesis without a concomitant increase in catabolic activities in cartilage and meniscal explants than single spin protocols. This project was a collaborative study by Drs. Kisiday, Frisbie, and McIlwraith of the ORC with Drs. Rodkey and Steadman of the Steadman Philippon Research Institute.

Methods
Samples were obtained from five healthy two- to five-year-old horses. Blood and tissues. Blood was drawn into anticoagulant citrate dextrose at a ratio of 10:1. Articular cartilage and menisci were retrieved from the femorotibial joint. Full-thickness (1-2 mm) sections of articular cartilage were removed from the femoral condyle and divided into 5 mm by 5 mm explants. Three mm thick meniscal explants were harvested from the femoral articulating surface of the avascular portion of medial menisci. PRP was prepared using Arthrex ACP™ according to the manufacturer’s single protocol (referred to as Single Spin Kit). PRP from Harvest Smart Prep 2™ was prepared according to the manufacturer’s double spin protocol (referred to as Double Spin Kit). Laboratory PRP was created by centrifuging blood at 200 g for 18 minutes and harvesting the plasma. A portion of this PRP (referred to as Single Spin Lab), was set aside for experimentation. The remaining PRP was centrifuged at 1000 g for 15 minutes. The platelet-poor plasma (PPP) supernatant was removed, and PPP was added back to the centrifuged platelets in reduced volumes that resulted in 3x, 6x, and 9x concentrations of platelets relative to Single Spin Lab PRP. Hereafter, these PRP preparations are referred to as Double Spin 3x, 6x, and 9x, respectively. Culture medium: PRP was mixed with equal volumes of low glucose DMEM plus ascorbate and antibiotics. Half of the cultures received 10 ng/ml of recombinant human IL-1β resuspended to produce a proinflammatory environment (4). Evaluation of extracellular matrix synthesis: Explants were evaluated for 35S-sulfate and 3H-proline incorporation as measures of proteoglycan and protein synthesis, respectively. These data were normalized to total DNA (5). Gene expression of catabolic enzymes: RNA was extracted from explants and reverse transcribed to cDNA using random hexamers. cDNA and TaqMan Gene Expression Master Mix were mixed with primer/probes for the catabolic enzymes ADAMTS-4, ADAMTS-5, MMP1, MMP13, and the housekeeping gene GAPDH, and expression levels were determined using semi-quantitative real-time PCR. Gene expression was
Summaries: Focus 4
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse

normalized to GAPDH. (6). Data analysis: The analysis of cartilage and meniscal explants was repeated for blood and tissue samples from five donor horses, with blood and tissues paired in an autologous fashion. All data were analyzed using a mixed model analysis of variance, with the donor animal used as a random effect. Individual comparisons were made using least square means procedure. Individual comparisons of main effects or interactions were indicated based on a protected f-test. p-values less than 0.05 were considered significant. Data are reported as mean +/- sem.

Results

Cellular content of PRP preparations. The concentration of platelets in Single Spin Lab PRP (317 +/- 22 thousand/βl), was not significantly different from Single Spin Kit PRP (276 +/- 8 thousand/βl) (p=0.20). Double Spin Kit PRP contained 2.3 and 2.6-fold higher platelet concentrations (725 +/- 95 thousand/βl) relative to Single Spin Lab and Single Spin Kit PRP, respectively. White blood cell counts in Single Spin Lab PRP (0.04 +/- 0.001 thousand/βl) were not significantly different from Single Spin Kit PRP (0.03 +/- 0.01 thousand/βl) (p=0.98). Double Spin Kit PRP contained at least a 400-fold higher concentration of white blood cells (14.8 +/- 3.0 thousand/βl) relative to Single Spin Lab and Single Spin Kit PRP.

Extracellular matrix synthesis. Cartilage (Fig. 1): ^3H-proline – In the absence of IL-1β, ^3H-proline incorporation in Single Spin Lab cultures was not significantly different from Single Spin Kit cultures (p=0.22). ^3H-proline incorporation in Single Spin Lab PRP was 31-64% higher than Double Spin 3x, 6x, and 9x, and Double Spin Kit cultures. In Single Spin Kit cultures, ^3H-proline incorporation was 31% and 20% higher than Double Spin 3x and Double Spin Kit cultures, respectively. In Double Spin Kit cultures, ^3H-proline incorporation was not significantly different from Double Spin 3x PRP (p=0.25). No significant differences were found among Double Spin 3x, 6x, and 9x cultures (p=0.07-0.58). ^3H-proline incorporation decreased with the addition of IL-1β for Single Spin Lab cultures only. In IL-1β medium, ^3H-proline incorporation was not significantly different among Single Spin Lab, Double Spin 3x, and Single and Double Spin Kit cultures. (p=0.22-0.98).

^3H-proline incorporation in Double Spin 6x and 9x cultures was approximately 15% lower than Single and Double Spin Kit cultures. ^35S-sulfate – In the absence of IL-1β, ^35S-sulfate incorporation in Single Spin Lab cultures was not significantly different from Single Spin Kit cultures (p=0.28). ^35S-sulfate incorporation in Single Spin Lab cultures was 32-72% higher than Double Spin 3x, 6x, and 9x, and Double Spin Kit cultures. ^35S-sulfate incorporation in Single Spin Kit cultures was 38-50% higher than that in Double Spin 3x, 6x, and 9x cultures. No significant differences were detected among Double Spin 3x, 6x, and 9x PRP (p=0.47-0.97). ^35S-sulfate incorporation in Double Spin Kit cultures was not significantly different from Single Spin Kit and Double Spin, 3x, 6x, and 9x PRP cultures (p=0.07-0.27). ^35S-sulfate incorporation decreased with the addition of IL-1β for Single Spin Lab, Single Spin Kit, and Double Spin Kit cultures. In IL-1β cultures, ^35S-sulfate incorporation among all media was not significantly different (p=0.47-0.99). Meniscus (Fig. 2): ^3H-proline – Interactions between PRP preparations and IL-1β were not significant (p=0.78). When considering the effect of PRP independent of IL-1β, ^3H-proline incorporation in Single Spin Lab and Double Spin 3x cultures was not significantly different (p=0.46). ^3H-proline incorporation in Double Spin 6x and 9x cultures were not significantly different (p=0.15), and both were significantly lower than Single Spin Lab and Double Spin 3x cultures. Single Spin Kit cultures were not significantly different from all other cultures (p=0.06-0.35) except for Double Spin 9x PRP. ^3H-proline incorporation in Double Spin Kit cultures was less than Single Spin Lab and Double Spin 3x cultures only. ^35S-sulfate – In the absence of IL-1β, ^35S-sulfate incorporation was not significantly different among Single Spin Lab, Double Spin 3x, and Single Spin Kit cultures (p=0.28-0.67). ^35S-sulfate incorporation in Double Spin 6x and 9x, and Double Spin Kit cultures was not significantly different (p=0.40-0.74). ^35S-sulfate incorporation in Double Spin 6x and 9x, and Double Spin Kit cultures was approximately 40% less than...
Single Spin Lab, Double Spin 3x, and Single Spin Kit cultures. $^{35}$S-sulfate incorporation decreased with the addition of IL-1β for Single Spin Lab, Double Spin 3x, and Single Spin Kit PRP. IL-1β cultures, $^{35}$S-sulfate incorporation among all media was not significantly different (p=0.30-0.89).

**Gene expression of catabolic enzymes. Cartilage:**
Interactions between PRP formulation and IL-1β were not significant for MMP1 (p=0.47), MMP13 (p=0.12), and ADAMTS-5 (p=0.19). In the absence of IL-1β, ADAMTS4 expression in Double Spin 6x cultures was 3.4- to 8.9-fold higher than Single Spin Lab, Single Spin Kit, and Double Spin 3x cultures. ADAMTS-4 expression in Double Spin Kit cultures was not significantly different from Double Spin 6x cultures (p=0.78), and significantly higher than all other IL-1β-free cultures. The addition of IL-1β to the culture medium increased ADAMTS-4 expression for Double Spin 9x cultures (11-fold) only. In IL-1β medium, ADAMTS expression was not significantly different between Single Spin Lab and Double Spin 3x cultures (p=0.97). ADAMTS-4 expression increased approximately 5-fold for Double Spin 6x and 22-fold for Double Spin 9x cultures. ADAMTS-4 expression in Single Spin Kit cultures was not significantly different from all laboratory preparations (p=0.16-0.18) except for Double Spin 9x. ADAMTS-4 expression in Double Spin Kit cultures was 2.1-fold higher than Single Spin Kit, approximately 5-fold higher than Single Spin Lab and 3x, and not significantly different from Single Spin 6x (p=0.68) cultures. **Meniscus:** Expression levels of MMP1 and 13 were not analyzed as many samples resulted in expression levels near the PCR detection limit. Interactions between PRP formulations and IL-1β were not significant for ADAMTS-4 (p=0.48) and ADAMTS-5 (p=0.33) (data not shown).

**Conclusions**
This study evaluated PRP formulations across a range of platelet concentrations as an indicator of whether differences exist among the various PRP kits that are commercially available. These data reject the hypothesis that increases the concentration of platelets in PRP stimulates ECM synthesis in cartilage and the meniscus; furthermore, these findings suggest that high platelet concentrations for intra-articular injection should be considered with caution. When projecting the results of in vitro studies to clinical applications, certain limitations of laboratory models must be considered. While the dilution of PRP by 50% was intended to mimic the dilution of an intra-articular injection in synovial fluid, tissue culture does not allow for clearance of the growth factors (7) as may occur in joints. Therefore, the laboratory model may overestimate the concentration of growth factors that is present in vivo. Importantly, the acute response of cartilage and meniscal explants does not necessarily recapitulate the response that occurs over weeks of clinical healing. In vivo testing will be necessary to address these limitations.

**Acknowledgments**
Funded by the Steadman Philippon Research Institute, Vail, Colo., and discretionary funds from the Orthopaedic Research Center at Colorado State University. We thank Dr. David Karli of the Steadman Clinic for his technical assistance.

**References**
**Summaries: Focus 4**

*Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis, and Osteoarthritis in the Horse*


---

**Figure 1:** Cartilage – Radiolabel Incorporation

**Figure 2:** Meniscus – Radiolabel Incorporation
Gene Therapy Approach to Treat Osteoarthritis Using AAVIRAP

Take Home Message
Gene therapy vectors were used to deliver IL-1ra to joint tissues and appeared to significantly increase protein production in equine joint tissues. When scAAVIL-1ra was injected into metacarpal phalangeal and middle carpal joints of horses, IL-1ra was produced for 23 and 183 days, respectively. No evidence of intra-articular toxicity was noted throughout the study and horses remained sound for the duration of the testing periods.

Introduction
Osteoarthritis (OA) is a chronic and incurable disease that affects over 40 million Americans per year with estimated costs of over $100 billion yearly. Gene therapy offers a radically different approach to the treatment of osteoarthritis. Interleukin receptor antagonist protein (IRAP) is antiarthritic due to its ability to effectively block or antagonize interleukin-1 (IL-1) which is a cytokine present in OA joint fluid and considered pivotal in the induction of osteoarthritis. An effective AAVIRAP vector would result in long-term abrogation of IL-1 and its devastating effects in the joint. This collaborative study was done by Nikki Phillips with Drs. Goodrich and McIlwraith of CSU, along with Drs. Samulski and Foti of the University of North Carolina, with the objective of constructing an AAVIRAP vector that would inhibit inflammation within the joint. Our hypothesis was that this vector would produce high levels of functional IRAP protein in the joint for up to six months.

Materials and Methods
An equine optimized IL-1ra gene was cloned into a mammalian expression vector, and transfected into AD293 cells. The vector was then cloned into an adeno-associated viral vector containing a CMV promoter. The scAAVIRAP vectors were tested for functionality against IL-1 stimulation in synoviocytes, and evaluated with a PGE2 ELISA. Two equines were evaluated for a pilot study in which joints were dosed with scAAVIRAP, scAAVGFP or saline. Synovial fluid was collected prior to dosing, two weeks after dosing, every week thereafter for 14 weeks, and every other week until termination of the study. IRAP levels were evaluated with an equine ELISA kit. White blood cell counts and total protein values were also measured.

Results
The equine optimized IL-1ra gene produced IRAP in transfected 293 cells, with levels greater than 15 ng/ml two days post-transfection. The scAAVIRAP vector produced similar levels in transduced synoviocytes (12 ng/ml), and was able to reduce the response of synoviocytes to IL-1 stimulation by 90%. Levels of IRAP protein were consistently high in the scAAVIRAP dosed joints of the pilot study animals with a peak occurring around week 8 (Fig. 1). Levels were between 400 and 1200 ng/ml and stayed above 400 ng for at least four months following injection. Study animals are ongoing and will continue to be monitored for at least two additional months. White blood cell count and total protein values rose only slightly in the scAAVIRAP or scAAVGFP injected joints and values stayed below that which is consistent with inflammation. Elevations of IRAP in saline injected joints were not detected.

Discussion
Our results suggest that the scAAVIRAP vector will produce extremely high levels of IRAP protein in the cells of joints and cause minimal to no toxicity in these tissues. The functional assay reveals that the IRAP protein produced effectively ameliorates the inflammatory cascade as evidenced by extreme reduction in PGE2. The viral vectors (scAAVGFP or scAAVIRAP) injected into the joints were well tolerated and didn’t result in pain or joint swelling. This is the beginning of a gene therapy protocol that will be tested in horses with induced osteoarthritis to reveal if OA can be reduced or halted. Our objectives of this study were met and our hypothesis that scAAVIRAP would produce high levels of functional IRAP in the joint was proven. Further studies will define whether this gene therapy approach can result in the effective treatment and prevention of OA.
Summaries: Focus 4
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

Acknowledgment
Funded by the National Institute of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the Grayson-Jockey Club Research Foundation.

References

Figure 1A. Clinical design for the dosing of Horse 2. The blue circles correspond to the carpal joints, and the green circles correspond to the metacarpal phalangeal joints. ScAAV constructs were given at specific concentrations per joint, whereas 5 ml of saline was administered into the joint receiving that treatment.
**Summaries: Focus 4**

*Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse*

---

**Figure 1B.** IL1ra expression and WBC counts ($10^3$ /μl) in the synovial fluid of the carpus and metacarpal phalangeal joints of Horse 2. Each joint is graphed separately over time. IL1ra levels were assessed with an equine IL1ra ELISA kit. Note: the WBC numbers on the top right graph are higher due to a higher WBC count in that joint. WBC counts were not determined at D23.
Summaries: Focus 4
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

Figure 1C. Clinical design for the dosing of Horse 1. The blue circles correspond to the carpal joints, and the green circles correspond to the metacarpal phalangeal joints. ScAAV constructs were given at specific concentrations per joint, whereas 5 ml of saline was administered into the joint receiving that treatment.

Figure 1D. IL1ra expression and WBC counts (10^3/ul) in the synovial fluid of the carpus and metacarpal phalangeal joints of Horse 1. Each joint is graphed separately over time. IL1ra levels were assessed with an equine IL1ra ELISA kit.
Take Home Message
Age does not appear to significantly influence the efficacy of gene transduction using scAAV in synoviocytes and chondrocytes in horses. Because the adult population may be more prone to receiving gene therapy than neonatal of young animals this is valuable information.

Introduction
Self-complementary adeno-associated viral vectors (scAAV) have shown promising results for gene delivery to cells of joint tissues. To test these vectors in vitro, it is most common to utilize cell cultures from skeletally immature animals due to the increased metabolic activity and recovery rate from cryopreservation of these cells compared to those from older animals.[1, 2] While initial investigation of transduction in neonatal tissue is relevant, it is important to determine if transduction of scAAV vectors is similar in adolescent and adult tissue since this is the population that would most frequently require gene therapeutic measures. This study was done by Nicki Phillips, Drs. Goodrich and McIlwraith of CSU and Dr. Jude Samulski of the Gene Therapy Center, University of North Carolina, and examined the transduction efficiency of scAAV in joint tissues from animals that represent a range of clinically applicable ages. Viral transduction efficiency was measured along with protein production from chondrocytes and synoviocytes of equine neonates (0-3 mth), weanlings (4-8 mth) and adults (2-5 yr). We hypothesized that scAAV transduction efficiency in chondrocytes and synoviocytes would decrease with age.

Methods
Cell Culture: Cartilage and synovial samples were taken from normal cadaveric stifle joints of neonates, weanlings, and adult equines within 4 hours of death. Age groups consisted of three to five individuals per group. Isolated chondrocyte cultures were plated immediately for use at passage 0 (P0), while synoviocytes were expanded to P2 to ensure a pure population of cells prior to experimental use. ScAAV Transduction: Chondrocytes and synoviocytes were plated to 50% confluence 48 hours prior to transduction with scAAV constructs expressing GFP and IL1-ra at a concentration of 6000 viral particles per cell (vpc). Transductions were carried out for three hours and evaluated at four and eight days post transduction. GFP Evaluation: GFP (green fluorescent protein) expression was determined with a spectrophotometer and samples were normalized against the negative controls to account for auto fluorescence. Equine IL1-ra ELISA Evaluation: Culture media samples were collected at four and eight days post-transduction. Non-transduced samples and those transduced with IL1-ra were evaluated using a commercially available Equine IL1-ra ELISA kit (R&D Systems). Cultures expressing IL1-ra were normalized to their negative controls. Cell Scoring: Cultures were scored on a scale 0-5 based on the number of cells exhibiting abnormal morphology and complete cell death. A score of 0 had no abnormalities, 1 = 1-20% abnormality, 2 = 20-40%, 3 = 40-60%, 4 = 61-80% and 5 = >80%.

A one way ANOVA was performed to detect difference between age groups. A p value of <0.05 was considered significant.

Results
There were minimal differences observed in the transduction efficiency of synoviocytes between age groups at day 4 (data not shown) and day 8 post-transduction (Fig. 1). Fluorescent analysis revealed a gradual increase in fluorescence of chondrocytes with age and this trend was further emphasized by fluorescent microscopy (Fig. 2, C and D). However; this increase was not seen with IL1-ra protein production (Fig. 2). Transduction of synoviocytes with scAAVGFP did not change with age group.

Similarly, there were minimal differences in the associated protein production of synoviocytes between age groups at day 4 (data not shown) and day 8. Protein production in weanling chondrocytes were
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

markedly reduced compared to those of neonates and adults (with similar production) (Fig. 3).

Cell morphology scores for adult synoviocytes were considerably higher (worse) at day eight, with minimal changes observed between chondrocytes and synoviocytes for neonates and weanlings (data not shown).

Discussion
Our results suggest that age does not significantly decrease scAAV transduction and associated protein production. Surprisingly, transduction with scAAVGFP actually increased in chondrocytes in adults although this was not demonstrated in IL1-ra production. This data is important when considering gene therapeutic protocols in adult animals since this population is more likely to receive gene therapeutic measures to treat joint disease. To our knowledge, age differences of scAAV transduction has not been investigated. This information will be important to clinicians choosing viral dosages for \textit{in vivo} gene therapy trials.

Acknowledgments
Funded by NIH grant K08AR054903-01A2.

References

\textbf{Figure 1.} D8 GFP expression in chondrocyte and synoviocyte cultures taken from neonates, weanlings, and adults.
Figure 2. Fluorescent microscopy of chondrocytes (A) and synoviocytes (B) 8 days post-transduction with IRAP (top) and GFP (bottom) scAAV.
Figure 3. D8 IL1-ra expression in chondrocyte and synoviocyte cultures taken from neonates, weanling and adults.
**Mesenchymal Stem Cell Proliferation and Expression of Growth Factors in Response to Extracorporeal Shock Wave Therapy Treatment**

**Take Home Message**
While extracorporeal shock wave therapy (ESWT) has been shown to enhance the therapeutic potential of certain cell types, its effect on equine mesenchymal stem cells (MSCs) is not known. We report that ESWT does not enhance MSC proliferation *in vitro*, and that gene expression of selected growth factors is not affected. For proliferation cultures, the first application of ESWT decreased growth relative to unshocked MSCs, although subsequent ESWT treatments did not affect MSC proliferation. These data suggest that it may be possible to administer multiple ESWT treatments to defects containing MSCs without harming the repair response of transplanted MSCs.

**Methods**

**Proliferation:** The effect of ESWT on MSC proliferation in monolayer culture was evaluated over a ten day timecourse. Equine MSCs were plated at a concentration of 12,000 MSCs/cm² and maintained in baseline media containing 10% FBS. Half of the cultures were fed baseline media, while a second group was fed baseline media plus 2 ng/ml fibroblast growth factor 2 (FGF). Control groups received no additional treatment. Experimental groups were subjected to 500 pulses using energy level E2 prior to the first plating and in between passages. ESWT was administered to MSCs in suspension within 2 ml of baseline medium held within 15 ml centrifuge tubes. For each passage, MSCs were allowed to grow for two days, a point where control cultures in FGF-2 medium reached near confluence. At this point the cells were lifted using trypsin, counted, and replated at a concentration of 12,000 MSCs/cm². The cultures were expanded as such five times, resulting in five passages over 10 days. At each passage, the cell yield was divided by the number of cells plated at the start of the experiment to obtain a fold-change in cell number. The log of the fold-change was calculated to determine the number of population doublings. This experimental protocol was repeated for MSCs from three animals.

**Gene expression of growth factors:** ESWT was administered to MSCs in suspension as previously described, and then seeded at 20x10³ cells/cm² in monolayer culture in alphaMEM with or without 10% FBS. Control cells that did not receive ESWT were seeded in parallel. After four hours, RNA was harvested from monolayer cultures and isolated using the RNeasy Mini Kit according to the manufacturer’s instructions. RNA was reverse transcribed to cDNA in the presence of random hexamers. Semiquantitative real time PCR was performed for vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and transforming growth factor beta (TGFβ) using the Applied Biosystems 7000 system and TaqMan Universal
PCR Master Mix. For each sample, expression was normalized to 18S threshold values.

Statistical Analysis: Proliferation assays were conducted using MSCs from three donor horses, while gene expression analysis was evaluated using MSCs from four donor horses. Log transformed data were analyzed using a mixed model analysis of variance, with the donor animal used as a random effect. Individual comparisons were made using least square means procedure. For MSC proliferation through the first five passages, ESWT, FGF, and passage were considered main effects as well as their interactions. For cumulative proliferation through the first five passages, ESWT and FGF were considered main effects as well as their interactions. For gene expression analysis, ESWT and FBS were considered main effects as well as their interactions. Individual comparisons were made when main effects or interactions resulted in an f-value less than 0.05. For individual comparisons, p-values less than 0.05 were considered significant. Data are reported as mean +/- standard error of the mean.

Results
Proliferation: Interactions among ESWT, FGF, and passage were not significant (p = 0.91). When considering the effects of ESWT and passage independent of FGF, at passage one, ESWT cultures (0.71 +/- 0.17 population doublings) experienced 0.95 fewer population doublings than control cultures (1.66 +/- 0.17) (p < 0.001, Fig. 1). For passages two through five, the number of population doublings in ESWT cultures were not significantly different from controls for each passage (p = 0.24-0.95). When considering the effect of FGF independent of ESWT and passage, FGF+ cultures (1.86 +/- 0.09) averaged 0.59 more population doublings compared to FGF- cultures (1.27 +/- 0.09) (p < 0.001, data not shown). For the cumulative population doublings over the first five passages, interactions between ESWT and FGF were not significant (p = 0.32). When considering the effect of ESWT independent of FGF, ESWT cultures (7.35 +/- 0.40) resulted in 0.90 fewer population doublings than control cultures (8.25 +/- 0.40) (p < 0.005, data not shown). For MSCs from FGF+ cultures that were expanded through a sixth passage, the number of population doublings by MSCs that received ESWT throughout the first five passages was not significantly different from that in control cultures that did not receive ESWT (p = 0.87) (data not shown). MSCs from control cultures that were subjected to ESWT for the first time prior to seeding into passage six experienced approximately 0.3 fewer population doubling than cultures treated with ESWT throughout the six passages and untreated controls (p < 0.05).

Gene expression of growth factors: For IGF-1, TGFβ, and VEGF, interactions between ESWT and FBS were not significant (p = 0.67-0.79) (data not shown). When considering the main effect of FBS, gene expression of IGF-1 in FBS-free conditions were 4.3-fold higher than FBS cultures, while gene expression of TGFβ and VEGF in serum-free cultures conditions was 2.1- and 9.3-fold lower than controls (p < 0.05). When considering the main effect of ESWT, gene expression of IGF-1, TGFβ, and VEGF were not significantly different (p = 0.45-0.92).

Conclusion
ESWT and MSCs are used separately to treat equine tendonitis, and it is not know how ESWT applied following the injection of MSCs may affect healing. This in vitro study did not demonstrate a benefit of ESWT on MSC proliferation or gene expression of growth factors; however, our data suggest that the only negative effect of ESWT is a short-term decrease in MSC proliferation following the initial treatment only.

Acknowledgments
Funded by Pulse Veterinary Technologies, Alpharetta, Ga.
Summaries: Focus 4

Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

References


Take Home Message
Intra-articular corticosteroids are potent anti-inflammatory agents with prolonged effectiveness for traumatic joint disease in the horse. Generalizations about harmful effects of intra-articular corticosteroids are inappropriate, and research has defined differences in beneficial and deleterious effects. There is also no evidence that intra-articular corticosteroids cause harm to subchondral bone or promote catastrophic injury. Sound evidence linking laminitis to corticosteroid injection of normal doses of corticosteroids is lacking.

Introduction
The Thoroughbred horse-racing industry has come under renewed scrutiny in recent years in the United States because of horses suffering from catastrophic injury during high-profile events. Consequently the public outcry from these events has led to Congressional oversight and investigation into the industry, which has led to significant scrutiny of medications that are used in sport. Anabolic steroids were banned in 2009 and now, other medications are also being critically reviewed. Intra-articular use of corticosteroids has recurred as a focus of attention. Proponents of intra-articular corticosteroid treatment argue that such therapy is needed to decrease inflammation and musculoskeletal pain, which is common in Thoroughbred racehorses, and more importantly, to avoid overloading of the other limbs, possibly leading to catastrophic injury. However, opponents of corticosteroid use feel that it is merely masking pain and results in joint deterioration. Much of this perception of harm is based on opinion and has been passed down through the literature.

This paper was a review of the clinical use and scientific basis of intra-articular corticosteroid administration that was generated by a request to Dr. McIlwraith by the American Association of Equine Practitioners Racing Committee and the Racing Medication and Testing Consortium (RMTC) to critically review the scientific data regarding intra-articular corticosteroids. After doing this review Dr. McIlwraith has published a full review in *Equine Vet Journal* and it was also presented at the Annual Meeting of AAEP in December 2010.

Summary of Important Points
- The use of hydrocortisone in the treatment of a variety of musculoskeletal conditions in 94 horses and cattle was first reported in 1955 by Wheat. The author cited profound improvements in clinical signs in most cases but also cautioned treated animals should be rested after injection to allow healing of affected animals.
- This report was followed by multiple investigations that showed positive effects by Van Pelt and colleagues.
- The first paper indicting corticosteroids as harmful in the horse was written in 1968 and was based on an anonymous paper in the human literature. The statement, “an endless destructive cycle is set into motion which, if continued, will produce a steroid arthropathy which can render the horse useless” was referenced and the reference was an abstract written by an anonymous author. In a subsequent textbook chapter on drugs in the performance horse a number of statements were made regarding corticosteroids and their harmful effect on joints.
- Early studies evaluating the effect of methylprednisolone acetate (MPA) injected into normal joints showed deleterious effects.
- Based on observations of the lack of secondary cartilage damage when doing arthroscopic surgery for joints with osteochondral fragmentation, research projects were commenced at the ORC at Colorado State University.
- The initial project was done with betamethasone esters and there were no harmful side effects observed in an experimental model in which a chip fragment was created and horses exercised on the treadmill.
- Subsequent evaluation of MPA showed definite deleterious side effects using the osteochondral fragment model that was modified and has been
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

• Triamcinolone acetonide (TA) was then evaluated using the osteochondral fragment model and protective effects to the cartilage as well as good clinical effects in lowering inflammation were found.

• There had been a long fear of the use of TA potentiating development of laminitis. Early work had recommended that a total body dose of 18 mg not be exceed. Subsequent to that a clinical paper showed use of doses up to 40 mg were not associated with laminitis. More recently a report of intra-articular injection of corticosteroids in 2,000 cases revealed laminitis being associated with this treatment in three cases. The majority of the time TA was used at higher dose rates ranging from 20-45 mg.

• A traditional concept has been that a load is better not to use MPA in high motion joints, but its use in low motion joints (such as the distal tarsal joints) is appropriate. There certainly has been decreased use of TA by sport horse veterinarians even in low motion joints, but the use persists in racehorses but there is no evidence either way that this practice needs to be continued. While MPA is believed to be longer acting there is questionable logic to selective harm to articular cartilage.

• There is no association of intra-articular use of triaminolone acetonide or methylprednisolone acetate causing harm to the bone and predisposition to fracture and catastrophic injury based on controlled studies in horses.

• Anti-inflammatory actions of corticosteroids are mediated through cytoplasmic receptors which lead to gene-regulation changes and consequent changes in protein expression through signaling pathways. The anti-inflammatory effects are quite long acting and the pharmacologic presence in the joint. There are a number of pharmacokinetic studies being done with corticosteroids but it is difficult to directly transpose pharmacokinetic data into biologic potency or activity. Measuring gene expression using pharmacogenomic methods provides the potential of more global assessment or pharmacodynamics responses after intra-articular corticosteroid injection.

• There is no current evidence that combination therapy with HA can mitigate the negative effects associated with MPA but recent work shows that HA does have chondroprotective effects in combination therapy with TA or betamethasone esters is appropriate.

References


**Summaries: Focus 4**

*Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse*

**scAAV Transduction Efficiencies in Joint Tissue Monolayer and Explant Cultures and the Effects of Synovial Fluid Neutralization**

**Take Home Message**

Gene transduction of chondrocyte and synovial monolayer is significantly different than cartilage and synovial explants and this study highlights the necessity to test gene therapeutic tissue in situ. Furthermore, neutralizing antibodies exist in both the synovial fluid and serum which can reduce efficient gene transduction. It is important to determine which serotypes have antibodies that exist in the horse.

**Introduction**

Within the joint there are two major tissues currently targeted by gene therapy vectors to treat osteoarthritis. Synoviocytes are within the synovial membrane which has fimbria that extend into the synovial fluid. Chondrocytes are surrounded by matrix in the cartilage layer. Although transduction efficiency has been well quantified in chondrocyte and synoviocyte monolayers, transduction of explants of cartilage and synovium has not been thoroughly investigated. Although efficient transduction of synoviocytes and chondrocytes is important to ex vivo gene therapy, it is important to determine if self-complimentary adeno-associated viral (scAAV) vectors can transduce cells in situ. scAAV is currently the vector of choice being investigated to carry therapeutic genes to both the synovium and cartilage. There are many serotypes of AAV each with specific and variable tissue tropisms. Furthermore, neutralizing antibodies have been identified in the synovial fluid of humans which results in decreased scAAV transduction of tissue. The purpose of this study done by Daniel Hemphill together with Drs. McIlwraith and Goodrich of the ORC and Dr. Jude Samulski of the University of North Carolina was to compare scAAV transduction in monolayer to explant tissue of synovium and cartilage and to investigate whether the presence of synovial fluid inhibits efficient transduction in joint tissue. Our goal was to identify which serotype of AAV leads to efficient transduction in both synovium and cartilage in the horse model. We hypothesized that monolayer transduction efficiency is similar to explant transduction efficiency and that neutralizing antibodies exist in synovial fluid that will decrease transduction efficiency.

**Methods**

Synovioum from the femoropatellar joint capsule and cartilage from the patella were aseptically harvested post-mortem from three horses 2-5 years of age. Each tissue was cut into pieces of similar size for explants with the remainder digested overnight in collagenase type II solution. The isolated chondrocytes and synoviocytes were expanded one passage and then plated in 48 well plates at 50,000 cells/cm\(^2\) for synoviocytes and 100,000 cells/cm\(^2\) for chondrocytes. After two days all explants and monolayers were transduced with scAAV-GFP at 8000 virus particles per cell for four hours at 37°C. Fluorescent microscopy pictures were taken every three days and flow cytometry was performed 35 days after the transduction. Multivariable ANOVA was performed on the data and results with p < 0.05 chosen as statistically significant.

**Figure 1.** Explant experiment transduction efficiencies for serotypes averaged across all tissue types. On left showing the percentage of cells expressing GFP at significant levels and on right average intensity of fluorescence.
Synovial fluid was aseptically collected post-mortem from five horses 2-5 years of age. Synoviocytes and chondrocytes were plated in 48 well plates at the densities previously mentioned. Three days after plating, 4000 virus particles per cell were incubated with a 1:2 or 1:200 synovial fluid dilution for one hour at 37°C. Immediately following, the cells were transduced with the virus and synovial fluid mixture for four hours at 37°C. Plates were read using a fluorometric plate reader every two days. One way ANOVA was performed and p < 0.05 chosen as statistically significant.

Results

In vitro, explants and monolayers were successfully transduced and there was no difference in transduction efficiency between monolayer and explants when analyzing the percentage of cells transduced. The mean fluorescence intensity of the vector gene expression revealed that monolayer cells appeared more fluorescent than explants cells. When percentage of cells transduced and mean expression intensity were combined, horses did not show statistical difference, but virus serotypes did show statistical differences with S2 > (S3, S5, S2.5, S6); only these serotypes were significantly different from the control. Furthermore, cartilage showed statistically higher transduction efficiency than synovium.

Virus incubation with synovial fluid decreased GFP production in synoviocytes for several serotypes of virus, although averaging over all serotypes showed no difference. While specifically testing individual serotypes: 2, 2.5, 5, and 6 revealed significant differences following synovial fluid incubation. There was no statistical difference between the five horses tested.

Discussion

The results of this study suggest that cell culture monolayer is a good indicator for actual tissue tropism of scAAV serotypes in the joint as tissue explants (both cartilage and synovium) are efficiently transduced with various serotypes. These results suggest that when scAAV vector is placed into the joint environment, vector can transduce chondrocytes and synoviocytes efficiently in situ. Furthermore serotype 2 appears to be the best option for total transduction of joint tissue. However, synovial fluid has a negative effect on transduction efficiency with AAV serotypes 2, 2.5, and 6. This suggests that, in addition to identifying the optimal serotype for transducing joint tissues, some attention must be paid to identifying a serotype that will not be inhibited by synovial fluid; or the removal of synovial fluid through joint lavage should be considered in a treatment. Despite monolayers and explants having similar transduction efficiencies, the intensity of gene expression was higher in monolayers than in explants.
expression differed between the two and this deserves further investigation. The clinical significance of this study is that specific serotypes have been identified that will efficiently transduce synoviocytes and chondrocytes in situ and while neutralizing antibodies appear to exist, significant transduction can still occur.

References
**Take Home Message**

The field of mesenchymal stem cell research is an ever evolving science and much work is still needed in the clinical application of this treatment modality. Some good basic science studies have been done over recent years but equally importantly, clinicians need to continue communicate openly on the success and failures with this emerging modality under evidence-based (EBM) conditions.

Given the amount of information and misconception that has been introduced into the veterinary and lay press, Drs. Frisbie and Roger Smith of the Royal Veterinary College, London published a review article to try and clarify key points of the stem cell technology and research. The following is a summary of that publication.

The manuscript focused on the clinical use of mesenchymal stem cells (MSCs) in horses and the justification for, as well as issues surrounding, their use. Many of the early reports used bone marrow as a source of these cells, but other sources have been more recently demonstrated. For example, muscle, cartilage, and adipose tissue all have been shown to contain multipotent MSCs. Direct comparisons of the two most commonly used clinical sources of cells, bone marrow and fat derived, have shown superior cells from bone marrow when tested in a joint environment. Work to compare the best source for tendon is yet to be published; however, work done after the current publication suggests bone marrow may be better for tendon repair as well.

Various methods of preparing stem cells from bone marrow aspirates have been used. They range from injecting the raw aspirate to picking out stem cells and culture expanding them. While the direct injection of aspirate was first labeled as stem cell treatment it has been shown only 2,000 stem cells/ml are contained in such a preparation, thus significantly below what is believed to be needed (1-5 million cells). More recently bone marrow concentration has been proposed. This method concentrated the stem cells found in the raw aspirate approximately 12 times however, given the initial volume limitations the final number of cells is usually in the hundreds of thousands, not millions. Thus culture expanding the stem cells to provide adequate stem cell numbers is still the gold standard. While some have looked at using allogeneic cells or cells derived from another horse, this process has not been approved by the Food and Drug Administration (FDA).

Research has been done looking at horses with experimental osteoarthritis, in this study published in the *Journal of Orthopaedic Research* a significant decrease in PGE2 (an inflammatory mediator) was seen in response to a single treatment with bone marrow derived stem cells. While this is encouraging, it is not clear given the cost of stem cell treatment that the improvement warrants the expense. Stem cells have also been used to treat clinical cases of joint disease. A group of horses that have undergone surgery to ascertain a definitive diagnosis as well as determine the degree of pathology were followed for almost two years. The majority of these horses had meniscal damage and were treated surgically, as well as with bone derived culture expanded stem cells. These horses were more likely to go back to work compared to a previously published group of horses that received surgery alone, especially in cases of severe damage. These results have provided encouragement for continued intraarticular treatment of horses with stem cells.

The publication also detailed reports of horses that sustained tendon or ligamentous injuries that were treated with rehabilitation and stem cells and then compared to those treated with rehabilitation alone. It
Summaries: Focus 4
Continued Development of Novel Therapies for Traumatic Synovitis, Capsulitis and Osteoarthritis in the Horse

has been shown that stem cells can help these horses go back to work and in flat racing horses decrease the incidence of re-injury after they have gone back to work, when compared to rehabilitation alone.

In conclusion, the field of stem cell research is an ever evolving science and much work is still needed in the clinical application of this treatment modality. It is important for clinicians to continue to communicate openly on the success and failures with the emerging modality, under evidence-based (EBM) conditions.

References
The Role of Aquatic Therapy in Managing Equine Osteoarthritis

Take Home Message
Aquatic therapy has become increasingly popular for the rehabilitation of equine musculoskeletal injuries; unfortunately, there has been no scientific evaluation of its effectiveness for the treatment of OA and its associated alterations in musculoskeletal function in horses. The purpose of this review is to define the proposed mechanisms of action of aquatic therapy and to determine its efficacy in the treatment of equine OA.

Introduction
Osteoarthritis (OA) is one of the most debilitating musculoskeletal disorders among equine athletes. It is a common cause of poor performance, early retirement, and reduced life expectancy. Medical and surgical management of equine associated lameness disorders cost more than $700 million within the United States in 1998. Osteoarthritis is a progressive disease characterized by joint pain, inflammation, synovial effusion, limited range of motion, and a progressive deterioration of articular cartilage. The ensuing disease process affects not only the articular cartilage but also the surrounding articular tissues, including subchondral bone, joint capsule, synovial membrane, and periarticular soft tissues. As joint disease progresses, characteristic pathologic changes occur including fibrosis and thickening of the joint capsule, articular cartilage fibrillation and erosion, and osteophyte formation, which all lead to functional impairments. Unremitting joint pain and inflammation often cause adaptive muscle guarding and altered weight bearing to protect the affected limb from further discomfort and injury. Compensatory muscular adaptations are characterized by inefficient muscle activity leading to muscle weakness, joint instability, and altered limb loading. Maladaptive musculoskeletal responses may produce additional gait alterations and predispose other articulations to an increased risk of injury (i.e., compensatory lameness). In humans, compensatory changes in posture and movement exacerbate the initial joint injury, which cause further alterations in limb biomechanics and contribute to the progression of OA. Similar compensatory mechanisms such as delayed muscle activation, muscle weakness, restricted joint range of motion, and a redistribution of limb loading are likely to also occur in horses.

Physical rehabilitation has become an effective treatment option for improving deficiencies and weaknesses associated with primary joint injuries, as well as reducing harmful compensatory gait abnormalities in humans. Rehabilitation programs that address OA and musculoskeletal injuries often incorporate some form of aquatic exercise. Therapeutic aquatic interventions can be used to optimize the treatment of sensory and motor disturbances in order to achieve the functional restoration of full athletic performance. Aquatic therapies, such as underwater treadmill exercise have been reported in humans to increase cardiovascular endurance, improve muscle strength and timing, decrease limb edema, improve range of motion, decrease pain, and reduce mechanical stresses applied to the limb. Exercising in water provides a medium in which the effects of increased buoyancy, hydrostatic pressure, and the viscosity of water along with the ability to alter both temperature and salinity combine to play an important role in musculoskeletal rehabilitation (Fig. 1). The increased resistance and buoyancy inherent in aquatic exercise increases joint stability and reduces weight bearing stress on muscles and joints. The immersion of the distal limb in water applies a circumferential compression of equal magnitude that increases with depth below the surface of the water, increasing extravascular hydrostatic pressure, which in turn promotes circulation and reduces edema. Hydrotherapy can also aid in decreasing pain through the application of either cold or warmer water conditions. Warm water causes blood vessels to dilate increasing circulation and decreasing muscle spasms, while colder water acts to reduce inflammation by restricting blood flow. Aquatic conditions with higher solute concentrations provide an osmotic effect, which ultimately reduces edema and decreases pain. Aquatic therapy is a versatile treatment modality, capable of producing a
Focus 5
Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease

wide variety of therapeutic effects and therefore is an effective method of rehabilitation for individuals with OA that have difficulty with weight bearing associated with land exercise (Table 1).

**Effectiveness of aquatic therapy in human OA patients**

Rehabilitation protocols used to address OA co-morbidities often focus on improving muscle function and joint biomechanics. Aquatic therapy is frequently prescribed for rehabilitation of orthopaedic injuries in humans, with the goal of improving the overall function of the affected limb and preventing further musculoskeletal injury. Following aquatic rehabilitation, human patients have demonstrated normalized muscle activation patterns and improved joint stability, joint range of motion, and proprioception. Joint replacement and arthroscopic surgery patients are also commonly referred postoperatively for aquatic therapy intervention. Aquatic exercise decreases the weight bearing stresses applied to the operated joint, which allows an earlier and more intensive but less painful rehabilitation program without risk of overloading the injured joint. Human patients undergoing surgical reconstruction of their anterior cruciate ligament demonstrate improved knee range of motion and quadriceps strength following aquatic therapy, compared to traditional clinic based rehabilitation programs.

**Aquatic therapy in dogs**

Although aquatic therapy is widely used in rehabilitation programs for humans; there are few investigations into the benefits of this form of exercise for equine patients. However, several studies on aquatic therapy have been conducted in dogs that primarily demonstrate significant improvements in joint range of motion following aquatic exercise. Aquatic therapy in dogs post cranial cruciate ligament reconstruction produces significant increases in joint range of motion, not only in the operated stifle, but also in the non-operated stifle. A similar canine study demonstrated improved pelvic limb biomechanics, with no difference in peak vertical force or vertical impulse, as measured by force platform analysis between the repaired and contralateral limb at six-months follow up. Kinematic analysis of dogs walking in an underwater treadmill demonstrated that joint flexion is maximized when the depth of the water is maintained above the joint of interest. Clinical outcome measures of thigh circumference and stifle joint range of motion were assessed in cranial cruciate ligament-deficient dogs after tibial plateau osteotomy. Underwater treadmill exercise improved stifle passive joint range of motion and increased thigh circumference, compared to cage rest and controlled walking. Six weeks after surgery, there was no difference in thigh circumference and joint range of motion between the affected and unaffected limbs in the aquatic therapy group. In contrast, the cage rest and controlled walking group demonstrated continued progression in joint stiffness and muscle atrophy.

**Aquatic therapy in horses**

Unlike the canine studies, equine investigations into aquatic therapy focus mainly on the horse’s cardiovascular and respiratory responses to exercising in water. Equine swim training programs report an improvement in cardiovascular function, a reduction in locomotor disease, and an increase in the development of fast-twitch, high-oxidative muscle fibers, reflecting improved aerobic capacity. Fine-wire EMG electrodes have been used to demonstrate the increased muscle intensity of the equine thoracic limbs during a pool swimming exercise program compared to overground walking. A recent equine study assessed changes in stride parameters while walking in various depths of water. Underwater treadmill walking with water at the level of the ulna resulted in a longer stride length with a reduced stride frequency, compared to walking in water at the level of the pastern joint. To date there are no objective studies that have determined the ability of underwater treadmill exercise to improve muscle activation patterns or limb biomechanics in the horse. There are also no studies that have objectively assessed the effects of aquatic therapy on diminishing the progression of equine OA.

**Conclusion**

Osteoarthritis in horses is typically managed with conventional therapies aimed at reducing...
inflammation. There are a limited number of therapies that have demonstrated disease-modifying effects however; no one therapeutic agent has effectively eliminated the progression of joint disease. Any form of treatment that can retard the progression of OA is of great importance, both for continued athletic performance and for quality of life. From the human and canine literature and limited equine studies reviewed, aquatic therapy has a beneficial effect on pain reduction and related musculoskeletal outcome measurements. Similar results such as improving joint range of motion, motor control, and joint stability as well as decreasing pain and soft tissue swelling following aquatic therapy are expected to occur in our equine patients.

References
Summaries: Focus 5
Validation of Rehabilitation and Physical Therapy Techniques for Musculoskeletal Disease


Figure 1: Graph illustrating the combined variables involved in aquatic therapy.
Table 1. Summary of the reported therapeutic effects of aquatic therapy.

<table>
<thead>
<tr>
<th>Aquatic Therapy Variables</th>
<th>Reported Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buoyancy</td>
<td>• Reduces weight bearing stresses on joint and soft tissue structures</td>
</tr>
<tr>
<td></td>
<td>• Improves joint range of motion</td>
</tr>
<tr>
<td>Viscosity</td>
<td>• Increases muscle activity</td>
</tr>
<tr>
<td></td>
<td>• Enhances neuromuscular control</td>
</tr>
<tr>
<td>Hydrostatic Pressure</td>
<td>• Reduces edema</td>
</tr>
<tr>
<td></td>
<td>• Increases joint range of motion</td>
</tr>
<tr>
<td></td>
<td>• Decreases pain</td>
</tr>
<tr>
<td>Temperature</td>
<td>• Increases soft tissue perfusion and lymphatic drainage (warm)</td>
</tr>
<tr>
<td></td>
<td>• Reduces blood flow and decreases inflammation and pain (cold)</td>
</tr>
<tr>
<td>Osmolality</td>
<td>• Improves mechanical nociceptive thresholds</td>
</tr>
<tr>
<td></td>
<td>• Reduces edema</td>
</tr>
</tbody>
</table>
Take Home Message
Current saddle fitting methods do not provide a quantifiable or standardized method for assessing three-dimensional trunk morphometry. The Equine Back Profiling System (EBPS) was able to reliably capture a wide variety of dorsal trunk contours of horses ridden under English dressage or jumping saddles as well as Western saddles. The EBPS provides a significant advancement as we are now able to better communicate findings or changes in dorsal trunk contours related to saddle fit to colleagues or owners and trainers.

Introduction
The goal of saddle makers and fitters is to match the size and shape of a specific saddle as closely as possible to an individual horse's dorsal trunk contour in an effort to maximize surface area and to provide uniform, low-pressure distribution patterns without limiting performance. However, current saddle fitting methods do not provide a quantifiable or standardized method to assess three-dimensional morphometry, which means that saddle manufacturers are unable to produce a consistent product that is able match the wide variability present in different body types and trunk morphologies. Even after centuries of applying saddles to ridden horses, there is no established industry-wide standard for assessing the size or shape of a horse's trunk in an effort to improve saddle fit and reduce associated back pain. Unfortunately, the majority of descriptions of equine trunk shape and size are nondescript and not clinically useful. Morphometric features (i.e., height, length, depth, and width) of a horse's trunk can provide objective measures of body size or shape that are required to quantify specific segmental characteristics or general body conformations. However, it continues to be difficult to capture and quantify surface contours, which are considered critically important for establishing uniformity between the contours of the ventral surface of the saddle and the dorsal surface of the trunk of the horse.

The EBPS consists of a series of durable plastic cards with cut-out contours that are positioned at several predetermined anatomical sites along the dorsal trunk in an effort to provide an objective assessment of conformation and contours relevant to proper saddle construction and fitting. The cards are reportedly easy to use and provide a potential method for quantifying the dorsal trunk morphology across a wide-variety of body types and breeds of horses. The EBPS may provide a standardized method to quantify the shape of a horse's trunk, which would be a significant advancement in improving saddle construction, standardizing saddle fit, and reducing the prevalence of trunk pain in ridden horses. The objective of this study was to assess the ability of the EBPS to readily quantify the contours of the dorsal trunk in several breeds of horses used in different athletic disciplines.

This project was completed by Drs. Kevin Haussler, Ashley Hill, Wayne McIlwraith, and Chris Kawcak with Sierra L. Blauvelt and Jodi Callison at Colorado State University.

Methods
Each EBPS transverse card contained three or four cut-out contours that were able to capture a total of 33 different transverse contours of the dorsal trunk (Figure 1). The cards were placed transversely at six specified dorsal trunk locations that included the following sites: 1) widest portion of the withers, 2) highest point of the withers, 3) caudal edge of the scapula, 4) base of the withers (i.e., where the slope of the withers transitions into a more horizontal curvature of the trunk), 5) lowest point of the trunk, and 6) the thoracolumbar junction (Figure 2). These six vertebral locations were judged to be the minimum number of sites needed to optimally capture potential variations in the dorsal trunk contours across different breeds of horses using both English and Western saddles.

The EBPS also contains two cards used to capture the parasagittal contours of the dorsal trunk in the...
region of typical Western saddle tree bar or English panel placement (Figure 3). The parasagittal cards were positioned 10-cm lateral to the dorsal midline of the trunk over the left and right epaxial musculature to assess bilateral longitudinal contours. Chi-squared analysis was used for nominal (unordered) data and Spearman Rank correlations was used for ordered and continuous data comparisons. Kruskal-Wallis one-way analysis of variance was done using Bonferroni adjustment.

Results
The EBPS readily quantified the dorsal trunk contours in these horses. The transverse contours at the widest point of the withers were mostly narrow and 35% \((n=73)\) of cards were judged to have good fit \((≤ 0.5\, \text{cm})\). At the highest point of the withers, 39% \((n=82)\) of transverse cards had a good fit. The widest and highest points of the withers were located at the same site in 64% \((n=135)\) of horses. At the caudal aspect of the scapula, 89% \((n=188)\) of transverse cards had a good fit and only 4% of regions had a gap height > 0.5 cm. At the base of the withers, 77% \((n=163)\) of cards had a good fit and 5% of regions had a gap height > 0.5 cm. At the lowest point of the trunk, 97% \((n=205)\) of cards had a good fit and 1% of regions within a card had a gap height > 0.5 cm. At the thoracolumbar junction, 91% \((n=191)\) of cards had a good fit and 2% of regions within a card had a gap height > 0.5 cm. The transverse contour measurements at the three cranial vertebral locations (i.e., widest, highest and caudal scapula sites) were not significantly different from each other; however, the caudal three vertebral locations (i.e., base, lowest and thoracolumbar sites) were all significantly different from the cranial vertebral locations and each other.

Over the left epaxial musculature, 89% \((n=187)\) of parasagittal cards had a good fit and 2% of quadrants had a gap height > 0.5 cm. Over the right epaxial musculature, 92% \((n=195)\) of cards had a good fit and 2% of quadrants had gap heights > 0.5 cm. There were significant associations between the parasagittal card sizes and breed and athletic discipline. Warmbloods had flatter longitudinal contours and Morgans had more epaxial muscle concavity. For use, hunter-jumpers had the least amount of longitudinal epaxial muscle concavity and Morgans had the most muscular concavity.

Discussion
The objective of this study was to assess the ability of the EBPS to readily quantify the contours of the dorsal trunk in several breeds of horses used in different athletic disciplines. Using the three transverse locations and the left parasagittal site recommended by the EBPS manufacturer, the overall success rate was 92% as defined by overall gap heights ≤ 0.5 cm within a card. The parasagittal cards had similar high rate of success (89-92%) as did the transverse cards at the manufacturer’s recommended sites for measuring dorsal trunk contours. Across all four recommended vertebral locations, there was a 72% percent chance that all four cards had a good fit with gap heights ≤ 0.5 cm within an individual horse. The EBPS was easy to use and was able to quantitatively capture subtle differences in trunk contours across horses of significantly different ages, wither heights, body weights, breeds, and uses of horses judged to have diverse trunk conformations. This suggests that the EBPS can be used to reliably capture the dorsal trunk contours in horses in an effort to improve saddle fit and construction in ridden horses.

Acknowledgment
Supported in part (or total) by the PVM student grant program in the Center for Companion Animal Studies at Colorado State University.

References


**Figure 1.**

**Figure 2.**

**Figure 3.**